

**Christopher M. O'Connor, M.D., MACC, FESC, FHFSA  
CURRICULUM VITAE**

**Contact Information:**

Address: Inova Heart and Vascular Institute  
3300 Gallows Road / IHVI Administration, Suite 1225  
Falls Church, VA 22042  
Phone: 703-776-3593

**Current Position:** President and Executive Director, Inova Heart and Vascular Institute

**Primary Academic Appointment:** Adjunct Professor of Medicine, Duke University

**Present Academic Rank and Title:** Adjunct Professor of Medicine, Duke University

**Date and Rank of First Duke Faculty Appointment:** Associate in Medicine - 7/1/89 - 6/30/90

**Specialty Certification and Dates:** American Board of Internal Medicine-Cardiovascular  
Disease, 11/8/89  
American Board of Internal Medicine, 1/1/88  
National Board of Medical Examiners, 01/24/87

<b>Education:</b>	<b>Place</b>	<b>Date</b>	<b>Degree</b>
<b>High School:</b>	Highpoint High Beltsville, Maryland	1975	Diploma
<b>College:</b>	University of Maryland College Park, Maryland	9/75 - 6/79	B.S.: Chemistry
<b>Graduate or Professional School:</b>	University of Maryland Baltimore, Maryland	9/79 - 6/83	M.D.: Medicine

**Scholarly Societies:**

Alpha Omega Alpha Medical Honor Society, Univ. of Maryland  
Cum Laude, Univ. of Maryland School of Medicine  
Magna Cum Laude, Univ. of Maryland  
Phi Beta Kappa National Honor Society, Univ. of Maryland  
Phi Kappa Phi National Honor Society  
Phi Eta Sigma National Honor Society  
Mortar Board National Honor Society

**Professional Training and Academic Career:**

1977	NIH Student Fellowship, Jackson Laboratory (mouse models of leukemia) Bar Harbor, Maine
1979 - 1982	Research Associate NIH / NINDS (imaging, neurology, and oncology) Bethesda, Maryland
07/01/1983 - 06/30/1984	Intern in Medicine

	Duke University Medical Center Durham, North Carolina
07/01/1984 – 06/30/1985	Junior Assistant Resident Duke University Medical Center Durham, North Carolina
07/01/1985 - 06/30/1986	Senior Assistant Resident Duke University Medical Center Durham, North Carolina
07/01/1986 - 06/30/1987	Assistant Chief Medical Resident Duke University Medical Center Durham, North Carolina
07/01/1987 - 06/30/1988	Chief Medical Resident Durham Veterans Administration Hospital Durham, North Carolina
07/01/1988 - 06/30/1989	Fellow, Division of Cardiology Duke University Medical Center Durham, North Carolina
07/01/1989 - 06/30/1990	Associate in Medicine Duke University Medical Center Durham, North Carolina
01/01/1990 - 12/31/1991	Attending, Coronary Care Unit Duke University Medical Center Durham, North Carolina
07/01/1990 - 11/30/1996	Assistant Professor of Medicine Duke University Medical Center Durham, North Carolina
07/01/1991 – 06/30/2000	Co-Director, Duke University Cooperative Cardiovascular Studies Organization Duke University Medical Center Durham, North Carolina
12/01/1996 – 03/30/2003	Associate Professor of Medicine Duke University Medical Center Durham, North Carolina
04/01/1998 – Present	Senior Investigator Duke Clinical Research Institute Durham, North Carolina
02/01/2000 – 04/30/2008	Director, Duke Heart Failure Program Duke University Medical Center Durham, North Carolina
11/01/2001 – 01/31/2015	Chief, Division of Clinical Pharmacology Duke University Medical Center Durham, North Carolina

03/01/2003 – Present	Professor of Medicine (Adjunct since 2015) Duke University Medical Center Durham, North Carolina
04/30/2007 – 01/30/2015	Director, Duke Heart Center Duke University Medical Center Durham, North Carolina
07/01/2010 – 01/30/2015	Chief, Division of Cardiology Duke University Medical Center Durham, North Carolina
04/1/2012 – 7/1/2022	Editor-In-Chief Journal of the American College of Cardiology: Heart Failure American College of Cardiology
04/01/2015 – Present	President and Executive Director Inova Heart and Vascular Institute Falls Church, Virginia
7/01/2012- Present	Guest Editor-In-Chief Journal of the American College of Cardiology American College of Cardiology

**Additional Training:**

Sixth Annual Fuqua/Coach K Leadership and Success Course, Duke University, Durham, North Carolina, 10/22/2004.

Advanced Studies in Medical Biometry, Duke University Medical Center, Durham, North Carolina, 09/1986 – 06/1990.

Harvard School of public Health Leadership Course, Boston, MA. 01/2015

**Patents:**

New use of selective serotonin reuptake inhibitors for treatment of human patients with chest pain of noncardiac origin or with gastroesophageal reflux disease. Drs. Ranga Krishnan, Christopher O'Connor, Indira Varia.

Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors. Drs. Victor L. Serebruany, Paul A. Gurbel, and Christopher M. O'Connor.

E-Care Software for Disease Management. Glenn P. Vonk, David Joshua Whellan, Richard Charles Rumbaugh, Christopher M. O'Connor.

A health outcomes and disease management network and related method for providing improved patient care.

Bisphosphonate compositions and methods for treating congestive heart failure. Drs Kenneth Lyles, Cathleen Colón-Emeric, and Christopher O'Connor.

Co-Founder, Cardio-Bis, Inc. (a company exploring novel heart failure therapeutics) Louis Lange, Richard Stack, Kathleen Colón-Emeric, Kenneth Lyles, Christopher O'Connor.

### **Research Interests:**

Phenotypic characterization and risk prognostication of patients with heart failure.

Co-morbidity characterization (stress and mood disorders) in heart failure.

Role of surrogate and nonfatal endpoints in clinical heart failure trials.

Ischemic biomarkers (troponin, imaging, and platelet function) in heart failure

Novel pharmacological and non-pharmacological approaches to heart failure.

### **Refereed manuscripts: (H-index=113)**

1. Reith KG, Fujiwara K, DiChiro G, Klatzo I, Brooks RA, Johnston GS, **O'Connor CM**, Mitchell LG. Serial measurements of CT attenuation and specific gravity in experimental cerebral edema. *Radiology*. 1980;135(2):343-348. doi:10.1148/radiology.135.2.6768102
2. Brooks RA, Keller MR, **O'Connor CM**, Sheridan WT. Progress toward quantitative computed tomography. *IEEE Transaction on Nuclear Science* 1980;NS-27 (No. 3).
3. Sheridan WT, Keller MR, **O'Connor CM**, Brooks RA. Evaluation of edge induced streaking artifacts in CT scanners. *Med Phys* 1980;7(2).
4. Brooks RA, Mitchell LG, **O'Connor CM**, DiChiro G. On the relationship between computed tomography numbers and specific gravity. *Phys Med Biol* 1981;26(Pt. 1):141-147.
5. Patronas NJ, Brooks RA, DeLaPaz RL, Kornblith PK, Smith BH, Rizzoli HV, Kessler RM, Manning RG, Channing M, Wolf AP, **O'Connor CM**. (18-F) Fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain. *Radiology*. 1982;144(4):885-889. doi:10.1148/radiology.144.4.6981123
6. Stack RS, **O'Connor CM**, Mark DB, Hinohara T, Phillips HR, Ramirez NM, O'Callaghan WG, Simonton CA, Carlson EB, Morris KG, Behar VS, Kong Y, Peter RH, Califf RM. Coronary perfusion during acute myocardial infarction with a combined therapy of coronary angioplasty and high dose intravenous streptokinase. *Circulation*. 1988;77(1):151-161. doi:10.1161/01.cir.77.1.151
7. Stack RS, Califf RM, Hinohara T, Phillips HR, Pryor DB, Simonton CA, Carlson EB, Morris KG, Behar VS, Kong Y, Peter RH, Hlatky MA, **O'Connor CM**, Mark DB. Survival and cardiac event rates in the first year following emergency angioplasty for acute myocardial infarction. *J Am Coll Cardiol* 1988;11(6):1141-9.
8. Hlatky MA, Cotugno HE, Mark DB, **O'Connor CM**, Califf RM, Pryor DB. Trends in physician management of uncomplicated acute myocardial infarction, 1970-1987. *Am J Card* 1988; Mar 1; 61:515-8.

9. Hlatky MA, Cotugno HE, **O'Connor CM**, Mark DB, Pryor DB, Califf RM. Adoption of thrombolytic therapy in the management of acute myocardial infarction. *Am J Card* 1988; Mar 1;61:510-4.
10. Simonton CA, Mark DB, Hinohara T, Rendall DS, Phillips HR, Peter RH, Behar VS, Kong Y, O'Callaghan WG, **O'Connor CM**, Califf RM, Stack RS. Late restenosis after emergent coronary angioplasty for acute myocardial infarction: comparison with elective coronary angioplasty. *J Am Coll Card* 1988 Apr;11(4):698-705.
11. Mark DB, Hlatky MA, **O'Connor CM**, Pryor DB, Wall TC, Honan MB, Phillips HR 3rd, Califf RM. Administration of thrombolytic therapy in the community hospital: established principles and unresolved issues. *J Am Coll Card* 1988 Dec;12(6 Suppl A):32A-43A.
12. **O'Connor CM**, Mark DB, Hinohara T, Stack RS, Rendall D, Hlatky MA, Pryor DB, Phillips HR, Califf RM. Rescue coronary angioplasty after failure of intravenous streptokinase in acute myocardial infarction: In-hospital and long-term outcomes. *J Invasive Cardiol* 1989;1:85-95.
13. **O'Connor CM**, Califf RM, Massey EW, Mark DB, Kereiakes DJ, Candela RJ, Abbottsmith C, George B, Stack RS, Aronson L, Mantell S, Topol EJ. Stroke and acute myocardial infarction in the thrombolytic era: clinical correlates and long-term prognosis. *J Am Coll Cardiol*. 1990 Sep;16(3):533-40.
14. Blumenthal JA, **O'Connor CM**. Stress and silent myocardial ischemia. A new research study at Duke University Medical Center. *North Carolina Medical Journal* 1990 Apr;51(4):135-8.
15. Uglietta JP, **O'Connor CM**, Boyko OB, Aldrich H, Califf RM, Massey EW, Heinz ER. The CT patterns of intracranial hemorrhage complicating thrombolytic therapy for acute myocardial infarction. *Radiology* 1991 Nov;181(2):555-9.
16. Wallis DE, Boden W, Califf R, Crawford MH, Hakki AH, Iskandrian AS, Labovitz A, **O'Connor CM**, Sutton R, Scanlon PJ. Failure of adjuvant heparin to reduce myocardial ischemia in the early treatment of patients with unstable angina. *Am Heart J* 1991;122:949-954.
17. Ortel TL, Gockerman JP, Califf RM, McCann RL, **O'Connor CM**, Metzler DM, Greenberg CS. Parenteral anticoagulation with the heparinoid lomoparan (Org 10172) in patients with heparin induced thrombocytopenia and thrombosis. *Thrombosis and Hemostasias* 1992 Mar 2;67(3):292-6.
18. **O'Connor CM**, Califf RM. Aggressive therapy of acute MI in the elderly. HP Publishing Company, David Fisher, Editorial Director, New York City, New York. *Hospital Practice* 1992 Feb 15;27(2):59-62, 66, 69 passim.
19. Wall TC, Campbell PT, **O'Connor CM**, Van Trigt P, Kenney RT, Sheikh KH, Kisslo JA, Corey GR. Diagnosis and management (by subxiphoid pericardiectomy) of large pericardial effusions causing cardiac tamponade. *Am J Card* 1992 Apr 15;69(12):1075-8.
20. Campbell PT, Van Trigt P, Wall TC, Kenney RT, **O'Connor CM**, Sheikh KH, Kisslo JA, Baker ME, Corey GR. Subxiphoid pericardiectomy in the diagnosis and management of large pericardial effusions associated with malignancy. *Am Coll Chest Physicians* 1992 Apr;101(4):938-43.
21. Van Trigt P, Douglas JM, Smith PK, Campbell PT, Wall TC, Kenney RT, **O'Connor CM**, Sheikh KH, Corey GR. A prospective trial of subxiphoid pericardiectomy in the diagnosis and treatment of large pericardial effusion. A follow-up report. *Annals of Surgery* 1993 Dec;218(6):777-82.

22. Ohman EM, **O'Connor CM**, Califf RM. Role of thrombolytic therapy in the treatment of acute myocardial infarction. *Cardiology in the Elderly* 1993;1:54-61.
23. **O'Connor CM**, Hathaway WR. Beyond thrombolysis: pharmacologic adjunctive therapies in myocardial infarction. *Cardiac Chronicle* 1993;7(10):1-10.
24. Corey GR, Campbell PT, Van Trigt P, Kenney RT, **O'Connor CM**, Sheikh KH, Kisslo JA. Etiology of large pericardial effusions. *Am J Med* 1993 Aug;95(2):209-13.
25. Krucoff MW, Croll MA, Pope JE, Granger CB, **O'Connor CM**, Sigmon KN, Wagner BL, Ryan JA, Lee KL, Kereiakes DJ, Samaha JK, Worley SJ, Ellis SG, Wall TC, Topol EJ, Califf RM for the TAMI 7 Study Group. Continuous 12-Lead ST-segment recovery analysis in the TAMI 7 study. Performance of a noninvasive method for real-time detection of failed myocardial reperfusion. *Circulation* 1993 Aug;88(2):437-46.
26. **O'Connor CM**, Meese R, Carney R, Smith J, Conn E, Burks J, Hartman C, Roark S, Shadoff N, Heard M, Mittler B, Collins G, Navetta F, Lee K, Califf RM for the Duke University Clinical Cardiology Study Group. A randomized trial of intravenous heparin in conjunction with anistreplase (anisoylated plasminogen streptokinase activator complex) in acute myocardial infarction: the Duke University Clinical Cardiology Study (DUCCS) 1. *J Am Coll Card* 1994 Jan;23(1):11-8.
27. Koenig HG, **O'Connor CM**, Guarisco SA, Zabel KM, Ford SM. Depressive disorder in older medical inpatients on general medicine and cardiology services at a university teaching hospital. *American J Geriatric Psychiatry* 1993; 1:197-211.
28. Slaughter TE, Mody EA, Oldham HN, Reves JG, **O'Connor CM**, Parker JK, Greenberg CS. Management of a patient with Type IIC von Willebrand's Disease during coronary artery bypass graft surgery. *Anesthesiology* 1993 Jan;78(1):195-7.
29. Kenney RT, Li JS, Clyde WA, Wall TC, **O'Connor CM**, Campbell PT, VanTrigt P, Corey RG. Mycoplasmal pericarditis: evidence of invasive disease. *Clin Infectious Disease* 1993 Aug;17 Suppl 1:S58-62. Review.
30. Jiang W, Hayano J, Coleman ER, Hanson MW, Frid DJ, **O'Connor CM**, Thurber D, Waugh RA, Blumenthal JA. Relation of cardiovascular responses to mental stress and cardiac vagal activity in coronary artery disease. *Am J Card* 1993 Sep 1;72(7):551-4.
31. Larsen RL, Behar VS, Brazer SR, Chen J, **O'Connor CM**. Chest pain presenting as ischemic heart disease: Congenital absence of the pericardium. *North Carolina Medical Journal* 1994 Jul;55(7):306-8.
32. Selker HP, Beshansky JR, Schmid CH, Griffith JL, Longstreth WT, **O'Connor CM**, Caplan LR, Massey EW, D'Agostino RB, Laks MM, Lee KL, Maynard C, Wagner GS, Weaver WD, Califf RM. Presenting pulse pressure predicts thrombolytic therapy-related intracranial hemorrhage: Thrombolytic Predictive Instrument (TPI) project results. *Circulation* 1994; 90:1657-1661.
33. Jiang W, Trauner MA, Coleman RE, Waugh RA, Hanson MW, Frid DJ, Phillips BG, Morris JJ Jr, **O'Connor C**, Blumenthal JA. Association of physical fitness and transient myocardial ischemia in patients with coronary artery disease. *Journal of Cardiopulmonary Rehabilitation* 1995 Nov-Dec;15(6):431-8.
34. TheI MC, **O'Connor CM**. Magnesium in acute myocardial infarction. *Coronary Artery Disease* 1995 Oct;6(10):831-7. Review.

35. Blumenthal JA, Jiang W, **O'Connor CM**, Coleman RE, Waugh RA, Hanson M, Frid DJ, Phillips BG, Morris JJ. Mental stress-induced ischemia in the laboratory and ambulatory ischemia during daily life. Association and hemodynamic features. *Circulation* 1995; 92(8):2102-2108.
36. Gurbel PA, **O'Connor CM**. Zofenopril after acute myocardial infarction (letter to the editor). *New Engl J Med* 1995;332:1715.
37. Jiang W, Blumenthal JA, Hanson MW, Coleman RE, **O'Connor CM**, Frid D, Morris JJ, Waugh RA. Relative importance of electrode placement and number of channels in transient myocardial ischemia detection by holter monitoring. *Am J Card* 1995 Aug 15;76(5):350-4.
38. Campbell PT, Li JS, Wall TC, **O'Connor CM**, VanTrigt P. Cytomegalovirus pericarditis: a case series and review of the literature. *Am J of Medical Sciences* 1995 Apr;309(4):229-34.
39. **O'Connor CM**, Meese RB, McNulty S, Lucas KD, Carney RJ, LeBoeuf RPh, Maddox W, Bethea CF, Shadoff N, Trahey TF, Heinsimer JA, Burks JM, O'Donnell G, Krucoff MW, Califf RM. A randomized factorial trial of reperfusion strategies and aspirin dosing in acute myocardial infarction. The DUCCS-II Investigators. *Am J Card* 1996;77:791-797.
40. Gonzales MB, Snyderman TB, Colket J, Arias P, Jiang JW, **O'Connor CM**, Krishnan KR. Depression in patients with coronary artery disease. *Depression* 1996;4:57-62.
41. Mahaffey KW, Granger CB, Califf RM, **O'Connor CM**, Bleich SD, Col JJ, Ohman M. Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. *Am J Card* 1996 Mar 15;77(8):551-6.
42. Jiang W, Babyak M, Krantz DS, Waugh RA, Coleman E, Hanson MW, Frid DJ, McNulty S, Morris JJ, **O'Connor CM**, Blumenthal JA. Mental stress-induced myocardial ischemia and cardiac events. *JAMA* 1996 Jun 5;275(21):1651-6.
43. Packer M, **O'Connor CM**, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, Neuberg GW, Frid D, Wertheimer JH, Meese RB, Old WD, Willis PW, Cropp AB, Anderson SA, DeMets DL for the Prospective Amlodipine Survival Evaluation (PRAISE) Study Group. Effect of Amlodipine on morbidity and mortality in severe chronic heart failure. *New Engl J Med* 1996;335:1107-1114.
44. Barefoot JC, Helms MJ, Mark DB, Blumenthal JA, Califf RM, Haney TL, **O'Connor CM**, Siegler IC, Williams RB. Depression and long term mortality risk in patients with coronary artery disease. *Am J Card* 1996 Sep 15;78(6):613-7.
45. Bart BA, Gattis WA, Diem SJ, **O'Connor CM**. Reasons for underuse of angiotensin-converting enzyme inhibitors in patients with heart failure and left ventricular dysfunction. *Am J Card* 1997 Apr 15;79(8):1118-20.
46. Gullette ECD, Blumenthal JA, Babyak M, Jiang W, Waugh RA, Frid DJ, **O'Connor CM**, Morris JJ, Krantz DS. Effects of mental stress on myocardial ischemia during daily life. *JAMA* 1997 May 21;277(19):1521-6.
47. **O'Connor CM**, Hathaway WR, Bates ER, Leimberger JD, Sigmon KN, Kereiakes DJ, George BS, Samaha JK, Abbottsmith CW, Candela RJ, Topol EJ, Califf RM. Clinical characteristics and long-term outcome of patients in whom congestive heart failure develops after thrombolytic therapy for acute myocardial infarction: Development of a predictive model. *Am Heart J* 1997 Jun;133(6):663-73.

48. Jiang W, Hathaway WR, McNulty S, Larsen RL, Hansley KL, Zhang Y, **O'Connor CM**. Ability of heart rate variability to predict prognosis in patients with advanced congestive heart failure. *Am J Card* 1997 Sep 15;80(6):808-11.
49. Cuffe MS, Rao S, **O'Connor CM**. Heart failure and special therapeutic considerations in older patients. *Clinical Geriatrics* 1997;3(5):56-71.
50. Bart BA, Shaw LK, McCants CB, Fortin DF, Lee KL, Califf RM, **O'Connor CM**. Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. *J Am Coll Card* 1997 Oct;30(4):1002-8.
51. Hayano J, Jiang W, Waugh R, **O'Connor CM**, Frid D, Blumenthal JA. Stability over time of circadian rhythm of variability of heart rate in patients with stable coronary artery disease. *Am Heart J* 1997;134:411-418.
52. Cuffe MS, **O'Connor CM**. Pharmacologic management of acute heart failure. *Current Opinion in Critical Care* 1997;3:386-390.
53. Blumenthal JA, Jiang W, Babyak MA, Krantz DS, Frid DJ, Coleman RE, Waugh R, Hanson M, Appelbaum M, **O'Connor CM**, Morris JJ. Stress management and exercise training in cardiac patients with myocardial ischemia. Effects on prognosis and evaluation of mechanisms. *Arch Intern Med* 1997 Oct 27;157(19):2213-23.
54. Fuster V, Califf RM, Chesebro JH, Cohen M, Comp PC, Gheorghide M, Hall J, Halperin J, Khan S, Kopecky S, Langer A, Molk B, Moss A, **O'Connor CM**, Ogara PT, Raskob E, Sutton J, Braunwald E, Bell WR, Furberg C, Rapaport E, Demets D, Goldstein S, Richardson D, Hillis D, et al. Coumadin Aspirin Reinfarction Study (CARS) Investigators. Randomized double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. *Lancet* 1997;350(9075):389-396.
55. Theil MC, Armstrong AL, McNulty SE, Califf RM, **O'Connor CM**. Randomised trial of magnesium in in-hospital cardiac arrest. Duke Internal Medicine Housestaff. MAGIC. *Lancet* 1997 Nov 1;350(9087):1272-6
56. Blumenthal JA, **O'Connor CM**, Hinderliter A, Fath K, Hegde SB, Miller G, Puma J, Sessions W, Sheps D, Zakhary B, Williams RB. Psychosocial factors and coronary disease. A national multicenter clinical trial (ENRICH) with a North Carolina focus. *NC Med J* 1997 Nov-Dec;58(6):440-4. Review.
57. Packer M, **O'Connor CM**, DeMets. Amlodipine in chronic heart failure. Letter to the Editor. *New Engl J Med* 1997;336(14):1024.
58. Serebruany VL, Atar D, Dalesandro MR, **O'Connor CM**, Gurbel PA. Changes in hemostasis after parenteral magnesium in myocardial ischemia-reperfusion: from animal studies to clinical trials. *Magnesium Research* 1998;11(2):133-141.
59. **O'Connor CM**, Gattis WA, Swedberg K. Current and novel pharmacologic approaches in advanced heart failure. *Am Heart J* 1998 Jun;135(6 Pt 2 Su):S249-63. Review.
60. Gattis WA, Larsen RL, Hasselblad V, Bart BA, **O'Connor CM**. Is optimal angiotensin-converting enzyme inhibitor dosing neglected in elderly patients with heart failure? *Am Heart J* 1998 Jul;136(1):43-8.
61. Theil MC, Armstrong AL, McNulty SE, Califf RM, **O'Connor CM**. Magnesium in in-hospital cardiac arrest – Reply (Letter). *Lancet* 1998;351(9100):446



62. Shah BR, Lin C, Maynard C, Bart B, Selvester RH, Shaw LK, **O'Connor CM**, Wagner GS. Specificity of electrocardiographic myocardial infarction screening criteria in patients with nonischemic cardiomyopathies. *Am Heart J* 1998 Aug;136(2):314-9.
63. Serebruany VL, Bahr RD, **O'Connor CM**, Lowry DR, Gurbel PA for the GUSTO-III Platelet Substudy. Antecedent aspirin therapy inhibits baseline platelet activity in patients presenting with acute myocardial infarction. *Cardiology* 1998;90:37-42.
64. Guyton JR, Goldberg AC, Kreisberg RA, Sprecher DL, Superko HR, **O'Connor CM**. Effectiveness of once-nightly dosing of extended-release Niacin alone and in combination for hypercholesterolemia. *Am J Card* 1998 Sep 15;82(6):737-43.
65. **O'Connor CM**, Carson PE, Miller AB, Pressler ML, Belkin RN, Neuberger GW, Frid DJ, Cropp AB, Anderson S, Wertheimer JH, DeMets DL. Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial. Prospective Randomized Amlodipine Survival Evaluation. *Am J Cardiol*. 1998 Oct 1;82(7):881-7.
66. Krishnan KR, George LK, Pieper CF, Jiang W, Arias R, Look A, **O'Connor C**. Depression and social support in elderly cardiac patients. *Am Heart J* 1998 Sep;136(3):491-5.
67. Flack JM, **O'Connor CM**, Wei JY. Four commonly seen cardiovascular diseases. Patient Care. *The Practice Journal for Primary Care Physicians*. 1998 May 15:98-130.
68. **O'Connor CM**. Heart Failure (comments regarding Effect of Amlodipine on morbidity and mortality in severe chronic heart failure – NEJM 335:1107-1114, 1996). Editorial Hot Papers Section. *The Scientist*. Oct. 12, 1998;12(20):11.
69. Packer M, Cohn J (Guest Editors), on behalf of the Steering Committee and **Membership Of the Advisory Council to Improve Outcomes Nationwide in Heart Failure**. Consensus Recommendations for the Management of Chronic Heart Failure. *Am J Card* 1999;83(2A):1A – 38A.
70. Thel MC, **O'Connor CM**. Cardiopulmonary resuscitation: Historical perspective to recent investigations. *Am Heart J* 1999 Jan;137(1):39-48. Review
71. Whellan DJ, Gattis WA, Gaudin L, Granger B, **O'Connor CM**. Disease management of congestive heart failure. *Am J Managed Care* 1999 Apr;5(4):499-507; quiz 508-9.
72. Kong DF, Blazing MA, **O'Connor CM**. The Health Care Burden of Unstable Angina. *Cardiology Clinics* 1999 May;17(2):247-61. Review.
73. Shapiro PA, Lespérance F, Frasure-Smith N, **O'Connor CM**, Baker B, Jiang JW, Dorian P, Harrison W, Glassman AH. An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (the SADHAT Trial). Sertraline Anti-Depressant Heart Attack Trial. *Am Heart J* 1999 Jun;137(6):1100-6.
74. **O'Connor CM**, Gattis WA, Zannad F, McNulty SE, Gheorghide M, Adams KF, Califf RM, McKenna WJ, Soler-Soler J, Swedberg K. Beta-blocker therapy in advanced heart failure: clinical characteristics and long-term outcomes. *European J Heart Failure* 1999 Mar;1(1):81-8.
75. **O'Connor CM**, Gurbel PA, Serebruany VL. Usefulness of soluble and surface-bound P-selectin in detecting heightened platelet activity in patients with congestive heart failure. *Am J Card*. 1999 May 1;83(9):1345-9.
76. **O'Connor CM**, Gattis WA, Swedberg K. Current and novel pharmacologic approaches in advanced heart failure. *Heart and Lung* 1999 Jul-Aug;28(4):227-42. Review.

77. Blazing MA, **O'Connor CM**. Evidence supporting secondary prevention strategies. *Current Opinion in Cardiology*. 1999 Jul;14(4):303-9. Review.
78. **O'Connor CM**, Gattis WA, Uretsky BF, Adams KF Jr, McNulty SE, Grossman SH, McKenna WJ, Zannad F, Swedberg K, Gheorghiade M, Califf RM. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). *Am Heart J*. 1999 Jul;138(1 Pt 1):78-86.
79. Gurbel PA, **O'Connor CM**, Cummings CC, Serebruany VL. Clopidogrel: The future choice for preventing platelet activation during coronary stenting? *Pharmacological Research* 1999;40(2):107-111. Review.
80. Nair GV, Gurbel PA, **O'Connor CM**, Gattis WA, Murugesan SR, Serebruany VL. Depression, coronary events, platelet inhibition, and serotonin reuptake inhibitors. *Am J Card* 1999 Aug 1;84(3):321-3, A8. Review.
81. **O'Connor CM**, Radensky PW, Unger AN, Martin BC. Hospital use and costs among patients with nonischemic cardiomyopathy in the first prospective randomized amlodipine survival evaluation study. *Clinical Therapeutics* 1999 Jul;21(7):1254-65.
82. Bart BA, **O'Connor CM**. Clinical determinants of mortality in patients with cardiomyopathy. *Cardiology Review* 1999 16(7):8-11
83. Gattis WA, Hasselblad V, Whellan DJ, **O'Connor CM**. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: Results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study. *Arch Intern Med* 1999 Sep 13;159(16):1939-45.
84. Doraiswamy PM, MacFall J, Krishnan KR, **O'Connor CM**, Wan X, Benaur M, Lewandowski M, Fortner M. Magnetic resonance assessment of cerebral perfusion in depressed cardiac patients: preliminary findings. *Am J Psychiatry* 1999 Oct;156(10):1641-3.
85. Adams KF, Sueta CA, Gheorghiade M, **O'Connor CM**, Schwartz TA, Koch GG, Uretsky B, Swedberg K, McKenna W, Soler-Soler J, Califf RM. Gender differences in survival in advanced heart failure: Insights from the FIRST study. *Circulation* 1999 Apr 13;99(14):1816-21.
86. **O'Connor CM**, Gattis WA, Gheorghiade M, Granger CB, Gilbert J, McKenney JM, Messineo FC, Burnett JC, Katz SD, Elkayam U, Kasper EK, Bornemann M, Goldstein S, Cody RJ, Massie BM, for the U.S. Ecadotril Investigators. Randomized trial of Ecadotril versus placebo in patients with mild to moderate heart failure: The U.S. Ecadotril Pilot Safety Study. *Am Heart J* 1999 Dec;138(6 Pt 1):1140-8.
87. Velazquez E, **O'Connor CM**. Heart failure after myocardial infarction: A good heart is hard to find. *Am Heart J* 1999 Dec;138(6 Pt 1):1009-11.
88. Del Carlo C, **O'Connor CM**. Cardiac troponins in congestive heart failure. *Am Heart J* 1999 Oct;138(4 Pt 1):646-53. Review.
89. Serebruany VL, Murugesan SR, Pothula H, Atar D, Lowry DR, **O'Connor CM**, Gurbel PA. Increased soluble platelet endothelial cellular adhesion molecule-1 and osteonectin levels in patients with severe congestive heart failure. Independence of disease etiology, and antecedent aspirin therapy. *Eur J Heart Failure* 1999 Aug;1(3):243-9.

90. Langer A, Fisher M, Califf RM, Goodman S, **O'Connor CM**, Harrington RA, Fuster V. Higher rates of coronary angiography and revascularization following myocardial infarction may be associated with greater survival in the United States than in Canada. The CARS Investigators (Coumadin/Aspirin Reinfarction Study). *Can J Card*. 1999 Oct;15(10):1095-102.
91. Orloff DG, Blazing MA, **O'Connor CM**. Atherosclerotic disease in non-insulin dependent diabetes mellitus: role of abnormal lipids and the place for lipid-altering therapies. *Am Heart J* 1999 Nov;138(5 Pt 1):S406-12.
92. Steffans DC, **O'Connor CM**, Jiang WJ, Pieper CF, Kuchibhatla MN, Arias RM, Look A, Davenport C, Krishnan RR. The effect of major depression on functional status in patients with coronary artery disease. *J Am Geriatrics Society* 1999 Mar;47(3):319-22.
93. Fortner M, Brown K, Varia IM, Gersing KR, **O'Connor CM**, Doraiswamy PM. Effect of Bupropion SR on the quality of life of elderly depressed patients with comorbid disorders. *The Primary Care Companion in the Journal of Clinical Psychiatry* 1999 Dec;1(6):174-179.
94. Cuffe MS, Califf RM, Adams KF, Bourge RC, Colucci W, Massie B, **O'Connor CM**, Piñal, Quigg R, Silver M, Robinson LA, Leimberger JD, Gheorghide M. Rationale and design of the OPTIME CHF Trial: outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure. *Am Heart J*. 2000 Jan;139(1 Pt 1):15-22.
95. Enhancing recovery in coronary heart disease patients (**ENRICHD**): **study design and methods**. The **ENRICHD** investigators. *Am Heart J*. 2000 Jan;139(1 Pt 1):1-9.
96. Gurbel PA, Kereiakes DJ, Dalesandro MR, Bahr RD, **O'Connor CM**, Serebruany VL. Role of soluble and platelet-bound P-selectin in discriminating cardiac from noncardiac chest pain at presentation in the emergency department. *Am Heart J*. 2000 Feb;139(2 Pt 1):320-8.
97. Serebruany VL, Lowry DR, Fuzaylov SY, Levine DJ, **O'Connor CM**, Gurbel PA. Moderate alcohol consumption is associated with decreased platelet activity in patients presenting with acute myocardial infarction. *J Thromb Thrombolysis*. 2000 Apr;9(3):229-34
98. Califf RM, **O'Connor CM**. Beta-blocker therapy for heart failure. The evidence is in, now the work begins. *JAMA*. 2000 Mar 8;283(10):1335-7.
99. McKenzie ME, Pothula A, Gurbel PA, Fuzaylov SY, **O'Connor CM**, Gattis WA, Serebruany VL. Failure of thrombin generation markers to triage patients presenting with chest pain. *Card* 2000;92(1):53-58.
100. Shah A, Wagner GS, Granger CB, **O'Connor CM**, Green CL, Trollinger KM, Califf RM, Krucoff MW. Prognostic implications of TIMI flow grade in the infarct related artery compared with continuous 12-lead ST-segment resolution analysis. Re-examining the "Gold Standard" for myocardial reperfusion assessment. *J Am Coll Card*. 2000 Mar 1;35(3):666-72.
101. Carson PA, **O'Connor CM**, Miller AB, Anderson S, Belkin R, Neuberg GW, Wertheimer JH, Frid D, Cropp A, Packer M. Circadian rhythm and sudden death in heart failure: Results from the Prospective Randomized Amlodipine Survival Trial. *J Am Coll Card*. 2000;369(2):541-546.
102. Gattis W, **O'Connor CM**. Calcium antagonist use in heart failure. A re-evaluation of treatment options. *Drugs* 2000;59(2):17-24.
103. **O'Connor CM**, Gattis WA, Ryan TJ. The role of clinical non-fatal endpoints in cardiovascular phase II/III clinical trials. *Am Heart J* 2000;139:S143-S154.

104. Varia I, Logue E, **O'Connor CM**, Newby K, Wagner HR, Davenport C, Rathey K, Krishnan KR. Randomized trial of sertraline in patients with unexplained chest pain of non-cardiac origin. *Am Heart J*. 2000;140:367-372.
105. **O'Connor CM**, Gurbel PA, Serebruany VL. Depression and ischemic heart disease. *Am Heart J*. 2000;140(4):S63-S69.
106. Nemeroff CB, **O'Connor CM**. Guest Editors. Depression as a risk factor for Cardiovascular and cerebrovascular disease: emerging data and clinical perspectives. *Am Heart J*. 2000;140(4):S55-S56.
107. **O'Connor CM**, Gattis WA, Shaw L, Cuffe MS, Califf RM. Clinical characteristics and long-term outcome of patients with heart failure and preserved systolic function. *Am J Card*. 2000;86:863-867.
108. Shah MR, **O'Connor CM**. The Congestion Score: A simple tool for a complicated disease? *Am Heart J* 2000;140(6):824-826.
109. Davis CJ, Gurbel PA, Gattis WA, Fuzaylov SV, Nair GV, **O'Connor CM**, Serebruany VL. Hemostatic abnormalities in patients with congestive heart failure: diagnostic significance and clinical challenge (review). *International J Card*. 2000;75(1):15-21.
110. Bosworth HB, Steffans DC, Kuchibhatla MN, Jiang WJ, Arias RM, **O'Connor CM**, Krishnan RR. The relationship of social support, social networks, and negative events with depression in patients with coronary artery disease. *Aging and Mental Health* 2000;4(3):253-258.
111. Serebruany VL, Davis CJ, Meister AF, Atar D, Whellan D, **O'Connor CM**. Biomarkers and exercise training: A possible missing link between physical activity and mortality benefit in patients with heart failure. *Heart Drug* 2001;1:110-124.
112. Shah MR, **O'Connor CM**, Sopko G, Hasselblad V, Califf RM, Stevenson LW for the ESCAPE Investigators. Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE): Design and rationale. *Am Heart J* 2001;141:528-535.
113. Shah M, Stinnett SS, McNulty SE, Gheorghide M, Zannad F, Uretsky B, Adams KF, Califf RM, **O'Connor CM**. Hemodynamics as surrogate endpoints for survival in advanced heart failure: an analysis from FIRST. *Am Heart J* 2001;141(6):908-914.
114. Shah MR, Hasselblad V, Stinnett SS, Gheorghide M, Swedberg K, Califf RM, **O'Connor**. Hemodynamic profiles of advanced heart failure: association with clinical characteristics and long-term outcomes. *J Cardiac Failure* 2001;7(2):105-113.
115. Alexander KP, Newby LK, Hellkamp AS, Harrington RA, Peterson ED, Kopecky S, Langer A, O'Gara P, **O'Connor CM**, Daly RN, Califf RM, Khan S, Fuster V. Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up. *J Am Coll Card* 2001;38(1):1-7.
116. Whellan DJ, Shaw LK, Bart BA, Kraus WE, Califf RM, **O'Connor CM**. Cardiac rehabilitation and survival in patients with left ventricular systolic dysfunction. *Am Heart J* 2001;142(1):160-166
117. Felker M, **O'Connor CM**. Inotropic therapy for heart failure: An evidence-based approach. *Am Heart J* 2001;142(3):393-401.

118. Serebruany VL, Alford AB, Fuzaylov SY, Gattis WA, Gurbel PA, **O'Connor CM**. Clinical utility of the platelet function analyzer (PFA-100) for the assessment of the platelet status in patients with congestive heart failure (EPCOT trial). *Thrombosis Research* 2001;101(6):427-433.
119. Gattis WA, Galanos A, **O'Connor CM**. Angiotensin-converting enzyme inhibitor dosing in heart failure: What is optional? Editorial. *Am Heart J* 2001;141(3):331-333.
120. Gurbel PA, **O'Connor CM**, Dalsandro MR, Serebruany VL. Relation of soluble and platelet P-Selectin to early outcome in patients with acute myocardial infarction after thrombolytic therapy. *Am J Card* 2001;87(6):774-777.
121. Jiang W, Alexander J, Christopher E, Kuchibhalta M, Gaulden LH, Cuffe MS, Blazing MA, Davenport C, Califf RM, Krishnan RR, **O'Connor CM**. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. *Arch Intern Med* 2001;161(15):1849-1856.
122. **O'Connor CM**, Gattis WA, Hellkamp AS, Langer A, Larsen RL, Harrington RA, Berkowitz SD, O'Gara PT, Kopecky SL, Gheorghiade M, Daly R, Califf RM, Fuster V. Comparison of two aspirin doses on ischemic stroke in post myocardial infarction patients in the warfarin (coumadin) aspirin reinfarction study (CARS). *Am J Card* 2001;88:541-546.
123. Serebruany VL, **O'Connor CM**, Gurbel PA. Effect of selective serotonin reuptake inhibitors on platelets in patients with coronary artery disease. *Am J Card* 2001;87:1398-1400.
124. Carney RM, Blumenthal JA, Stein PK, Watkins L, Catellier D, Berkman LF, Czajkowski SM, **O'Connor CM**, Stone PH, Freedland KE. Depression, heart rate variability, and acute myocardial infarction. *Circulation* 2001;104(17):2024-2028.
125. Shah MR, Hasselblad V, Gheorghiade M, Adams KF, Swedberg K, Califf RM, **O'Connor CM**. Prognostic usefulness of the six-month walk in patients with advanced congestive heart failure secondary to ischemic or nonischemic cardiomyopathy. *Am J Card* 2001;88(4):987-993.
126. Felker GM, **O'Connor CM**. Between Scylla and Charybdis: The choice of inotropic agent for decompensated heart failure. *Am Heart J* 2001;142(6):932-933.
127. Whellan DJ, Gaulden L, Gattis W, Granger B, Russell SD, Blazing MA, Cuffe MS, **O'Connor CM**. The benefit of implementing a Heart Failure Disease Management Program. *Arch Intern Med* 2001;161(18):2223-2228.
128. Serebruany VL, Gurbel PA, **O'Connor CM**. Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. *Pharmacological Research*. 2001;43(5):453-462.
129. Jiang W, Krishnan R, **O'Connor CM**. Depression and heart disease: Evidence of a link, and its therapeutic implications. *CNS Drugs* 2002;16(2):111-127.
130. Cuffe M, Califf RM, Adams KF, Benza R, Bourge R, Colucci W, Massie B, **O'Connor CM**, Piñal, Quigg R, Silver MA, Gheorghiade M, for the Outcomes of a Prospective Trial of Intravenous Milrinone for exacerbations of chronic heart failure (OPTIME-CHF) Investigators. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: A randomized controlled trial. *J Am Med Assoc* 2002;287(12):1541-1547.
131. Jiang W, Krishnan R, **O'Connor CM**. Depression and major outcomes in older patients with heart failure. *Arch Intern Med* 2002;162(3):362-364.

132. Felker GM, Shaw LK, **O'Connor CM**. A standardized definition of ischemic cardio-myopathy for use in clinical research. *J Am Coll Card* 2002;39(2):210-218.
133. Gottlieb SS, Abraham W, Butler J, Forman DE, Loh E, Massie BM, **O'Connor CM**, Rich MW, Stevenson LW, Young J, Krumholz HM. The prognostic importance of different definitions of worsening renal function in congestive heart failure. *J Cardiac Failure* 2002;8(3):136-141.
134. Neuberg GW, Miller AB, **O'Connor CM**, Belkin RN, Carson PE, Cropp AB, Frid DJ, Nye RG, Pressler ML, Wertheimer JH, Packer M, for the PRAISE Investigators. Diuretic resistance predicts mortality in patients with advanced heart failure. *Am Heart J* 2002;144:31-38.
135. Whellan DJ, **O'Connor CM**. The state of exercise training: A need for action. (Editorial) *Am Heart J* 2002;144(1):1-4.
136. Gurbel PA, Gattis WA, Fuzaylov SF, Gauden L, Hasselblad V, Serebruany VL, **O'Connor CM**. Evaluation of platelets in heart failure: Is platelet activity related to etiology, functional class, or clinical outcomes? *Am Heart J* 2002;143:1068-1075.
137. Shah MR, Hasselblad V, Stinnett SS, Kramer JM, Grossman S, Gheorghide M, Adams KF, Swedberg K, Califf RM, **O'Connor CM**. Dissociation between hemodynamic changes and symptom improvement in patients with advanced congestive heart failure. *Eur J Heart Failure* 2002;4(3):297-304.
138. Jiang W, **O'Connor CM**. Depression and cardiac health in women: How close is the relationship? Clinical caveats, concerns, and recommendations. *Women Health Primary Care* 2002;5(6):393-404.
139. Glassman AH, **O'Connor CM**, Califf RM, Swedberg K, Schwartz P, Bigger JT, Krishnan KRR, Zyl van LT, Swenson JR, Finkel MS, Landau C, Shapiro PA, Pepine CJ, Mardekian J, Harrison WM, for the Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) Group. Sertraline treatment of major depression in patients with acute MI or unstable angina. *J Am Med Assoc* 2002;288:701-709.
140. **O'Connor CM**, Velazquez EJ, Gardner LH, Smith PK, Newman MF, Landolfo KP, Lee KL, Califf RM, Jones RH. Comparison of coronary artery bypass grafting versus medical therapy on long-term outcome in patients with ischemic cardiomyopathy (A 25-year experience from the Duke Cardiovascular Databank). *Am J Card* 2002;90:101-107.
141. **O'Connor CM**, Gattis WA, Adams KF, Shah MR, Kobrin I, Frey A, Gheorghide M, for the RITZ-4 Investigators. Tezosentan in patients with acute heart failure and acute coronary syndromes: Design of the Randomized Intravenous Tezosentan Study (RITZ-4). *Am Heart J* 2002;144:583-588.
142. Serebruany VL, McKenzie ME, Meister AF, Fuzaylov SY, Gurbel PA, Atar D, Gattis WA, **O'Connor CM**. Whole blood impedance aggregometry for the assessment of platelet function in patients with congestive heart failure (EPCOT Trial). *Eur J Heart Failure* 2002;4(4):461-467.
143. Trichon BH, **O'Connor CM**. Secondary mitral and tricuspid regurgitation accompanying left ventricular systolic dysfunction: is it important, and how is it treated? (letter to the editor). *Am Heart J* 2002;144(3):373-376.
144. Borque JM, Velazquez EJ, Borges-Neto S, Hasselblad V, **O'Connor CM**. A reappraisal of myocardial viability testing in patients with coronary artery disease and left ventricular dysfunction: Can meta-analysis be trusted? *HeartDrug* 2002;2:204-205.

145. Gurbel PA, Malinin AI, Callahan KP, Serebruany VL, **O'Connor CM**. Effect of loading with clopidogrel at the time of coronary stenting on platelet aggregation and glycoprotein IIb/IIIa expression and platelet-leukocyte aggregate formation. *Am J Card* 2002;90(3):312-315.
146. Jiang W, Hasselblad V, Krishnan RR, **O'Connor CM**. Patients with CHF and depression have greater risk of mortality and morbidity than patients without depression. (letter). *J Am Coll Card* 2002;39(5):919-921.
147. Blumenthal JA, Babyak M, Wei J, **O'Connor CM**, Waugh R, Eisenstein E, Mark D, Sherwood A, Woodley PA, Irwin RJ, Reed G. Usefulness of psychosocial treatment of mental stress-induced myocardial ischemia in men. *Am J Card* 2002;89(2):164-168.
148. Shah BR, Velazquez E, Shaw LK, Bart B, **O'Connor CM**, Wagner GS. Revascularization improves survival in ischemic cardiomyopathy regardless of electrocardiographic criteria for prior small-to-medium myocardial infarcts. *Am Heart J* 2002;143(1):111-117.
149. Serebruany VL, McKenzie ME, Meister AF, Fuzaylov SY, Gurbel PA, Atar D, Gattis WA, **O'Connor CM**. Failure of platelet parameters and biomarkers to correlate platelet function to severity and etiology of heart failure in patients enrolled in the EPCOT Trial. *Pathophysiology of Haemostasis & Thrombosis* 2002;32:8-15.
150. Gattis WA, **O'Connor CM**, Gheorghiade M. The Initiation Management of PredischARGE Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) Study: Design and implications. *Reviews in Cardiovascular Medicine* 2002;3(3):S48-S54.
151. Gheorghiade M, Gattis WA, **O'Connor CM**. Treatment gaps in the pharmacologic management of heart failure. *Reviews in Cardiovascular Medicine* 2002;3(3):S11-S19.
152. Gheorghiade M, Gattis WA, Lukas MA, **O'Connor CM**. Rationale and design of the initiation management predischARGE: process for assessment of carvedilol therapy for heart failure (IMPACT-HF) Study. *Am Heart J* 2003; Feb 145(2):S60-S61.
153. Hasdai D, Topol EJ, Kilaru R, Battler A, Harrington RA, Vahanian A, Ohman M, Granger CB, Van de Werf F, Simoons ML, **O'Connor CM**, Holmes DR. Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: Lessons from 4 international fibrinolytic therapy trials. *Am Heart J* 2003;145(1):73-79.
154. Gheorghiade M, Gattis W, **O'Connor CM**, Adams KF. Editors. Introduction – The Management of Decompensated Heart Failure Resulting in Hospitalization: Proceedings from an Expert Meeting to Review Current Concepts and to Define Future Directions. *Am Heart J* 2003;145(2):S1 – S3.
155. Felker GM, Adams KF, Konstam MA, **O'Connor CM**, Gheorghiade M. The problem of decompensated heart failure: nomenclature, classification, and risk stratification. *Am Heart J* 2003;145(2):S18 – S26.
156. **O'Connor CM**, Gattis WA, Teerlink JR, Adams KF, Gheorghiade M. Design considerations and proposed template for clinical trials in hospitalized patients with decompensated chronic heart failure. *Am Heart J* 2003;145(2):S47 – S51.
157. Gheorghiade M, Gattis WA, Barbagelata A, Elkayam U, Adams KF, Orlandi C, **O'Connor CM**, for the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and

- chronic outcomes of patients hospitalized with worsening congestive heart failure. *Am Heart J* 2003;145(2):S51-S55.
158. Gheorghiade M, Gattis WA, Adams KF, Jaffe AS, **O'Connor CM**, for the Duke University Cooperative Cardiovascular Studies (DUCCS) Investigators. Rationale and design of the Pilot Randomized Study of Nesiritide versus Dobutamine in Heart Failure (PRESERVD-HF). *Am Heart J* 2003;145(2):S55-S58.
159. Zampino M, **O'Connor CM**, Gattis WA, Adams KF, Gheorghiade M. Concomitant use of a positive inotropic agent to create a bridge to the successful initiation of B-blocker therapy in patients with heart failure: A proposal for a trial. *Am Heart J* 2003;142(2):S62-S67.
160. Gheorghiade M, Adams KF, Gattis WA, Teerlink JR, Orlandi C, **O'Connor CM**. Surrogate endpoints in heart failure trials. *Am Heart J* 2003;142(2):S67-S70.
161. Felker GM, **O'Connor CM**. A bridge for the 21<sup>st</sup> century in heart transplantation? *Am Heart J* 2003; Feb 142(2):198-199.
162. Malinin AI, **O'Connor CM**, Dzhanashvili AI, Sane DC, Serebruany VL. Platelet activation in patients with congestive heart failure: Do we have enough evidence to consider clopidogrel? *Am Heart J* 2003;145:397-403.
163. **O'Connor CM**, Gattis WA, Adams KF, Hasselblad V, Chandler B, Frey A, Kobrin I, Rainisio M, Shah MR, Teerlink J, Gheorghiade M, for the RITZ-4 Investigators. Tezosentan in patients with acute heart failure and acute coronary syndromes: Results of the Randomized Intravenous Tezosentan Study (RITZ-4). *J Am Coll Cardiol* 2003; May 7 41(9):1452-1457.
164. Gattis WA, **O'Connor CM**, Leimberger JD, Felker GM, Adams KF, Gheorghiade M. Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure. *Am J Card* 2003;91:169-174.
165. Bourque JM, Velazquez EJ, Borges-Neto S, Shaw LK, Whellan DJ, **O'Connor CM**. Radionuclide viability testing: Should it affect treatment strategy in patients with cardiomyopathy and significant coronary artery disease? *Am Heart J* 2003;145(5):758-767.
166. Lee CR, Watkins ML, Patterson H, Gattis W, **O'Connor CM**, Gheorghiade M, Adams KF. Vasopressin: A new target for the treatment of heart failure. *Am Heart J* 2003;146:9-18.
167. Serebruany VL, Malinin AI, **O'Connor CM**, Gurbel PA. Roxifiban Oral Compound Kinetics Evaluation Trial-I Platelet Substudy. Effects of roxifiban on platelet Aggregation and Major Receptor Evaluation Trial-I Platelet Substudy (ROCKET-I Platelet Substudy). *Am Heart J* 2003;146:91-98.
168. Jiang W, Babyak MA, Rozanski A, Sherwood A, **O'Connor CM**, Waugh RA, Coleman RE, Hanson MW, Morris JJ, Blumenthal JA. Depression and increased myocardial ischemic activity in patients with ischemic heart disease. *Am Heart J* 2003;146:55-61.
169. Gurbel PA, Bliden KP, Hiatt BL, **O'Connor CM**. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. *Circulation* 2003;107:2908-2913.
170. Klein L, **O'Connor CM**, Gattis WA, Zampino M, de Luca L, Vitarelli A, Fedele F, Gheorghiade M. Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations. (Review). *Am J Card* 2003;91:18F-40F.



171. Trichon BH, Felker GM, Shaw LK, Cabell CH, **O'Connor CM**. Relation of frequency and severity of mitral regurgitation to survival among patients with left ventricular systolic dysfunction and heart failure. *Am J Cardiol* 2003;March 1 91(5):538-43.
172. Felker GM, Benza RL, Chandler AB, Leimberger JD, Cuffe MS, Califf RM, Gheorghiade M, **O'Connor CM**. OPTIME-CHF Investigators. Heart failure etiology and response to Milrinone in decompensated heart failure: results from the OPTIME-CHF Study. *J Am Coll Cardiol* 2003; March 19 41(6):997-1003.
173. Bourque JM, Hasselblad V, Velazquez EJ, Borges-Neto S, **O'Connor CM**. Revascularization in patients with coronary artery disease, left ventricular dysfunction, and viability: a meta-analysis. *Am Heart J* 2003;146(4):621-627.
174. Serebruany VL, Malinin AI, Jerome SD, Lowry DR, Morgan AW, Sane DC, Tanguay JF, Steinhubl SR, **O'Connor CM**. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: The Plavix Use for Treatment of Congestive Heart Failure (PLUTO-CHF) trial. *Am Heart J* 2003;146(4):713-720.
175. **O'Connor CM**, Dunne M, Pfeffer MA, Muhlestein JB, Yao L, Gupta S, Benner RJ, Fisher MR, Cook TD, for the Investigators in the WIZARD Study. Azithromycin for the secondary prevention of coronary heart disease events. The WIZARD Study: A randomized controlled trial. *JAMA* 2003;290(11):1459-1466.
176. Joynt KE, Whellan DJ, **O'Connor CM**. Depression and cardiovascular disease: mechanisms of interaction. *Biol Psychiatry* 2003;54(3):248-261. Review
177. Serebruany VL, Glassman AH, Malinin AI, Nemeroff CB, Musselman DL, van Zyl LT, Finkel MS, Krishnan KR, Gaffney M, Harrison W, Califf RM, **O'Connor CM**, Sertraline Anti-Depressant Heart Attack Randomized Trial Study Group. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) platelet substudy. *Circulation* 2003;108(8):939-944.
178. Serebruany VL, Glassman AH, Malinin AI, Atar D, Sane DC, Oshrine BR, Ferguson JJ, **O'Connor CM**. Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin. *Eur J Heart Failure* 2003;5(4):517-521.
179. Hernandez AF, **O'Connor CM**. Sparing a little may save a lot: lessons from the Studies of Left Ventricular Dysfunction (SOLVD). *J Am Coll Cardiol* 2003;42(4):709-711.
180. Felker GM, Gattis WA, Leimberger JD, Adams KF, Cuffe MS, Gheorghiade M, **O'Connor CM**. Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. *Am J Cardiol* 2003;Sept 1 92(5):625-628.
181. Serebruany VL, Glassman AH, Malinin AI, Sane DC, Finkel MS, Krishnan RR, Atar D, Lekht V, **O'Connor CM**. Enhanced platelet/endothelial activation in depressed patients with acute coronary syndromes: evidence from recent clinical trials. *Blood Coagulation Fibrinolysis* 2003;14(6):563-567.
182. Trichon BH, Glower DD, Shaw LK, Cabell CH, Anstrom KJ, Felker GM, **O'Connor CM**. Survival after coronary revascularization, with and without mitral valve surgery, in patients with ischemic mitral regurgitation. *Circulation* 2003;108(supplement 1):I1103-110.

183. Swenson JR, **O'Connor CM**, Barton D, Van Zyl LT, Swedberg K, Forman LM, Gaffney M, Glassman AH: Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) Group. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. *Am J Cardiol* 2003;92(11):1271-1276.
184. Hernandez AF, **O'Connor CM**. AAFP Home Study: A Self-Assessment Program: Epidemiology and definition, cardiac physiology and pathophysiology, diagnosis and Management. In: *Update in Heart Failure*. March 2004;13-15; 21-28;15-17;29-41.
185. Cabell CH, Trichon BH, Velazquez EJ, Dumesnil JG, Anstrom KJ, Ryan T, Miller AB, Belkin RN, Cropp AB, **O'Connor CM**, Jollis JG. Importance of echocardiography in patients with severe nonischemic heart failure: the second Prospective Randomized Amlodipine Survival Evaluation (PRAISE-2) echocardiographic study. *Am Heart J* 2004;147(1):151-157.
186. Forman DE, Butler J, Wang Y, Abraham WT, **O'Connor CM**, Gottlieb SS, Loh E, Massie BM, Rich MW, Stevenson LW, Young JB, Krumholz HM. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. *J Am Coll Cardiol* 2004;43(1):61-67.
187. Whellan DJ, **O'Connor CM**, Piñal. Training trials in heart failure: time to exercise restraint? *Am Heart J* 2004;147(2):190-192.
188. Butler J, Forman DE, Abraham WT, Gottlieb SS, Loh E, Massie BM, **O'Connor CM**, Rich MW, Stevenson LW, Wang Y, Young JB. Relationship between heart failure treatment and development of of worsening renal function among hospitalized patients. *Am Heart J* 2004;147(2):331-338.
189. Hudson MP, **O'Connor CM**, Gattis WA, Tasissa G, Hasselblad V, Holleman CM, Gauden LH, Sedor F, Ohman EM. Implications of elevated cardiac troponin T in ambulatory patients with heart failure: a prospective analysis. *Am Heart J* 2004;147(3):546-552.
190. Joynt KE, Gattis WA, Hasselblad V, Fuzaylov SY, Serebrany VL, Gurbel PA, Gauden LH, Felker GM, Whellan DJ, **O'Connor CM**. Effect of antitensin-converting enzyme inhibitors, beta blockers, statins, and aspirin on C-reactive protein levels in outpatients with heart failure. *Am J Cardiol* 2004; March 15 93(6):783-785.
191. Bourque JM, Velazquez EJ, Borges-Neto S, Shaw LK, Whellan DJ, **O'Connor CM**. Clinical characteristics and referral pattern of patients with left ventricular dysfunction and significant coronary artery disease undergoing radionuclide imaging. *J Nuclear Cardiol* 2004;11(2):118-125.
192. Serebrany VL, Malinin AI, Lowry DR, Sane DC, Webb RL, Gottlieb SO, **O'Connor CM**, Hennekens CH. Effects of valsartan and valeryl 4-hydroxy valsartan on human on platelets: a possible additional mechanism for clinical benefits. *J Cardiovasc Pharmacol* 2004;43(5):677-684.
193. Klein L, Gattis WA, Borrello F, Wu E, **O'Connor CM**, Gheorghide M. Effects of amino acid supplementation on left ventricular remodeling in patients with chronic heart failure with decreased systolic function and diabetes mellitus: rationale and design of a magnetic resonance imaging study. *Am J Cardiol* 2004;93(8A):44A-46A.
194. Massie BM, Krol WF, Ammon SE, Armstrong PW, Cleland JG, Collins JF, Ezekowitz M, Jafri SM, **O'Connor CM**, Packer M, Schulman KA, Teo K, Warren S. The Warfarin and Antiplatelet Therapy in Heart Failure Trial (WATCH): Rationale, design, and baseline patient characteristics. *J Card Failure* 2004;10(2):101-112.

195. Gheorghiade M, Gattis WA, **O'Connor CM**, Adams KF, Elkayam U, Barbagelata A, Ghali JK, Benza RL, McGrew FA, Klapholz M, Ouyang J, Orlandi C, Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. *J Am Med Assoc* 2004; 291(16):1963-1971
196. Gattis WA, **O'Connor CM**, Gallup DS, Hasselblad V, Gheorghiade M: IMPACT-HF Investigators and Coordinators. PredischARGE Initiation of carvedilol in patients hospitalized for decompensated heart failure; results of the initiation management predischARGE: process for assessment of carvedilol therapy in heart failure (IMPACT-HF) trial. *J Am Coll Cardiol* 2004;43(9):1534-1541.
197. **O'Connor CM**, Joynt KE. Depression: are we ignoring an important comorbidity in heart failure? *J Am Coll Cardiol* 2004;43(9):1550-1552.
198. Joynt KE, Whellan DJ, **O'Connor CM**. Why is depression bad for the failing heart? A review of the mechanistic relationship between depression and heart failure. *J Card Failure* 2004;10(3):258-271.
199. Fonarow GC, Abraham WT, Albert NM, Gattis WA, Gheorghiade M, Greenberg B, **O'Connor CM**, Yancy CW, Young J. Organized Program to Initiate Lifesaving Treatment In Hospitalized Patients with Heart Failure (OPTIMIZE-HF): Rationale and design. *Am Heart J* 2004;148(1):43-51.
200. Harrington RA, Becker RC, Ezekowitz M, Meade TW, **O'Connor CM**, Vorchheimer DA, Guyatt GH. Antithrombotic therapy for coronary artery disease. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest* 2004;126:513S-548S.
201. Hedayati SS, Jiang W, **O'Connor CM**, Kuchibhatla M, Krishnan KR, Cuffe MS, Blazing MA, Szczech LA. The association between depression and chronic kidney disease and mortality among patients hospitalized with congestive heart failure. *Am J Kidney Dis* 2004;44:207-215.
202. Aguilar D, Solomon SD, Kober L, Rouleau JL, Skali H, McMurray JJV, Francis GS, Henis M, **O'Connor CM**, Diaz R, Belenkov YN, Varshavsky S, Leimberger JD, Velazquez EJ, Califf RM, Pfeffer MA. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction (VALIANT) Trial. *Circulation* 2004;110:1572-1578.
203. Hernandez AF, Whellan DJ, Stroud S, Sun JL, **O'Connor CM**, Jollis JG. Outcomes in heart failure patients after major noncardiac surgery. *J Am Coll Cardiol* 2004;44:1446-1453.
204. Velazquez EJ, Francis GS, Armstrong PW, Aylward PE, Diaz R, **O'Connor CM**, White HD, Henis M, Rittenhouse LM, Kilaru R, van Gilst W, Ertl G, Maggioni AP, Spac J, Weaver WD, Rouleau JL, McMurray JJV, Pfeffer MC, Califf RM. An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT Registry. *Eur Heart J* 2004;25(21):1911-1919.
205. Serebruany VL, Midei MG, Malinin AI, Oshrine BR, Lowry DR, Sane DC, Tanguay JF, Steinhubl SR, Berger PB, **O'Connor CM**, Hennekens CH. Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study. *Arch Intern Medicine* 2004;164(18):2051-7.
206. Hernandez AF, Newby LK, **O'Connor CM**. Preoperative evaluation for major noncardiac surgery: focusing on heart failure. *Arch Intern Med* 2004;164(16):1729-1736.
207. Felker GM, Adams KF Jr, Gattis WA, **O'Connor CM**. Anemia as a risk factor and therapeutic target in heart failure. *J Am Coll Cardiol* 2004;44(5):959-966. Review

208. Benza RL, Tallaj JA, Felker GM, Zabel KM, Kao W, Bourge RC, Pearce D, Leimberger JD, Borzak S, **O'Connor CM**, Gheorghiade M; OPTIME-CHF Investigators. The impact of arrhythmias in acute heart failure. *J Cardiac Failure* 2004;10(4):279-287.
209. Carney FM, Freedland KE, Jaffe AS, Frasure-Smith N, Lesperance F, Sheps DS, Glassman AH, **O'Connor CM**, Blumenthal JA, Kaufman PG, Czajkowski SM. Depression as a risk factor for post-MI mortality. *J Am Coll Cardiol* 2004;44(2):472-474.
210. East MA, Peterson ED, Shaw LK, Gattis WA, **O'Connor CM**. Racial differences in the outcomes of patients with diastolic heart failure. *Am Heart J* 2004;148(1):151-156.
211. Gattis WA, **O'Connor CM**, Hasselblad V, Adams KF Jr, Kobrin I, Gheorghiade M. Usefulness of an elevated troponin-I in predicting clinical events in patients admitted with acute heart failure and acute coronary syndrome (from the RITZ-4 Trial). *Am J Cardiol* 2004; 93(11): 1436-1437.
212. Gattis WA, **O'Connor CM**. PredischARGE initiation of carvedilol in patients hospitalized for decompensated heart failure. *Am J Cardiol* 2004;6:93(9A):74B-76B.
213. Al-Khatib SM, Shaw LK, Lee KL, **O'Connor C**, Califf CM. Is rhythm control superior to rate control in patients with atrial fibrillation and congestive heart failure? *Am J Cardiol* 2004; 94(6):797-800.
214. Felker GM, Leimberger JD, Califf RM, Cuffe MS, Massie BM, Adams KF, Jr, Gheorghiade M, **O'Connor CM**. Risk stratification after hospitalization for decompensated heart failure. *J Cardiac Failure* 2004;10(6):460-466.
215. Jiang W, Kuchibhatla M, Cuffe MS, Christopher EJ, Alexander JD, Clary GL, Blazing MA, Gaulden LH, Califf RM, Krishnan RR, **O'Connor CM**. Prognostic value of anxiety and depression in patients with chronic heart failure. *Circulation* 2004;110(22):3452-3456.
216. Al-Khatib SM, Anstrom KJ, Eisenstein EL, Peterson ED, Jollis JG, Mark DB, **O'Connor CM**, Shaw LK, Califf RM. Clinical and Economic Implications of the Multicenter Automatic Defibrillator Implantation Trial-II. *Annals Int Med* 2005;142:593-600.
217. Whellan DJ, Hasselblad V, Peterson E, **O'Connor CM**, Schulman KA. Metaanalysis and review of heart failure disease management randomized controlled clinical trials. *Am Heart J* 2005;149(4):722-729.
218. Teerlink JR, McMurray JJV, Bourge RC, Cleland JGF, Cotter G, Jondeau G, Krum H, Metra M, **O'Connor CM**, Parker JD, Torre-Amione G, Van Veldhuisen DJ, Frey A, Rainisio M, Kobrin I, and VERITAS Investigators. Tezosentan in patients with acute heart failure: Design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute Heart Failure Study (VERITAS). *Am Heart J* 2005;150(1):46-53.
219. Jiang W, Glassman A, Krishnan R, **O'Connor CM**, Califf RM. Depression and ischemic heart disease: What have we learned so far and what must we do in the future. *Am Heart J* 2005;150(1):54-78.
220. **O'Connor CM**, Gottlieb S, Bourque JM, Krause-Steinrauf H, Anand I, Anderson JL, Plehn JF, Silver MA, White M, Carson P, and the BEST Investigators. Impact of nonfatal myocardial infarction on outcomes in patients with advanced heart failure and the effect of bucindolol therapy. *Am J Cardiol* 2005;95(5):558-564.

221. **O'Connor CM**, Glassman AH, Harrison DJ. Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. *J Clin Psychiatry* 2005;66(3):346-352.
222. **O'Connor CM**, Stough WG, Gallup DS, Hasselblad V, Gheorghiade M. Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT-HF registry. *J Cardiac Failure* 2005;11(3):200-205.
223. Klein L, **O'Connor CM**, Leimberger JD, Gattis-Stough W, Piñal L, Felker GM, Adams KF, Jr., Califf RM, Gheorghiade M; OPTIME-CHF Investigators. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. *Circulation* 2005;111(19):2454-2460.
224. Serebruany VL, Suckow RF, Cooper TB, **O'Connor CM**, Malinin AI, Krishnan KR, van Zyl LT, Lekht V, Glassman AH. Sertraline Antidepressant Heart Attack Randomized Trial. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethysertraline in acute coronary syndrome patients receiving SSRI treatment for depression. *Am J Psychiatry* 2005;162(6):1165-1170.
225. Adams KF Jr, Patterson JH, Gattis WA, **O'Connor CM**, Lee CR, Schwartz TA, Gheorghiade M. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. *J Am Coll Cardiol* 2005;2:46(3) 497-504.
226. Felker GM, Stough WG, Shaw LK, **O'Connor CM**. Anemia and coronary artery disease severity in patients with heart failure. *Eur Heart J* 2005;Aug 18
227. Carson P, Anand I, **O'Connor CM**, Jaski B, Steinberg J, Lwin A, Lindenfeld J, Ghali J, Barnet JH, Feldman AM, Bristow MR. Mode of death in advanced heart failure: The Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial. *J Am Coll Cardiol* 2005;46(12):2329-2334.
228. Shah MR, Claise KA, Bowers MT, Bhapkar M, Little J, Nohria A, Gaulden LH, Mckee VK, Cozart KL, Mancinelli KL, Daniels H, Kinard T, Stevenson LW, Mancini DM, **O'Connor CM**, Califf RM. Testing new targets of therapy in advanced heart failure: the design and rationale of the strategies for tailoring advanced heart failure regimens in the outpatient setting: Brain Natriuretic Peptide Versus the Clinical Congestion Score (STARBRITE). *Am Heart J* 2005;150(893-898).
229. Hernandez AF, Velazquez EJ, Solomon SD, Kilaru R, Diaz R, **O'Connor CM**, Ertl G, Maggioni AP, Rouleau JL, van Gilst W, Pfeffer MA, Califf RM; VALIANT Registry. Left ventricular assessment in myocardial infarction: the VALIANT registry. *Arch Intern Med* 2005;165(18):2162-2169.
230. Serebruany VL, **O'Connor CM**, Krishnan RR, Hennekens CH. Hypothesis: antiplatelet effects of selective serotonin reuptake inhibitors cause clinical benefits on cardiovascular disease and increase risks of bleeding. *J Cardiovasc Pharmacol Ther* 2005;10(3):163-164.
231. Shah MR, Hasselblad V, Stevenson LW, Binanay C, **O'Connor CM**, Sopko G, Califf RM. Impact of the pulmonary artery catheter in critically ill patients: meta-analysis of randomized clinical trials. *J Am Med Assoc* 2005;294(13):1664-1670.
232. Binanay C, Califf RM, Hasselblad V, **O'Connor CM**, Shah MR, Sopko G, Stevenson LW, Francis GS, Leier CV, Miller LW; ESCAPE Investigators and ESCAPE Study Coordinators.

Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: The ESCAPE trial. *J Am Med Assoc* 2005;294(13):1625-1633.

233. Thomas KL, East MA, Velazquez EJ, Tuttle RH, Shaw LK, **O'Connor CM**, Peterson ED. Outcomes by race and etiology of patients with left ventricular systolic dysfunction. *Am J Cardiol* 2005;96(7):956-963.
234. Stough WG, **O'Connor CM**, Gheorghiade M. Overview of current noninodilator therapies for acute heart failure syndromes. *Am J Cardiol* 2005;96(6A):41G-46G. Review.
235. Gheorghiade M, Gattis Stough W, Adams KF Jr, Jaffe AS, Hasselblad V, **O'Connor CM**. The Pilot Randomized Study of Nesiritide versus Dobutamine in Heart Failure (PRESERVD-HF). *Am J Cardiol* 2005;96(6A):18G-25G.
236. Joynt KE, **O'Connor CM**. Lessons from SADHART, ENRICHHD, and other trials. *Psychosom Med* 2005;67(suppl 1):S63-S66.
237. Evans DL, Charney DS, Lewis L, Golden RN, Gorman RN, Gorman JM, Krishnan KR, Nemeroff CB, Bremner JD, Carney RM, Coyne JC, DeLong MR, Frasure-Smith N, Glassman AH, Gold PW, Grant I, Gwyther L, Ironson G, Johnson RL, Kanner AM, Katon WJ, Kauffman PG, Keefe FJ, Ketter T, Laughren TP, Leserman J, Lyketsos CG, McDonald WM, McEwen BS, Miller AH, Musselman D, **O'Connor CM**, Petitto JM, Pollock BG, Robinson RG, Roose SP, Rowland J, Sheline Y, Sheps DS, Simon G, Spiegel D, Stunkard A, Sunderland T, Tibbits PJr, Valvo WJ. Mood disorders in the medically ill: scientific review and recommendations. *Biol Psych* 2005;58(3):175-189.
238. Felker GM, Stough WG, Shaw LK, **O'Connor CM**. Anaemia and coronary artery disease severity in patients with heart failure. *Eur J Heart Fail* 2006(1):54-57.
239. Bourque JM, **O'Connor CM**, Velazquez EJ. Letter by Bourque et al regarding article, "Changing incidence and survival for heart failure in a well-defined older population, 1970-1974 and 1990-1994". *Circulation* 2006;114(7):e255.
240. Whellan DJ, Tuttle RH, Velazquez EJ, Shaw LK, Jollis JG, Ellis W, **O'Connor CM**, Califf RM, Borges-Neto S. Predicting significant coronary artery disease in patients with left ventricular dysfunction. *Am Heart J* 2006;152(2):340-347.
241. Aguilar D, Fisher MR, **O'Connor CM**, Dunne MW, Muhlestein JB, Yao L, Gupta S, Brenner RJ, Cook TD, Edwards D, Pfeffer MA; Investigators in the Weekly Intervention with Zithromax for Atherosclerosis and its Related Disorder Study. Metabolic syndrome, C-reactive protein, and prognosis in patients with established coronary artery disease. *Am Heart J* 2006;152(2):298-304.
242. Weaver WD, Finn PV, White HD, Marin-Neto JA, **O'Connor CM**, Pfeffer MA, Califf RM, Solomon SD; VALIANT Investigators. Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. *Am Heart J* 2006;152(1):183-189.
243. Jaffe AS, Krumholz HM, Catellier DJ, Freedland KE, Bittner V, Blumenthal JA, Calvin JE, Norman J, Sequeira R, **O'Connor CM**, Rich MW, Sheps D, Wu C; Enhancing Recovery in Coronary Heart Disease Patients (ENRICHHD) Trial Investigators. Prediction of medical morbidity and mortality after acute myocardial infarction in patients at increased psycho-social risk in the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHHD) study. *Am Heart J* 2006;152(1):126-135.

244. Xiong GL, Jiang W, Clare R, Shaw LK, Smith PK, Mahaffey KW, **O'Connor CM**, Krishnan KR, Newby LK. Prognosis of patients taking selective serotonin reuptake inhibitors before coronary artery bypass grafting. *Am J Cardiol* 2006;98(1):42-47.
245. Butler J, Young JB, Abraham WT, Bourge RC, Adams KF Jr, Clare R, **O'Connor CM**; ESCAPE Investigators. Beta-blocker use and outcomes among hospitalized heart failure patients. *J Am Coll Cardiol* 2006;47(12):2462-2469.
246. Cohn JN, Carson PE, **O'Connor CM**, Opasich C, PiñalL, Scherillo M, Sinagra G, Warner-Stevenson L, Tristani FE, Volpi A. Prognosis and mechanism of death in treated heart failure: data from the placebo arm of Val-HeFT. *Congest Heart Fail* 2006;12(3):127-131.
247. Wagoner LE, Starling RC, **O'Connor CM**. Cardiac function and heart failure. *J Am Coll Cardiol* 2006;47(11):D18-D22. Review.
248. Packer M, Abraham WT, Mehra MR, Yancy CW, Lawless CE, Mitchell JE, Smart FW, Bijou R, **O'Connor CM**, Masie BM, PiñalL, Greenberg BH, Young JB, Fishbein DP, Hauptman PJ, Bourge RC, Strobeck JE, Murali S, Shocken D, Teerlink JR, Levy WC, Trupp RJ, Silver MA; Prospective Evaluation and Identification of Cardiac Decompensation by ICG Test (PREDICT) Study Investigators and Coordinators. Utility of impedance cardiography for the identification of short-term risk of clinical decompensation in stable patients with chronic heart failure. *J Am Coll Cardiol* 2006;47(11):2245-2252.
249. Felker GM, Shaw LK, Stough WG, **O'Connor CM**. Anemia in patients with heart failure and preserved systolic function. *Am Heart J* 2006;151(2):457-462.
250. Davidson RM, McNeer JF, Logan L, Higginbotham MB, Anderson J, Blackshear J, Chu A, Hettleman B, McGrew F, Meese R, **O'Connor CM**, Schneider R, Wagner GS; EXERDUCCS Investigators. A cooperative network of trained sites for the conduct of a complex clinical trial: a new concept in multicenter clinical research. *Am Heart J* 2006;151(2):451-456.
251. Douglas P, Harrington RA, **O'Connor CM**, Stein JH, Wolff MR. President's page: New York 1952 to Atlanta 2006: celebrating the cardiovascular community. *J Am Coll Cardiol* 2006;47(1):203-204.
252. Serebruany VL, Pokov AN, Malinin AI, **O'Connor CM**, Bhatt DL, Tanguay JF, Sane DC, Hennekens CH. Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial. *Am Heart J* 2006;151(1):92-99.
253. Allen LA, **O'Connor CM**. Management of acute decompensated heart failure. *CMAJ* 2007;176(6):797-805.
254. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghide M, Greenberg BH, **O'Connor CM**, Sun JL, Yancy C, Young JB, on behalf of the OPTIMIZE-HF Investigators and Coordinators. Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: An analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). *Am Heart J* 2007;153(1):82-89.
255. Gheorghide M, Abraham WT, Albert NM, Greenberg BH, **O'Connor CM**, She L, Stough WG, Yancy CW, Young JB, Fonarow GC; OPTIMIZE-HF Investigators and Coordinators. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. *J Am Med Assoc* 2006;8:296(18):2217-2226.
256. Echols MR, Felker GM, Thomas KL, Pieper KS, Garg J, Cuffe MS, Georghide M, Califf RM, **O'Connor CM**. Racial differences in the characteristics of patients admitted for acute

decompensated heart failure and their relation to outcomes: results from the OPTIME-CHF Trial. *J Cardiac Fail* 2006;12(9):684-688.

257. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, **O'Connor CM**, Sun JL, Yancy C, Young JB; OPTIMIZE-HF Investigators and Coordinators. Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: an analysis from Organized Program to Initiate Lifesaving Treatment In Hospitalized Patients with Heart Failure (OPTIMIZE-HF). *Am Heart J* 2007;153(1):82e1-11.
258. Milo-Cotter O, Adams KF, **O'Connor CM**, Uriel N, Kaluski E, Felker GM, Weatherley B, Vered Z, Cotter G. Acute heart failure associated with high admission blood pressure: a distinct vascular disorder? *Eur J Hear Fail* 2007; Feb 9 (2):178-183.
259. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, **O'Connor CM**, Pieper K, Sun JL, Yancy C, Young JB: OPTIMIZE-HF Investigators and Hospitals. Association between performance measures and clinical outcomes for patients hospitalized with heart failure. *J Am Med Assoc* 2007;297(1):61-70.
260. Whellan DJ, Reed SD, Liao L, Gould SD, **O'Connor CM**, Schulman KA. Financial implications of a model heart failure disease management program for providers, hospital, healthcare systems, and payer perspectives. *Am J Cardiol* 2007;99(2):256-260.
261. Whellan DJ, **O'Connor CM**, Lee KL, Keteyian SJ, Cooper LS, Ellis SJ, Leifer ES, Kraus WE, Kitzman DW, Blumenthal JA, Rendall DS, Houston-Miller N, Fleg JL, Schulman KA, Piñal L; HF-ACTION Trial Investigators. Heart failure and a controlled trial investigating Outcomes of exercise training (HF-ACTION): design and rationale. *Am Heart J* 2007;153(2):201-211.
262. Malinin AI, Oshrine BR, Sane DC, **O'Connor CM**, Serebruany VL. Does heart failure etiology, New York Heart Association class, or ejection fraction affect the ability of clopidogrel to inhibit heightened platelet activity? *Blood Coagul Fibrinolysis* 2007;18(2):91-96.
263. Gheorghiade M, Abraham WT, Albert NM, Gattis Stough W, Greenberg BH, **O'Connor CM**, She L, Yancy CW, Young J, Fonarow GC; OPTIMIZE-HF Investigators and Coordinators. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF Registry. *Eur Heart J* 2007;28(8):980-988.
264. Sherwood A, Blumenthal JA, Trivedi R, Johnson KS, **O'Connor CM**, Adams KF Jr, Dupree CS, Waugh RA, Bensimhon DR, Gaulden L, Christenson RH, Koch GG, Hinderliter AL. Relationship of depression to death or hospitalization in patients with heart failure. *Arch Intern Med* 2007;167(4):367-373.
265. Bourque JM, Velazquez EJ, Tuttle RH, Shaw LK, **O'Connor CM**, Borges-Neto S. Mortality risk associated with ejection fraction differs across resting nuclear perfusion findings. *J Nucl Cardiol* 2007;14(2):165-173.
266. **O'Connor CM**. The new heart failure guidelines: strategies for implementation. *Am Heart J* 2007;153(4):2-5
267. Phillips HR, **O'Connor CM**, Rogers J. Revascularization for heart failure. *Am Heart J* 2007;153(4):65-73.
268. Albert NM, Fonarow GC, Abraham WT, Chiswell K, Stough WG, Gheorghiade M, Greenberg BH, **O'Connor CM**, Sun JL, Yancy CW, Young JB. Predictors of delivery of hospital-based heart failure patient education: a report from OPTIMIZE-HF. *J Card Failure* 2007;13(3):189-198.



269. Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL Jr, Kaplan NM, **O'Connor CM**, O'Gara PT, Oparil S: American Heart Association Council for High Blood Pressure Research; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Epidemiology and Prevention. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils On Clinical Cardiology and Epidemiology and Prevention. *Circulation* 2007;115(21):2761-2788.
270. Fonarow GC, Yancy CW, Albert NM, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, Mehra M, **O'Connor CM**, Reynolds D, Walsh MN. Improving the use of evidence-based heart failure therapies in the outpatient setting: the IMPROVE-HF performance improvement registry. *Am Heart J* 2007;154(1):12-38.
271. Bensimhon DR, Adams GL, Whellan DJ, Pagnanelli RA, Trimble M, Lee BA, Lee KL, Ellis SJ, Kraus WE, Rendall DS, Iskandrian AE, **O'Connor CM**, Borges-Neto S: HF-ACTION Investigators. Effect of exercise training on ventricular function, dyssynchrony, resting myocardial perfusion, and clinical outcomes in patients with heart failure: a nuclear ancillary study of Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION): design and rationale. *Am Heart J* 2007;154(1):46-53.
272. Jiang W, Kuchibhatla M, Claryu GL, Cuffe MS, Christopher EJ, Alexander JD, Califf RM, Krishnan RR, **O'Connor CM**. Relationship between depressive symptoms and long-term mortality in patients with heart failure. *Am Heart J* 2007;154(1):102-108.
273. Greenberg BH, Abraham WT, Albert NM, Chiswell K, Clare R, Stough WG, Gheorghiade M, **O'Connor CM**, Sun JL, Yancy CW, Young JB, Fonarow GC. Influence of diabetes on characteristics and outcomes in patients hospitalized with heart Hospitalized Patients with Heart Failure (OPTIMIZE-HF). *Am Heart J* 2007;154(2):277.e.-278.
274. Fonarow GC, Abraham WT, Albert NM, Gattis Stough W, Gheorghiade M, Greenberg BH, **O'Connor CM**, Pieper K, Sun JL, Yancy CW, Young JB; OPTIMIZE-HF Investigators and Hospitals. Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). *Arch Intern Med* 2007;167(14):1493-1502.
275. Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, **O'Connor CM**, Sun JL, Yancy CW, Young JB; OPTIMIZE-HF Investigators and Hospitals. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. *J Am Coll Cardiol* 2007;50(8):768-777.
276. Hasselblad V, Gattis Stough W, Shah MR, Lokhnygina Y, **O'Connor CM**, Califf RM, Adams KF Jr. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. *Eur J Heart Fail* 2007;10:1064-1069.
277. **O'Connor CM**, Arumugham P. Inotropic drugs and neurohormonal antagonists in the treatment of HF in the elderly. *Heart Fail Clinics* 2007;3(4):477-484.
278. Gheorghiade M, Rossi JS, Cotts W, Shin DD, Hellkamp AS, PiñalL, Fonarow GC, DeMarco T, Pauly DF, Rogers J, DiSalvo TG, Butler J, Hare JM, Francis GS, Stough WG, **O'Connor CM**. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial. *Arch Intern Med* 2007;167;(18):1998-2005.
279. Shah MR, Hasselblad V, Tasissa G, Christenson RH, Binanay C, **O'Connor CM**, Ohman EM, Stevenson LW, Califf RM. Rapid assay brain natriuretic peptide and troponin I in patients

hospitalized with decompensated heart failure (from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness Trial). *Am J Cardiol* 2007;100(9):1427-1433.

280. McMurray JJ, Teerlink JR, Cotter G, Bourge RC, Cleland JG, Jondeau G, Krum H, Metra M, **O'Connor CM**, Parker JD, Torre-Amione G, van Veldhuisen DJ, Lewsey J, Frey A, Rainisio M, Kobrin I; VERITAS Investigators. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. *J Am Med Assoc* 2007;298(17):2009-2019.
281. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, **O'Connor CM**, Sun JL, Yancy CW, Young JB; OPTIMIZE-HF Investigators and Coordinators. Prospective evaluation of beta-blocker use at the time of hospital discharge as a heart failure performance measure: results from OPTIMIZE-HF. *J Card Fail* 2007;13(9):722-731.
282. Velazquez EJ, Lee KL, **O'Connor CM**, Oh JK, Bonow RO, Pohost GM, Feldman AM, Mark DB, Panza JA, Sopko G, Rouleau JL, Jones RH; STICH Investigators. The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial. *J Thorac Cardiovasc Surg* 2007;134(6):1540-1547.
283. Cotter G, Felker GM, Adams KF, Milo-Cotter O, **O'Connor CM**. The pathophysiology of acute heart failure—is it all about fluid accumulation? *Am Heart J* 2008;155(1):9-18.
284. Young JB, Abraham WT, Albert NM, Gattis Stough W, Gheorghiade M, Greenberg BH, **O'Connor CM**, She L, Sun JL, Yancy CW, Fonarow GC; OPTIMIZE-HF Investigators and Coordinators. Relationship of low hemoglobin and anemia to morbidity and mortality in patients hospitalized with heart failure (Insight from the OPTIMIZE-HF Registry). *Am J Cardiol* 2008;101(2):223-230.
285. Milo-Cotter O, Cotter G, Weatherley BD, Adams KF, Kaluski E, Uriel N, **O'Connor CM**, Felker GM. Hyponatraemia in acute heart failure is a marker of increased mortality but not when associated with hyperglycaemia. *Eur J Heart Fail* 2008 Feb;10(2):196-200.
286. Hammill BG, Curtis LH, Bennett-Guerrero E, **O'Connor CM**, Jollis JG, Schulman KA, Hernandez AF. Impact of heart failure on patients undergoing major noncardiac surgery. *Anesthesiology* 2008 April;108(4):559-567.
287. Shah MR, Whellan DJ, Peterson ED, Nohria A, Hasselblad V, Xue Z, Bowers MT, **O'Connor CM**, Califf RM, Stevenson LW. Delivering heart failure disease management in 3 tertiary centers: key clinical components and venues of care. *Am Heart J* 2008 April;155(4):764.e1-5.
288. Yancey CW, Abraham WT, Albert NM, Clare R, Stough WG, Gheorghiade M, Greenberg BH, **O'Connor CM**, She L, Sun JL, Young JB, Fonarow GC. Quality of care and outcomes for African Americans hospitalized with heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) registry. *J Am Coll Cardiol* 2008 April 29;59(17):1675-1684
289. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, **O'Connor CM**, Pieper K, Sun JL, Yancy CW, Young JB; OPTIMIZE-HF Investigators and Hospitals. Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. *Arch Intern Med* 2008 April 28;168(8):847-854.
290. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, **O'Connor CM**, Nunez E, Yancy CW, Young JB. A smoker's paradox in patients hospitalized for heart failure: findings from OPTIMIZE-HF. *Eur Heart J* 2008 August 29(16):1983-1991.

291. Allen LA, Yager JE, Funk MJ, Levy WC, Tulskey JA, Bowers MT, Dodson GC, **O'Connor CM**, Felker GM. Discordance between patient-predicted and model-predicted life expectancy among ambulatory patients with heart failure. *J Am Med Assoc* 2008 June 4;299(21):2533-2542.
292. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorgiade M, Greenberg BH, **O'Connor CM**, Sun JL, Yancy CW, Young JB; OPTIMIZE-HF Investigators and Coordinators. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF Program. *J Am Coll Cardiol* 2008 July 15;52(3):190-199.
293. Becker RC, Meade TW, Berger PB, Ezekowitz M, **O'Connor CM**, Vorchheimer DA, Guyatt GH, Mark DB, Harrington RA; American College of Chest Physicians. The primary and Secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8<sup>th</sup> Edition). *Chest* 2008 June;133(6 suppl):776S-814S.
294. Abraham WT, Fonarow GC, Albert NM, Stough WG, Gheorghide M, Greenberg BH, **O'Connor CM**, Sun JL, Yancy CW, Young JB; OPTIMIZE-HF Investigators and Coordinators. Predictors of in-hospital mortality in patients hospitalized for heart failure: Insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). *J Am Coll Cardiol* 2008 July 29;59(5):347-356.
295. Bensimhon DR, Leifer ES, Ellis SJ, Fleg JL, Keteyian SJ, Piñall, Kitzman DW, McKelvieRS, Kraus WE, Forman DE, Kao AJ, Whellan DJ, **O'Connor CM**, Russell SD; HF-ACTION Trial Investigators. Reproducibility of peak oxygen uptake and other cardiopulmonary exercise testing parameters in patients with heart failure (from the Heart Failure and A Controlled Trial Investigating Outcomes of exercise trainiNg). *Am J Cardiol* 2008 September 15;102(6):717-717.
296. **O'Connor CM**, Abraham WT, Albert NM, Clare R, Gattis Stough W, Gheorgiade M, Greenberg BH, Yancy CW, Young JB, Fonarow GC. Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). *Am Heart J* 2008 October;156(4):662-673.
297. Cotter G, Dittrich HC, Weatherley BD, Bloomfield DM, **O'Connor CM**, Metra M, Massie BM; PROTECT Steering Committee, Investigators, and Coordinators. The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. *J Cardiac Failure* 2008 October;14(8):631-640.95
298. Allen LA, Rogers JG, Warnica JW, Disalvo TG, Tasissa G, Binanay C, **O'Connor CM**, Califf RM, Leier CV, Shah MR, Stevenson LW; ESCAPE Investigators and Coordinators. High mortality without ESCAPE: the registry of heart failure patients receiving pulmonary artery catheters without randomization. *J Cardiac Failure* 2008 October;14(8):661-669.
299. Allen LA, Metra M, Milo-Cotter O, Filippatos G, Reisin LH, Bensimhon DR, Gronda EG, Colombo P, Felker GM, Cas LD, Kremastnos DT, **O'Connor CM**, Gotter G, Davison BA, Dittrich HC, Velazquez EJ. Improvements in signs and symptoms during hospitalization for acute heart failure follow different patterns and depend on the measurement scales used: An international, prospective registry to evaluate the evolution of measures of disease severity in acute heart failure (MEASURE-AHF). *J Cardiac Failure* 2008 November;14(9):777-784.
300. **O'Connor CM**, Jiang W, Kuchibhatla M, Mehta RH, Clary GL, Cuffe MS, Christopher EJ, Alexander JD, Califf RM, Krishnan RR. Antidepressant use, depression, and survival in patients with heart failure. *JAMA Internal Medicine formerly Arch Intern Med* 2008 November 10;168(20):2232-2237.

301. Rossi JS, Flaherty JD, Fonarow GC, Nunez E, Gattis Stough W, Abraham WT, Albert NM, Greenberg BH, **O'Connor CM**, Yancy CW, Davidson CJ, Gheorghiade M. Influence of coronary artery disease and coronary revascularization status on outcome in patients acute heart failure syndromes: a report from OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure). *Eur J Heart Failure* 2008 December ; 10(12):1215-1223.
302. Stevenson LW, Hellkamp AS, Leier CV, Sopko G, Koelling T, Warnica JW, Abraham WT, Kasper EK, Rogers JG, Califf RM, Schramm EE, **O'Connor CM**. Changing preferences for survival after hospitalization with advanced heart failure. *J Am Coll Cardiol* 2008 November 18;52(21): 1702-1708.
303. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, **O'Connor CM**, Sun JL, Yancy CW, Young JB. Dosing of beta blocker therapy before, during, and after hospitalization for heart failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure). *Am J Cardiol* 2008 December 1;102 (11):1524-1529.
304. Hernandez AF, Shea AM, Milano CA, Rogers JG, Hammill BG, **O'Connor CM**, Schulman KA, Peterson ED, Curtis LH. Long-term outcomes and costs of ventricular assist devices among Medicare beneficiaries. *J Am Med Assoc* 2008 November 26;300(20):2398-2406.
305. Hauptman PJ, Rich MW, Heidenreich PA, Chin J, Cummings N, Dunlap ME, Edwards ML, Gregory D, **O'Connor CM**, Pezzella SM, Philbin E; Heart Failure Society of America. The Heart failure clinic: a consensus statement of the Heart Failure Society of America. *J Cardiac Failure* 2008 December 14;(10):801-815.
306. Whellan DJ, **O'Connor CM**, Ousdigian KT, Lung TH; PARTNERS-HF Study Investigators. Rationale, design, and baseline characteristics of a Program to Assess and Review Trend Information and Evaluate CorRelation to Symptoms in Patients with Heart Failure (PARTNERS HF). *Am Heart J* 2008 November; 156(5):833-839.
307. Mehta RH, Rogers JG, Hasselblad V, Tasissa G, Binanay C, Califf RM, **O'Connor CM**; Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) Trial Investigators. Association of weight change with subsequent outcomes in patients hospitalized with acute decompensated heart failure. *Am J Cardiol* 2009 Jan 1; 103(1):76-81.
308. Hernandez AF, Hammill BG, **O'Connor CM**, Schulman KA, Curtis LH, Fonarow GC. Clinical Effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. *J Am Coll Cardiol* 2009 January 13;53(2):184-192.
309. Fiuzat M, Felker GM, Donahue M, **O'Connor CM**. Using Genetic Information to Select Treatment for Heart Failure – Has the Time Come? *Personalized Medicine*. July 2009.6(4):385-392.
310. Ezekowitz JA, Hernandez AF, Starling RC, Yancy CW, Massie B, Hill JA, Krum H, Diaz R, Ponikowski P, Metra M, Howlett JG, Gennevois D, **O'Connor CM**, Califf RM, Fonarow GC. Standardizing care for acute decompensated heart failure in a large megatrial: the approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF). *Am Heart J* 2009 February; 157(2):219-228.
311. Hernandez AF, **O'Connor CM**, Starling RC, Reist CJ, Armstrong PW, Dickstein K, Lorenz TJ, Gibler WB, Hasselblad V, Komajda M, Massie B, McMurray JJ, Nieminen M, Rouleau JL, Swedberg K, Califf RM. Rationale and design of the Acute Study of Clinical Effectiveness of

Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). *Am Heart J* 2009 Feb;157(2):271-277.

312. Massie BM, Collins JF, Ammon SE, Armstrong PW, Cleland JG, Ezekowitz M, Jafri SM, Krol WF, **O'Connor CM**, Schulman KA, Teo K, Warren SR; WATCH Trial Investigators. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. *Circulation* 2009 March 31; 119(12):1616-1624.
313. Jones RH, Velazquez EJ, Michler RE, Sopko G, Oh JK, **O'Connor CM**, Hill JA, Menicanti L, Sadowski Z, Desvigne-Nickens P, Rouleau JL, Lee KL; STICH Hypothesis 2 Investigators. Coronary bypass surgery with or without surgical ventricular reconstruction. *New Engl J Med* 2009 April 23;360(17):1705-1717.
314. Yancy CW, Fonarow GC, Albert NM, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, McBride ML, Mehra MR, **O'Connor CM**, Reynolds D, Walsh MN. Influence of patient age and sex on delivery of guideline-recommended heart failure care in the outpatient cardiology practice setting: findings from IMPROVE-HF. *Am Heart J* 2009 April;157(4):754-762.
315. Albert NM, Fonarow GC, Abraham WT, Gheorghiade M, Greenberg BH, Nunez E, **O'Connor CM**, Stough WG, Yancy CW, Young JB. Depression and clinical outcomes in heart failure: an OPTIMIZE-HF analysis. *Am J Med* 2009 April ; 122(4):366-373.
316. Piccini JP, Berger JS, **O'Connor CM**. Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials. *Eur Heart J* 2009 May; 30(10):1245-1253.
317. **O'Connor CM**, Whellan DJ, Lee KL, Keteyian SJ, Cooper LS, Ellis SJ, Leifer ES, Kraus WE, Kitzman DW, Blumenthal JA, Rendall DS, Miller NH, Fleg JL, Schulman KA, McKelvie RS, Zannad F, PiñalL; HF-ACTION Investigators. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. *J Am Med Assoc* 2009 April 8;301(14):1439-1450.
318. Flynn KE, PiñalL, Whellan DJ, Lin L, Blumenthal JA, Ellis SJ, Fine LJ, Howlett JG, Keteyian SJ, Kitzman DW, Kraus WE, Miller NH, Schulman KA, Spertus JA, **O'Connor CM**, Weinfurt KP. Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. *J Am Medical Assoc* 2009 April 8;301(14):1451-1459.
319. Milo-Cotter O, Cotter G, Kaluski E, Rund MM, Felker GM, Adams KF, **O'Connor CM**, Weatherley BD. Rapid clinical assessment of patients with acute heart failure: first blood pressure and oxygen saturation –is that all we need? *Cardiology* 2009;114(1):75-82.
320. Adams KF Jr., Patterson JH, Oren RM, Mehra MR, **O'Connor CM**, PiñalL, Miller AB, Chiong JR, Dunlap SH, Cotts WG, Felker GM, Shocken D, Schwartz TA, Ghali JK: STAMINA-HFP Registry Investigators. Prospective assessment of the occurrence of anemia in patients with heart failure: results from the Study of Anemia in a Heart Failure Population (STAMINA-HFP). *Am Heart J* 2009 May;157(5):926-932.
321. Gheorghiade M, Adams KF, Cleland JG, Cotter G, Felker GM, Filippatos GS, Fonarow GC, Greenberg BH, Hernandez AF, Khan S, Komajda M, Konstam MA, Liu PP, Maggioni ASP, Massie BM, McMurray JJ, Mehra M, Metra M, O'Connell J, **O'Connor CM**, Pang PA, Piñall, Sabbah HN, Teerlink JR, Udelson JE, Yancy CW, Zannad F, Stockbridge; Acute Heart Failure Syndromes International Working Group. Phase III clinical trial end points in acute Heart failure syndromes: a virtual roundtable with the Acute Heart Failure Syndromes International Working Group. *Am Heart J* 2009 June; 157(6):957-970.

322. Flaherty JD, Rossi JS, Fonarow GC, Nunez E, Stough WG, Abraham WT, Albert NM, Greenberg BH, **O'Connor CM**, Yancy CW, Young JB, Davidson CJ, Gheorghiade M. Influence of coronary angiography on the utilization of therapies in patients with acute heart failure syndromes: findings from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). *Am Heart J* 2009 June; 157(6):1018-1025.
323. Allen LA, Hernandez AF, **O'Connor CM**, Felker GM. End points for clinical trials in acute heart failure syndromes. *J Am Coll Cardiol* 2009 June 16;53(24):2248-2258.
324. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, **O'Connor CM**, Sun JL, Yancy C, Young JB; OPTIMIZE-HF Investigators and Hospitals. Age- and gender-related differences in quality of care and outcomes of patients hospitalized with heart failure (from OPTIMIZE-HF). *Am J Cardiol* 2009 July 1;104(1):107-115.
325. Weatherley BC, Milo-Cotter O, Felker GM, Uriel N, Kaluski E, Vered Z, **O'Connor CM**, Adams KF, Cotter G. Early worsening of heart failure in patients admitted with acute heart failure – a new outcome measure associated with long-term prognosis? *Fundam Clin Pharmacology* 2009; Oct 23 (5):633-639.
326. McMurray JJ, Anand IS, Diaz R, Maggioni AP, **O'Connor CM**, Pfeffer MA, Polu KR, Solomon SD, Sun Y, Swedberg K, Tendera M, van Veldhuisen DJ, Wasserman SM, Young JB;RED-HF Committees and Investigators. Design of the reduction of events with darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. *Eur J Heart Fail* Aug 2009;11(8):795-801.
327. Felker GM, Hasselblad V, Hernandez AF, **O'Connor CM**. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. *Am Heart J*. Sept 2009;158(3):422-430.
328. Whellan DJ, Ellis SJ, Kraus WE, Hawthorne K, PiñalL, Keteyian SJ, Kitzman DW, Cooper L, Lee K, **O'Connor CM**. Method for establishing authorship in a multicenter clinical trial. *Annals Intern Med* Sept 2009;151(6):414-420.
329. Weatherley BD, Milo-Cotter O, Felker GM, Uriel N, Kaluski E, Vered Z, **O'Connor CM**, Adams KF, Cotter G. Early worsening heart failure in patients admitted with acute heart failure—a new outcome measure associated with long-term prognosis? *Fundam Clin Pharmacol* Oct. 2009;23(5):633-639.
330. Trivedi RB, Blumenthal JA, **O'Connor CM**, Adams K, Hinderliter A, Dupree C, Johnson K, Sherwood A. Coping styles in heart failure patients with depressive symptoms. *J Psychosom Res* Oct 2009;67(4):339-346.
331. **O'Connor CM**, Whellan DJ; HF-ACTION Investigators. Understanding heart failure through the HF-ACTION baseline characteristics. *Am Heart J* Oct 2009;158(Suppl):S1-S5.
332. PiñalL, Kokkinos P, Kao A, Bittner V, Saval M, Clare B, Goldberg L, Johnson M, Swank A, Venture H, Moe G, Fitz-Gerald M, Ellis SJ, Vest M, Cooper L, Whellan D: **HF-ACTION Investigators**. Baseline differences in the HF-ACTION trial by sex. *Am Heart J* Oct 2009;158(4 Suppl):S16 –S23.
333. Horwich TB, Leifer ES, Brawner CA, Fitz-Gerald MB, Fonarow GC; **HF-ACTION Investigators**. The relationship between body mass index and cardiopulmonary exercise testing in chronic systolic heart failure. *Am Heart J* Oct 2009;158( 4 Suppl):S31-S36.
334. Felker GM, Whellan D, Kraus WE, Clare R, Zannad F, Donahue M, Adams K, McKelvie R, PiñalL, **O'Connor CM**;HF-ACTION Investigators. N-terminal pro-brain natriuretic peptide and

exercise capacity in chronic heart failure: data from the Heart Failure and a Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) study. *Am Heart J* 2009 Oct. 2009;(4Suppl):S37-S44.

335. Gardin JM, Leifer ES, Fleg JL, Whellan D, Kokkinos P, Leblanc MH, Wolfel E, Kitzman DW; **HF-ACTION Investigators**. Relationship of doppler-echocardiographic left ventricular diastolic function to exercise performance in systolic heart failure: the HF-ACTION study. *Am Heart J* Oct. 2009;158(4 Suppl):S45-S52.
336. Atchley AE, Kitzman DW, Whellan DJ, Iskandrian AE, Ellis SJ, Pagnanelli RA, Kao A, Abdul-Nour K, **O'Connor CM**, Ewald G, Kraus WE, Borges-Neto S; HF-ACTION Investigators. Myocardial perfusion, function, and dyssynchrony in patients with heart failure: baseline results from single-photon emission computed tomography imaging ancillary study of the Heart Failure and a Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) Trial. *Am Heart J* Oct. 2009;158(4 Suppl):S53-S63.
337. Forman DE, Clare R, Kitzman DW, Ellis SJ, Fleg JL, Chiara T, Fletcher G, Kraus WE, WE; **HF-ACTION Investigators**. Relationship of age and exercise performance in Patients with heart failure: The HF-ACTION study. *Am Heart J* Oct. 2009;158(4 Suppl):S6-S15
338. Flynn KE, Lin L, Ellis SJ, Russell SD, Spertus JA, Whellan DJ, Piñall, Fine LJ, Schulman KA, Weinfurt KP; **HF-ACTION Investigators**. Outcomes, health policy, and managed care: relationships between patient-reported outcome measures and clinical measures in outpatients with heart failure. *Am Heart J* Oct. 2009;158(4 Suppl):S64-S71.
339. Keteyian SJ, Isaac D, Thadani U, Roy BA, Bensimhon DR, McKelvie R, Russell SD, Hellkamp AS, Kraus WE; **HF-ACTION Investigators**. Safety of symptom-limited cardio-pulmonary exercise testing in patients with chronic heart failure due to severe left ventricular systolic dysfunction. *Am Heart J* Oct Oct. 2009;(4 Suppl):S72-S77.
340. Felker GM, **O'Connor CM**, Braunwald E. Heart Failure Clinical Research Network Investigators. A necessary evil? *Circ Heart Fail* 2009; Jan 2 (1):S6-62.
341. Cotter G, Metra M, Weatherley BD, Dittrich HC, Massie BM, Ponikowski P, Bloomfield DM, **O'Connor CM**. Physician-determined worsening heart failure: a novel definition for early worsening heart failure in patients hospitalized for acute heart failure—association signs and symptoms, hospitalization duration, and 60-day outcomes. *Cardiology* 2010;115(1):29-36.
342. Mehra MR, Yancy CW, Albert NM, Curtis AB, Stough WG, Gheorghide M, Heywood JT, McBride ML, **O'Connor CM**, Reynolds D, Walsh MN, Fonarow GC. Evidence of clinical practice heterogeneity in the use of implantable cardioverter-defibrillators in heart failure and post-myocardial infarction left ventricular dysfunction: Findings from IMPROVE-HF. *Heart Rhythm* Dec 2009;6(12):1727-1734.
343. **O'Connor CM**, Fiuzat M. Antidepressant use, depression, and poor cardiovascular outcomes: The chicken or the Egg? Comment on "Antidepressant use and risk of incident cardiovascular morbidity and mortality among postmenopausal women in the "Women's Health Initiative Study". *Arch Intern Med* Dec 2009;169(22):2140-2141.
344. Hernandez AF, Fonarow GC, Hammill BG, Al-Khatib SM, Yancy CW, **O'Connor CM**, Schulman KA, Peterson ED, Curtis LH. Clinical effectiveness of implantable cardioverter-defibrillators among medicare beneficiaries with heart failure. *Circ Heart Fail* Jan 2010;3(1):7-13.
345. Adams KF Jr, Felker GM, Fraij G, Patterson JH, **O'Connor CM**. Biomarker guided therapy for heart failure: focus on natriuretic peptides. *Heart Failure Rev* 2010; July 15(4):351-370

346. Steffans DC, Jiang W, Krishnan KR, Karoly ED, Mitchell MW, **O'Connor CM**, Kaddurah-Daouk R. Metabolomic differences in heart failure patients with and without major depression. *J Geriatr Psychiatry Neurol* 2010;June 23(2):138-146.
347. French JK, Hellkamp AS, Armstrong PW, Cohen E, Kleiman NS, **O'Connor CM**, Holmes DR, Hochman JS, Granger CB, Mahaffey KW. Mechanical complications after percutaneous coronary intervention in ST-elevation myocardial infarction (from APEX-AMI). *Am J Cardiol* Jan 2010;105(1):59-63.
348. Yancy CW, Fonarow GC, Albert NM, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, McBride ML, Mehra MR, **O'Connor CM**, Reynolds D, Walsh MN. Adherence to guideline-recommended adjunctive heart failure therapies among outpatient cardiology practices (findings from IMPROVE-HF). *Am J Cardiol* Jan 2010;105(2):255-260.
349. **O'Connor CM**, Koch WJ, Mann DL. Highlights of the 2009 Scientific Sessions of the Heart Failure Society of America, Boston, MA, September 13-16, 2009. *J Card Failure* Jan 2010;16(1):2-8.
350. Weatherley BD, Cotter G, Dittrich HC, Delucca P, Mansoor GA, Bloomfield DM, Ponikowski P, **O'Connor CM**, Metra M, Massie BM;PROTECT Steering Committee, Investigators, and Coordinators. Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function. *J Card Fail* 2010;Jan 16(1):25-35.
351. Watkins LL, Blumenthal JA, Babyak MA, Davidson JR, McCants CB Jr, **O'Connor CM** Sketch MH Jr. Phobic anxiety and increased risk of mortality in coronary heart disease. *Psychosom Med* 2010; Sept;72(7):664-671.
352. Wang NC, Piccini JP, Konstam MA, Maggioni AP, Traver B, Swedberg K, Udelson JE, Zannad F, Cook T, **O'Connor CM**, Miller AB, Grinfeld L, Gheorghiade M; for the EVEREST Investigators. Implantable cardioverter-defibrillators in patients hospitalized for heart failure with chronically reduced left ventricular ejection fraction. *Am J Ther* 2010:July/August 17(4):e78-e87.
353. Heywood JT, Fonarow GC, Yancy CW, Albert NM, Curtis AB, Gheorghiade M, Johnson Inge P, McBride ML, Mehra MR, **O'Connor CM**, Reynolds D, Walsh NM. Comparison of medical therapy dosing in outpatients cared for in Cardiology practices with heart failure and reduced ejection fraction with and without device therapy: A report from IMPROVE-HF. *Circ Heart Fail* 2010; Sept 3(5):596-605.
354. Piccini JP, Starr AZ, Horton JR, Shaw LK, Lee KL, Al-Khatib SM, Iskandrian AE, **O'Connor CM**, Borges-Neto S. Single-photon emission computed tomography myocardial perfusion imaging and the risk of sudden cardiac death in patients with coronary artery disease and left ventricular ejection fraction >35%. *J Am Coll Cardiol* 2010:July 13:56(3):206-214.
355. Xiong GL, Jiang W, Clare RM, Shaw LK, Smith PK, **O'Connor CM**, Ranga K, Krishnan R, Newby L. Safety of selective serotonin reuptake inhibitor use prior to coronary artery bypass grafting. *Clin Cardiol* 2010;June 33(6):E94-E98.
356. Reed SD, Whellan DJ, Li Y, Friedman JY, Ellis SJ, Piñall, Settles SJ, Davidson-Ray L, Johnson JL, Cooper LS, **O'Connor CM**, Schulman KA; for the HF-ACTION Investigators. Economic evaluation of the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) randomized controlled trial: an exercise training study of patients with chronic heart failure. *Circ Cardiovasc Qual Outcomes* 2010:July 3(4):374-381.



357. Allen LA, Turer AT, Dewald T, Stough WG, Cotter G, **O'Connor CM**. Continuous versus bolus dosing of Furosemide for patients hospitalized with heart failure. *Am J Cardiol* 2010; June 15;105(12):1794-1797.
358. Albert NM, Fonarow GC, Yancy CW, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, McBride M, Mehra MR, **O'Connor CM**, Reynolds D, Walsh MN. Outpatient cardiology practices with advanced practice nurses and physician assistants provide similar delivery of recommended therapies (findings from IMPROVE-HF). *Am J Cardiol* 2010; June 15;105(12):1773-1779.
359. **O'Connor CM**, Miller AB, Blair JE, Konstam MA, Wedge P, Bahit MC, Carson P, Haass Hauptman PJ, Metra M, Oren RM, Patten R, Piñal, Roth S, Sackner-Bernstein JD, Traver B, Cook T, Gheorghiade M; Efficacy of Vasopressin Antagonism in heart Failure Outcome Study with Tolvaptan (EVEREST) Investigators. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program. *Am Heart J* 2010; May 159(5):841-849.
360. Whellan DJ, Ousidigian KT, Al-Khatib sM, Pu W, Sarkar S, Porter CB, Pavri BB, **O'Connor CM**; PARTNERS Study Investigators. Combined heart failure device diagnostics identify patients at higher risk of subsequent heart failure hospitalizations: results from PARTNERS HF (Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients with Heart Failure) study. *J Am Coll Cardiol* 2010; April 27;55(17):1803-1010.
361. Heywood JT, Fonarow GC, Yancy CW, Albert NM, Curtis AB, Stough WG, Gheorghiade M, McBride ML, Mehra MR, **O'Connor CM**, Reynolds D, Walsh MN. Influence of renal function on the use of guideline-recommended therapies for patients with heart failure. *Am J Cardiol* 2010; April 15;105(8):1140-1146.
362. Walsh MN, Yancy CW, Albert NM, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, McBride ML, Mehra MR, **O'Connor CM**, Reynolds D, Fonarow GC. Electronic health records and quality of care for heart failure. *Am Heart J* 2010; April 159(4):635-642.
363. Felker GM, Pang PS, Adams KF, Cleland JG, Cotter G, Dickstein K, Fillippatos GS, Fonarow GC, Greenberg BH, Hernandez AF, Khan S, Komajda M, Konstam MA, Liu PP, Maggioni AP, Massie BM, McMurray JJ, Mehra M, Metra M, O'Connell J, **O'Connor CM**, Piñal, Ponikowski P, Sabbah HN, Teerlink JR, Udelson JE, Yancy CW, Zannad F, Gheorghiade M; International AHFS Working Group. Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward. *Circ Heart Fail* 2010; March 3(2):314-325.
364. Metra M, Cleland JG, Weatherley BD, Dittrich HC, Givertz MM, Massie BM, **O'Connor CM**, Ponikowski P, Teerlink JR, Voors AA, Cotter G. Dyspnea in patients with acute heart failure: An analysis of its clinical course, determinants, and relationship to 60-day outcomes in the PROTECT pilot study. *Eur J Heart Fail* 2010; May;12(5):499-507.
365. **O'Connor CM**, Hasselblad V, Mehta RH, Tasissa G, Califf RM, Fiuzat M, Rogers JG, Leier CV, Stevenson LW. Triage after hospitalization with advanced heart failure: the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) risk model and discharge score. *J Am Coll Cardiol* 2010; March 2;55(9):872-878.
366. Blumenthal JA, **O'Connor CM**. No laughing matter. *J Am Coll Cardiol* 2010; Feb 23;55(8):836; author reply 836-837.
367. Albert NM, Fonarow GC, Yancy CW, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, McBride M, Mehra MR, **O'Connor CM**, Reynolds D, Walsh MN. Influence of dedicated heart failure clinics on delivery of recommended therapies in outpatient cardiology practices: findings

from the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE-HF). *Am Heart J* 2010;Feb;159(2):238-244.

368. Levy PD, Nandyal D, Welch RD, Sun JL, Pieper K, Ghali JK, Fonarow GC, Gheorghiade M, **O'Connor CM**. Does aspirin use adversely influence intermediate-term post discharge outcomes for hospitalized patients who are treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers? Findings from Organized Program to Facilitate Life-Saving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). *Am Heart J* 2010; Feb;159(2):222-230.
369. **O'Connor CM**, Fiuzat M. Is rehospitalization after heart failure admission a marker of poor quality? Time for re-evaluation. *J Am Coll Cardiol* 2010;56:369-371
370. Kong MH, Shaw LK, **O'Connor CM**, Califf RM, Blazing MA, Al-Khatib SM. Is rhythm-control superior to rate-control in patients with atrial fibrillation and diastolic heart failure? *Ann Noninvasive Electrocardiol* 2010 July 15(3):209-217.
371. Jones RH, White H, Velazquez EJ, Shaw LK, Pietrobon R, Panza JA, Bonow RO, Sopko G, **O'Connor CM**, Rouleau JL. STICH (Surgical Treatment for Ischemic Heart Failure) trial enrollment. *J Am Coll Cardiol* 2010;Aug 3;56(6):490-498.
372. **O'Connor CM**, Jiang W, Kuchibhatla M, Silva SG, Cuffe MS, Callwood DD, Zakhary B, Stough WG, Arias RM, Rivelli SK, Krishnan R; SADHART-CHF Investigators. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. *J Am Coll Cardiol* 2010;Aug. 24;56(9):692-699.
373. Kociol RD, Pang PS, Gheorghiade M, Fonarow GC, **O'Connor CM**, Felker GM. Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. *J Am Coll Cardiol* 2010;Sept 28;56(14):1071-1078.
374. Carson P, Fiuzat M, **O'Connor CM**, Anand I, Plehn J, Lindenfeld JA, Silver M, White M, Miller A, Davis G, Robertson AD, Bristow M, Gottlieb S. Determination of hospitalization type by investigator case report form or adjudication committee in a large heart failure trial (Beta Blocker Evaluation of Survival Trial – BEST ). *Am Heart J* 2010;Oct;160(4):649-654.
375. Massie BM, **O'Connor CM**, Metra M, Ponikowski P, Teerlink JR, Cotter G, Weatherley BD, Cleland JG, Givertz JG, Voors A, DeLucca P, Mansoor GA, Salerno CM, Bloomfield DM, Dittrich HC; PROTECT Investigators and Committees. Rolofylline, an adenosine A1-Receptor antagonist, in acute heart failure. *New Engl J Med* 2010;Oct 7;363(15):1419-1428.
376. Echols MR, **O'Connor CM**. Depression after myocardial infarction. *Curr Heart Failure Rep* 2010; Dec 7 (4):185-193.
377. Bettari L, Fiuzat M, Felker GM, **O'Connor CM**. Significance of hyponatremia in heart failure. *Heart Fail Rev.* 2010 Sep 14.
378. West RL, Hernandez AF, **O'Connor CM**, Starling RC, Califf RM. A review of dyspnea in acute heart failure syndromes. *Am Heart J* 2010; Aug 160(2):209-214
379. Povsic TJ, **O'Connor CM**. Cell therapy for heart failure: the need for a new therapeutic strategy. *Expert Rev Cardiovasc Ther* 2010;Aug 8(8):1107-1126.
380. Fonarow GC, Albert NM, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, McBride ML, Inge PJ, Mehra MR, **O'Connor CM**, Reynolds D, Walsh MN, Yancy CW. Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of The Registry to

Improve the Use of Evidence-Based Heart Failure Therapy in the Outpatient Setting (IMPROVE-HF). *Circ* 2010; Aug 10 122(6):585-596.

381. Peacock WF, Braunwald E, Abraham W, Albert N, Burnett J, Christenson R, Collins S, Diercks D, Fonarow G, Hollander J, Kellerman A, Gheorghide M, Kirk D, Levy P, Maisel A, Massie BM, **O'Connor CM**, Pang P, Shah M, Sopko G, Stevenson L, Storrow A, Teerlink J. National Heart, Lung, and Blood Institute working group on emergency department management of acute heart failure: research challenges and opportunities. *J Am Coll Cardiol* 2010; July 27 56(5):343-351.
382. Gottlieb SS, Givertz MM, Metra M, Gergich K, Bird S, Jones-Burton C, Massie B, Cotter G, Ponikowski P, Weatherley B, **O'Connor CM**, Dittrich H. The effects of adenosine A(1) receptor antagonism in patients with acute decompensated heart failure and worsening renal function: the REACH Up Study. *J Card Fail* 2010; Sept 16(9):714-719.
383. Ponikowski P, Mitrovic V, **O'Connor CM**, Dittrich H, Cotter G, Massie BM, Givertz MM, Chen E, Murray M, Weatherley BD, Fujita KP, Metra M. Haemodynamic effects of rolofylline in the treatment of patients with heart failure and impaired renal function. *Eur J Heart Fail* 2010; Nov 12(11):1238-1246.
384. Rouleau JL, Michler RE, Velazquez EJ, Oh JK, **O'Connor CM**, Desvigne-Nickens P, Sopko G, Lee KL, Jones RH. The STICH Trial: evidence-based conclusions. *Eur J Heart Failure* 2010; Oct 12(10):1028-1030.
385. Wu AH, Ghali JK, Neuberg GW, **O'Connor CM**, Carson PE, Levy WC. Uric acid level and allopurinol use as risk markers of mortality and morbidity in systolic heart failure. *Am Heart J* 2010; Nov 160(5):928-933.
386. Fiuzat M, Shaw LK, Thomas L, Felker GM, **O'Connor CM**. United States stock market performance and acute myocardial infarction rates in 2008-2009 (from the Duke Databank for Cardiovascular Disease). *Am J Cardiol* 2010; Dec 1: 106(11):1545-1549.
387. Walsh MN, Yancy CW, Albert NM, Curtis AB, Gheorghide M, Heywood JT, Inge PJ, McBride ML, Mehra MR, O'Connor CM, Reynolds D, Fonarow GC. Equitable improvement for women and men in the use of guideline-recommended therapies for heart failure: Findings from IMPROVE-HF. *J Card Fail* 2010; Dec 16(12):940-949.
388. Adams KF Jr, Mehra MR, Oren RM, **O'Connor CM**, Chiong JR, Ghali JK, Lenihan DJ, Dunlap SH, Patterson JH, Schwartz TA, Felker GM. Prospective evaluation of the association between cardiac troponin T and markers of disturbed erythropoiesis in patients with heart failure. *Am Heart J* 2010; Dec: 160(6):1142-1148.
389. **O'Connor CM**, Albert NM, Curtis AB, Gheorghide M, Heywood JT, McBride ML, Inge PJ, Mehra MR, Reynolds D, Walsh MN, Yancy CW, Fonarow GC. Patient and practice factors associated with improvement in use of guideline-recommended therapies for outpatients with heart failure (from the IMPROVE-HF Trial). *Am J Cardiol* 2011; Jan 107(2):250-258.
390. Sherwood A, Blumenthal JA, Hinderliter AL, Koch GG, Adams KF Jr, Dupree CS, Bensimhon DR, Johnson KS, Trivedi R, Bowers M, Christenson RH, **O'Connor CM**. Worsening depressive symptoms are associated with adverse clinical outcomes in patients with heart failure. *J Am Coll Cardiol* 2011; Jan: 57(4):418-423.
391. **O'Connor CM**, Koch WJ, Mann DL. Highlights of the 2010 scientific sessions of the Heart Failure Society of America; San Diego, California, September 12-15, 2010. *J Cardiol Fail* 2011; Feb 17(2):92-99.

392. Jiang W, Krishnan R, Kuchibhatla M, Cuffe MS, Martsberger C, Arias RM, **O'Connor CM**, SADHART-CHF Investigators. Characteristics of Depression Remission and Its Relation with Cardiovascular Outcome Among Patients with Chronic Heart Failure (from the SADHART-CHF Study). *Am J Cardiol* 2011; Feb 15;107(4):545-551.
393. Gheorghide M, Pang PS, **O'Connor CM**, Prasad K, McMurray J, Teerlink JR, Fiuzat M, Sabbah H, Komajda M. Clinical development of pharmacologic agents for acute heart failure syndromes: a proposal for a mechanistic translational phase. *Am Heart J* 2011; Feb (2):224-232.
394. Mahaffey KW, Wampole JL, Stebbins A, Berdan LG, McAfee D, Rorick TL, French JK, Kleiman NS, **O'Connor CM**, Cohen EA, Granger CB, Armstrong PW; for the APEX-AMI Investigators. Strategic lessons from the clinical event classification process for the assessment of pexelizumab in acute myocardial infarction (APEX-AMI) trial. *Contemp Clin Trials* 2011; March 32(2):178-187.
395. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, LeWiinter MM, Deswal A, Rouleau JL, Ofili EO, Anstrom KJ, Hernandez AF, McNulty SE, Velazquez EJ, Kfoury AG, Chen HH, Givertz MM, Semigran MJ, Bart BA, Mascette AM, Braunwald E, **O'Connor CM**; NHLBI Heart Failure Clinical Research Network. Diuretic strategies in patients with acute decompensated heart failure. *N Engl J Med* 2011 March 3:364(9):797-805.
396. Sherwood A, **O'Connor CM**, Routledge FS, Hinderliter AL, Watkins LL, Babyak MA, Koch GG, Adams KF Jr., Dupree CS, Chang PP, Hoffman BM, Johnson J, Bowers M, Johnson KS, Blumenthal JA. Coping effectively with heart failure (COPE-HF): design and rationale of a telephone-based coping skills intervention. *J Card Fail* 2011 March 17(3):201-220.
397. Fonarow GC, Albert NM, Curtis AB, Gheorghide M, Heywood JTG, Liu Y, Mehra R, **O'Connor CM**, Reynolds D, Walsh MN, Yancy CW. Associations between outpatient heart failure process-of-care measures and mortality. *Circulation* 2011 April 19;123(15):1601-1610.
398. Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, Ali IS, Pohost G, Gradinac S, Abraham WT, Yip M, Prabhakaran D, Szwed H, Ferrazi P, Petrie MC, **O'Connor CM**, Panchavinnin P, She L, Bonow RO, Rankin GR, Jones RH, Rouleau JL: STICH Investigators. Coronary artery bypass surgery in patients with left ventricular dysfunction. *N Engl J Med* 2011; April 28;364(17):1607-1616.
399. Voors AA, Dittrich HC, Massie BM, Delucca P, Mansoor GA, Metra M, Cotter G, Weatherley BD, Ponikowski P, Teerlink JR, Cleland JG, **O'Connor CM**, Givertz MM. Effects of the adenosine A(1) receptor antagonist rolofylline on renal failure in patients with acute heart failure and renal dysfunction results from PROTECT (Placebo-Controlled Randomized Study of the Selective A(1) Adenosine Receptor Antagonist Rolofoylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function). *J Am Coll Cardiol* 2011 May 10;57(19):1899-1907.
400. Bettari L, Fiuzat M, Becker R, Felker GM, Metra M, **O'Connor CM**. Thromboembolism and Antithrombotic therapy in patients with heart failure in sinus rhythm: current status and future directions. *Circ Heart Fail* 2011 May 1;4(3):361-368.
401. Atchley AE, Iskandrian AE, Bensimhon D, Ellis SJ, Kitzman DW, Shaw LK, Pagnanelli RA, Whellan DJ, Gardin JM, Kao A, Abdul-Nour K, Ewald G, Walsh MN, Kraus WE, **O'Connor CM**, Borges-Neto S. Relationship of technetium-99m tetrofosmin-gated rest single-photon emission computed tomography myocardial perfusion imaging to death and hospitalization in heart failure patients: results from the nuclear ancillary study of the HF-ACTION trial. *Am Heart J* 2011 June; 16(6):1038-1045.

402. Metra M, **O'Connor CM**, Davison BA, Cleland JG, Ponikowski P, Teerlink JR, Voors AA, Givertz MM, Mansoor GA, Bloomfield DM, Jia G, Delucca P, Massie B, Dittrich H, Cotter G. Early dyspnea relief in acute heart failure; Prevalence, association with mortality and effect of rolofylline in the PROTECT study. *Eur Heart J* 2011 June 32(12):1519-1534.
403. **O'Connor CM**, Starling RC, Hernandez AF, Armstrong P, Dickstein K, Hasselblad V, Heizer GM, Komajda M, Massie BM, McMurray JJ, Nieminen MS, Reist CJ, Rouleau JL, Swedberg K, Adams KF JR, Anker SD, Atar D, Battler A, Botero R, Bohidar NR, Butler J, Clausell N, Corbalan R, Costanzo MR, Dahlstrom U, Deckelbaum LI, Diaz R, Dunlap M, Ezekowitz JA, Feldman D, Felker GM, Fonarow GC, Gennevois D, Gottlieb SS, Hill JA, Hollander JE, Howlett JG, Hudson MP, Kociol R, Krum H, Laucevicius A, Levy WC, Mendez GF, Metra M, Mittal S, Oh BH, Pereira NL, Ponikowski P, Tang W, Tanomsup, Teerlink JR, Triposkiadis F, Troughton RW, Voors AA, Whellan DJ, Zannad F, Califf RM. Effect of nesiritide in patients with acute decompensated heart failure *New Engl J Med*. 2011 July 7;365(1):32-43.
404. French JK, Armstrong PW, Cohen E, Kleiman NS, **O'Connor CM**, Hellkamp AS, Stebbins A, Holmes DR, Hochman JS, Granger CE, Mahaffey KW. Cardiogenic shock and heart failure post-percutaneous coronary intervention in ST-elevation myocardial infarction: Observation from "Assessment of Pexelizumab in Acute Myocardial Infarction". *Am Heart J* 2011 July 16; 2(1):89-97.
405. Shah M, Califf RM, Nohria A, Bhapkar M, Bowers M, Mancini D, Fiuzat M, Stevenson LW, **O'Connor CM**. The STARBRITE Trial: A randomized, pilot study of B-Type natriuretic peptide-guided therapy in patients with advanced heart failure. *J Card Fail* 2011 Aug 17(8):613-621.
406. Jones WS, Clare R, Ellis SJ, Mills JS, Fischman DL, Kraus WE, Whellan DJ, **O'Connor CM**, Patel MR. Effect of peripheral arterial disease on functional and clinical outcomes in patients with heart failure (from HF-ACTION). *Am J Cardiol* 2011 Aug 1;108(3):380-384.
407. **O'Connor CM**, Fiuzat M, Swedberg K, Caron M, Koch B, Carson PE, Stough WG, Davis GW, Bristow MR. Influence of global region on outcomes in heart failure B-blocker trials. *J Am Coll Cardiol* 2011 Aug 23;58(9):915-922.
408. Kociol RD, Horton JR, Fonarow GC, Reyes EM, Shaw LK, **O'Connor CM**, Felker GM, Hernandez AF. Admission, discharge, or change in BNP and long-term outcomes: data from OPTIMIZE-HF linked to medicare claims. *Circ Heart Fail* 2011 Sept. 1;4(5):628-636.
409. West R, Liang L, Fonarow GC, Kociol R, Mills RM, **O'Connor CM**, Hernandez AF. Characterization of heart failure patients with preserved ejection fraction: A comparison between ADHERE-US registry and ADHERE-International registry. *Eur J Heart Fail* 2011 Sept. 13(9):945-952.
410. Mentz RJ, **O'Connor CM**. Cardiorenal syndrome clinical trial end points. *Heart Fail Clin* 2011 Oct; 7(4):519-528.
411. **O'Connor CM**, Mentz RJ, Whellan DJ. Covariate adjustment in heart failure randomized controlled clinical trials: A case analysis of the HF-ACTION trial. *Heart Fail Clin* 2011 Oct;7(4): 497-500.
412. **O'Connor CM**, Fiuzat M. Lessons learned from clinical trials in acute heart failure: phase 3 drug trials. *Heart Fail Clin* 2011 Oct; 7(4):451-456.
413. **O'Connor CM**, Fiuzat M. Clinical trials in acute decompensated heart failure over 50 years of research. *Heart Fail Clin* 2011 Oct; 7(4):451-456.

414. **O'Connor CM**, Fiuzat M, Lombardi C, Fujita K, Jia G, Davison BA, Cleland J, Bloomfield D, Dittrich HC, DeLuca P, Givertz MM, Mansoor G, Ponikowski P, Teerlink JR, Voors AA, Massie BM, Cotter G, Metra M. The impact of serial troponin release on outcomes in patients with acute heart failure: analysis from the PROTECT pilot study. *Circ Heart Fail* 2011 Nov 1; 4(6):724-32.
415. **O'Connor CM**, Fiuzat M, Lindenfeld J, Miller A, Lombardi C, Carson P, Shaw LK, Wang LJ, Connolly P, Mills R, Yancy C, Mahaffey K. Mode of death and hospitalization from the Second follow-up serial infusions of Nesiritide (FUSION II) trial and comparison of Clinical Event Committee adjudicated versus investigator reported outcomes. *Am J Cardiol* 2011 Nov 15;108(10):1449-57.
416. Povsic TJ, **O'Connor CM**, Henry T, Taussig A, Kereiakes DJ, Fortuin FD, Niederman A, Schatz R, Spencer R 4th, Owens D, Banks M, Joseph D, Roberts R, Alexander JH, Sherman W. A double-blind, randomized, controlled, multicent study to assess the safety and cardiovascular effects of skeletal myoblast implantation by catheter delivery in patients with chronic heart failure after myocardial infarction. *Am Heart J*. 2011 Oct;162(4):654-662.e1
417. Felker GM, Fiuzat M, Shaw LK, Clare R, Whellan DJ, Bettari L, Shirolkar SC, Donahue M, Kitzman DW, Zannad F, Piña IL, **O'Connor CM**. Galectin-3 in Ambulatory Patients With Heart Failure: Results From the HF-ACTION Study. *Circ Heart Fail*. 2012 Jan 1;5(1):72-8.
418. Jones WS, Patel MR, Holleran SA, Harrison JK, **O'Connor CM**, Phillips HR 3rd. Trends in the use of diagnostic coronary angiography, percutaneous coronary intervention, and coronary artery bypass graft surgery across North Carolina. *Am Heart J*. 2011 Nov;162(5):932-7.
419. **O'Connor CM**, Whellan DJ, Wojdyla D, Leifer E, Clare RM, Ellis SJ, Fine LJ, Fleg JL, Zannad F, Keteyian SJ, Kitzman DW, Kraus WE, Rendall D, Piña IL, Cooper LS, Fiuzat M, Lee KL. *Circ Heart Fail*. 2012 Jan 1;5(1):63-71.
420. Jiang W, Velazquez EJ, Samad Z, Kuchibhatla M, Martsberger C, Rogers J, Williams R, Kuhn C, Ortel TL, Becker RC, Pristera N, Krishnan R, **O'Connor CM**. Responses of mental stress-induced myocardial ischemia to escitalopram treatment: Background, design, and method for the Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment trial. *Am Heart J*. 2012 Jan;163(1):20-6.
421. Bettari L, Fiuzat M, Shaw LK, Wojdyla DM, Metra M, Felker GM, **O'Connor CM**. Hyponatremia and long-term outcomes in chronic heart failure-an observational study from the duke databank for cardiovascular diseases. *J Card Fail*. 2012 Jan;18(1):74-81.
422. **O'Connor CM**, Whellan DJ, Wojdyla D, Leifer E, Clare RM, Ellis SJ, Fine LJ, Fleg JL, Zannad F, Keteyian SJ, Kitzman DW, Kraus WE, Rendall D, Piña IL, Cooper LS, Fiuzat M, Lee KL. Factors Related to Morbidity and Mortality in Patients With Chronic Heart Failure With Systolic Dysfunction: The HF-ACTION Predictive Risk Score Model. *Circ Heart Fail*. 2012 Jan 1;5(1):63-71.
423. Gheorghide M, Albert NM, Curtis AB, Thomas Heywood J, McBride ML, Inge PJ, Mehra MR, **O'Connor CM**, Reynolds D, Walsh MN, Yancy CW, Fonarow GC. Medication Dosing in Outpatients With Heart Failure After Implementation of a Practice-Based Performance Improvement Intervention: Findings From IMPROVE HF. *Congest Heart Fail*. 2012 Jan;18(1):9-17.
424. Jiang W, Oken H, Fiuzat M, Shaw LK, Martsberger C, Kuchibhatla M, Kaddurah-Daouk R, Steffens DC, Baillie R, Cuffe M, Krishnan R, **O'Connor C**. Plasma omega-3 polyunsaturated fatty acids and survival in patients with chronic heart failure and major depressive disorder.; SADHART-CHF Investigators. *J Cardiovasc Transl Res*. 2012 Feb;5(1):92-9.

425. Mehra MR, Albert NM, Curtis AB, Gheorghiade M, Heywood JT, Liu Y, **O'Connor CM**, Reynolds D, Walsh MN, Yancy CW, Fonarow GC. Factors Associated with Improvement in Guideline-Based Use of ICDs in Eligible Heart Failure Patients. *Pacing Clin Electrophysiol*. 2012 Feb;35(2):135-145
426. Velazquez EJ, Williams JB, Yow E, Shaw LK, Lee KL, Phillips HR, **O'Connor CM**, Smith PK, Jones RH. Long-term survival of patients with ischemic cardiomyopathy treated by coronary artery bypass grafting versus medical therapy. *Ann Thorac Surg*. 2012 Feb;93(2):523-30.
427. Ahmad T, Fiuzat M, Felker GM, **O'Connor C**. Novel biomarkers in chronic heart failure. *Nat Rev Cardiol*. 2012 Mar 27.
428. Teerlink JR, Iragui VJ, Mohr JP, Carson PE, Hauptman PJ, Lovett DH, Miller AB, Piña IL, Thomson S, Varosy PD, Zile MR, Cleland JG, Givertz MM, Metra M, Ponikowski P, Voors AA, Davison BA, Cotter G, Wolko D, Delucca P, Salerno CM, Mansoor GA, Dittrich H, **O'Connor CM**, Massie BM. The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT. *Drug Saf*. 2012 Mar 1;35(3):233-44.
429. Walsh MN, Albert NM, Curtis AB, Gheorghiade M, Heywood JT, Liu Y, Mehra MR, **O'Connor CM**, Reynolds D, Yancy CW, Fonarow GC. Lack of association between electronic health record systems and improvement in use of evidence-based heart failure therapies in outpatient cardiology practices. *Clin Cardiol*. 2012 Mar;35(3):187-96.
430. Bart BA, Goldsmith SR, Lee KL, Redfield MM, Felker GM, **O'Connor CM**, Chen HH, Rouleau JL, Givertz MM, Semigran MJ, Mann D, Deswal A, Bull DA, Lewinter MM, Braunwald E. Cardiorenal rescue study in acute decompensated heart failure: rationale and design of CARRESS-HF, for the Heart Failure Clinical Research Network. *J Card Fail*. 2012 Mar;18(3):176-82.
431. Mentz RJ, Fiuzat M, Wojdyla DM, Chiswell K, Gheorghiade M, Fonarow GC, **O'Connor CM**. Clinical characteristics and outcomes of hospitalized heart failure patients with systolic dysfunction and chronic obstructive pulmonary disease: findings from OPTIMIZE-HF. *Eur J Heart Fail*. 2012 Apr;14(4):395-403.
432. Ezekowitz JA, Hernandez AF, **O'Connor CM**, Starling RC, Proulx G, Weiss MH, Bakal JA, Califf RM, McMurray JJ, Armstrong PW. Assessment of Dyspnea in Acute Decompensated Heart Failure: Insights from ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) on the Contributions of Peak Expiratory Flow. *J Am Coll Cardiol*. 2012 Apr 17;59(16):1441-8.
433. Mentz RJ, Fiuzat M, Shaw LK, Phillips HR, Borges-Neto S, Felker GM, **O'Connor CM**. Comparison of Clinical Characteristics and Long-Term Outcomes of Patients With Ischemic Cardiomyopathy With Versus Without Angina Pectoris (from the Duke Databank for Cardiovascular Disease). *Am J Cardiol*. 2012 May 1;109(9):1272-7.
434. Mentz RJ, Fiuzat M, Kraft M, Lindenfeld J, **O'Connor CM**. Bronchodilators in Heart Failure Patients With COPD: Is It Time for a Clinical Trial? *J Card Fail*. 2012 May;18(5):413-22.
435. **O'Connor CM**, Mentz RJ, Cotter G, Metra M, Cleland JG, Davison BA, Givertz MM, Mansoor GA, Ponikowski P, Teerlink JR, Voors AA, Fiuzat M, Wojdyla D, Chiswell K, Massie BM. The PROTECT in-hospital risk model: 7-day outcome in patients hospitalized with acute heart failure and renal dysfunction. *Eur J Heart Fail*. 2012 Jun;14(6):605-12.

436. Ambrosy AP, Fonarow GC, Albert NM, Curtis AB, Heywood JT, Mehra MR, **O'Connor CM**, Reynolds D, Walsh MN, Yancy CW, Gheorghiade M. B-type natriuretic peptide assessment in ambulatory heart failure patients: insights from IMPROVE HF. *J Cardiovasc Med* (Hagerstown). 2012 Jun;13(6):360-367.
437. Adams J, Kuchibhatla M, Christopher EJ, Alexander JD, Clary GL, Cuffe MS, Califf RM, Krishnan RR, **O'Connor CM**, Jiang W. Association of Depression and Survival in Patients with Chronic Heart Failure over 12 Years. *Psychosomatics* 2012 Jul-Aug;53(4):339-46.
438. Mentz RJ, Schmidt PH, Kwasny MJ, Ambrosy AP, **O'Connor CM**, Konstam MA, Zannad F, Maggioni AP, Swedberg K, Gheorghiade M. The Impact of Chronic Obstructive Pulmonary Disease in Patients Hospitalized for Worsening Heart Failure With Reduced Ejection Fraction: An Analysis of the EVEREST Trial. *J Card Fail*. 2012 Jul;18(7):515-23.
439. Farzaneh-Far A, Phillips HR, Shaw LK, Starr AZ, Fiuzat M, **O'Connor CM**, Sastry A, Shaw LJ, Borges-Neto S. Ischemia Change in Stable Coronary Artery Disease Is an Independent Predictor of Death and Myocardial Infarction. *J Am Coll Cardiol Img*. 2012 Jul 4;5(7):715-724.
440. Fiuzat M, Wojdyla D, Kitzman D, Fleg J, Keteyian SJ, Kraus WE, Piña IL, Whellan D, **O'Connor CM**. Relationship of Beta-Blocker Dose With Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction: Results From the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) Trial. *J Am Coll Cardiol*. 2012 Jul 17;60(3):208-15.
441. Blumenthal JA, Babyak MA, **O'Connor C**, Keteyian S, Landzberg J, Howlett J, Kraus W, Gottlieb S, Blackburn G, Swank A, Whellan DJ. Effects of exercise training on depressive symptoms in patients with chronic heart failure: the HF-ACTION randomized trial. *JAMA*. 2012 Aug 1;308(5):465-74.
442. Mentz RJ, Kaski JC, Dan GA, Goldstein S, Stockbridge N, Alonso-Garcia A, Ruilope LM, Martinez FA, Zannad F, Pitt B, Fiuzat M, **O'Connor CM**. Implications of geographical variation on clinical outcomes of cardiovascular trials. *Am Heart J*. 2012 Sep;164(3):303-12.
443. Dev S, Abernethy AP, Rogers JG, **O'Connor CM**. Preferences of people with advanced heart failure—a structured narrative literature review to inform decision making in the palliative care setting. *Am Heart J*. 2012 Sep;164(3):313-319.e5.
444. Ezekowitz JA, Hu J, Delgado D, Hernandez AF, Kaul P, Leader R, Proulx G, Virani S, White M, Zieroth S, **O'Connor C**, Westerhout CM, Armstrong PW. Acute Heart Failure: Perspectives from a Randomized Trial and a Simultaneous Registry. *Circ Heart Fail*. 2012 Nov;5(6):735-41.
445. **O'Connor CM**, Rogers JG. Evidence for Overturning the Guidelines in Cardiogenic Shock. *N Engl J Med*. 2012 Oct 4;367(14):1349-50. No abstract available.
446. **O'Connor CM**, Fiuzat M, Carson PE, Anand IS, Plehn JF, Gottlieb SS, Silver MA, Lindenfeld J, Miller AB, White M, Walsh R, Nelson P, Medway A, Davis G, Robertson AD, Port JD, Carr J, Murphy GA, Lazzeroni LC, Abraham WT, Liggett SB, Bristow MR. Combinatorial Pharmacogenetic Interactions of Bucindolol and  $\beta(1)$ ,  $\alpha(2C)$  Adrenergic Receptor Polymorphisms. *PLoS One*. 2012;7(10):e44324..
447. Xiong GL, Fiuzat M, Kuchibhatla M, Krishnan R, **O'Connor CM**, Jiang W. Health Status and Depression Remission in Patients with Chronic Heart Failure: Patient-Reported Outcomes from the SADHART-CHF Trial. *Circ Heart Fail*. 2012 Nov;5(6):688-92.



448. Dev S, Shirolkar SC, Stevens SR, Shaw LK, Adams PA, Felker GM, Rogers JG, **O'Connor CM**. Reduction in Body Weight but Worsening Renal Function with Late Ultrafiltration for Treatment of Acute Decompensated Heart Failure. *Cardiology*. 2012 Oct 27;123(3):145-153.
449. Mentz RJ, Bakris GL, Waeber B, McMurray JJ, Gheorghide M, Ruilope LM, Maggioni AP, Swedberg K, Piña IL, Fiuzat M, **O'Connor CM**, Zannad F, Pitt B. The past, present and future of renin-angiotensin aldosterone system inhibition. *Int J Cardiol*. 2013 Sep 1;167(5):1677-87.
450. Zannad F, Gattis Stough W, Rossignol P, Bauersachs J, McMurray JJ, Swedberg K, Struthers AD, Voors AA, Ruilope LM, Bakris GL, **O'Connor CM**, Gheorghide M, Mentz RJ, Cohen-Solal A, Maggioni AP, Beygui F, Filippatos GS, Massy ZA, Pathak A, Piña IL, Sabbah HN, Sica DA, Tavazzi L, Pitt B. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. *Eur Heart J*. 2012 Nov;33(22):2782-95.
451. Felker GM, Hasselblad V, Tang WH, Hernandez AF, Armstrong PW, Fonarow GC, Voors AA, Metra M, McMurray JJ, Butler J, Heizer GM, Dickstein K, Massie BM, Atar D, Troughton RW, Anker SD, Califf RM, Starling RC, **O'Connor CM**. Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study. *Eur J Heart Fail*. 2012 Nov;14(11):1257-64.
452. Zannad F, Gattis Stough W, Rossignol P, Bauersachs J, McMurray JJ, Swedberg K, Struthers AD, Voors AA, Ruilope LM, Bakris GL, **O'Connor CM**, Gheorghide M, Mentz RJ, Cohen-Solal A, Maggioni AP, Beygui F, Filippatos GS, Massy ZA, Pathak A, Piña IL, Sabbah HN, Sica DA, Tavazzi L, Pitt B. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. *Eur Heart J*. 2012 Nov;33(22):2782-95.
453. Felker GM, Hasselblad V, Tang WH, Hernandez AF, Armstrong PW, Fonarow GC, Voors AA, Metra M, McMurray JJ, Butler J, Heizer GM, Dickstein K, Massie BM, Atar D, Troughton RW, Anker SD, Califf RM, Starling RC, **O'Connor CM**. Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study. *Eur J Heart Fail*. 2012 Nov;14(11):1257-64.
454. Gupta A, Braunwald E, McNulty S, Felker GM, Gilbert EM, Alharethi R, Lee KL, Anstrom KJ, Redfield MM, Goldsmith SR, **O'Connor CM**, Bull DA, Stehlik J, Litwin SE. Obesity and the response to intensified diuretic treatment in decompensated heart failure: a DOSE trial substudy. *J Card Fail*. 2012 Nov;18(11):837-44.
455. Mentz RJ, Chung MJ, Gheorghide M, Pang PS, Kwasny MJ, Ambrosy AP, Vaduganathan M, **O'Connor CM**, Swedberg K, Zannad F, Konstam MA, Maggioni AP. Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: Findings from the EVEREST Trial. *Am Heart J*. 2012 Dec;164(6):884-892.e2.
456. Shah RV, McNulty S, **O'Connor CM**, Felker GM, Braunwald E, Givertz MM. Effect of admission oral diuretic dose on response to continuous versus bolus intravenous diuretics in acute heart failure: An analysis from Diuretic Optimization Strategies in Acute Heart Failure. *Am Heart J*. 2012 Dec;164(6):862-8.
457. **O'Connor CM**, Ahmad T. Can we prevent heart failure with exercise? *J Am Coll Cardiol*. 2012 Dec 18;60(24):2548-9. No abstract available.
458. Bart BA, Goldsmith SR, Lee KL, Givertz MM, **O'Connor CM**, Bull DA, Redfield MM, Deswal A, Rouleau JL, LeWinter MM, Ofili EO, Stevenson LW, Semigran MJ, Felker GM, Chen HH, Hernandez AF, Anstrom KJ, McNulty SE, Velazquez EJ, Ibarra JC, Mascette AM, Braunwald E; Heart Failure Clinical Research Network. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. *N Engl J Med*. 2012 Dec 13;367(24):2296-304.

459. Mentz RJ, Allen BD, Kwasny MJ, Konstam MA, Udelson JE, Ambrosy AP, Fought AJ, Vaduganathan M, **O'Connor CM**, Zannad F, Maggioni AP, Swedberg K, Bonow RO, Gheorghiuade M. Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial. *Eur J Heart Fail*. 2013 Jan;15(1):61-8.
460. Mentz RJ, Schulte PJ, Fleg JL, Fiuzat M, Kraus WE, Piña IL, Keteyian SJ, Kitzman DW, Whellan DJ, Ellis SJ, **O'Connor CM**. Clinical characteristics, response to exercise training, and outcomes in patients with heart failure and chronic obstructive pulmonary disease: Findings from Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION). *Am Heart J*. 2013 Feb;165(2):193-9.
461. Mentz RJ, Wojdyla D, Fiuzat M, Chiswell K, Fonarow GC, **O'Connor CM**. Association of Beta-Blocker Use and Selectivity With Outcomes in Patients With Heart Failure and Chronic Obstructive Pulmonary Disease (from OPTIMIZE-HF). *Am J Cardiol*. 2013 Feb 15;111(4):582-7.
462. Jiang W, Samad Z, Boyle S, Becker RC, Williams R, Kuhn C, Ortel TL, Rogers J, Kuchibhatla M, **O'Connor C**, Velazquez EJ. Prevalence and clinical characteristics of mental stress-induced myocardial ischemia in patients with coronary heart disease. *J Am Coll Cardiol*. 2013 Feb 19;61(7):714-22.
463. Lazzarini V, Mentz RJ, Fiuzat M, Metra M, **O'Connor CM**. Heart failure in elderly patients: distinctive features and unresolved issues. *Eur J Heart Fail*. 2013 Jul;15(7):717-23.
464. Kao DP, Davis G, Aleong R, **O'Connor CM**, Fiuzat M, Carson PE, Anand IS, Plehn JF, Gottlieb SS, Silver MA, Lindenfeld J, Miller AB, White M, Murphy GA, Sauer W, Bristow MR. Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. *Eur J Heart Fail*. 2013 Mar;15(3):324-33.
465. Fiuzat M, Neely ML, Starr AZ, Kraus WE, Felker GM, Donahue M, Adams K, Piña IL, Whellan D, **O'Connor CM**. Association between adrenergic receptor genotypes and beta-blocker dose in heart failure patients: analysis from the HF-ACTION DNA substudy. *Eur J Heart Fail*. 2013 Mar;15(3):258-66.
466. Kociol RD, McNulty SE, Hernandez AF, Lee KL, Redfield MM, Tracy RP, Braunwald E, **O'Connor CM**, Felker GM. Markers of Decongestion, Dyspnea Relief and Clinical Outcomes Among Patients Hospitalized with Acute Heart Failure. *Circ Heart Fail*. 2013 Mar 1;6(2):240-5.
467. McMurray JJ, Anand IS, Diaz R, Maggioni AP, **O'Connor C**, Pfeffer MA, Solomon SD, Tendera M, van Veldhuisen DJ, Albizem M, Cheng S, Scarlata D, Swedberg K, Young JB; on behalf of the RED-HF Committees Investigators. Baseline characteristics of patients in the Reduction of Events with Darbeoetin alfa in Heart Failure trial (RED-HF). *Eur J Heart Fail*. 2013 Mar;15(3):334-341.
468. Mentz RJ, Hernandez AF, Stebbins A, Ezekowitz JA, Felker GM, Heizer GM, Atar D, Teerlink JR, Califf RM, Massie BM, Hasselblad V, Starling RC, **O'Connor CM**, Ponikowski P. Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF. *Eur J Heart Fail*. 2013 Apr;15(4):456-64..
469. Shukla A, Curtis AB, Mehra MR, Albert NM, Gheorghiuade M, Heywood JT, Liu Y, **O'Connor CM**, Reynolds D, Walsh MN, Yancy CW, Fonarow GC. Factors Associated with Improvement in Utilization of Cardiac Resynchronization Therapy in Eligible Heart Failure Patients: Findings from IMPROVE HF. *Pacing Clin Electrophysiol*. 2013 Apr;36(4):433-43.

470. Wu AH, Levy WC, Welch KB, Neuberger GW, **O'Connor CM**, Carson PE, Miller AB, Ghali JK. Association Between Bilirubin and Mode of Death in Severe Systolic Heart Failure. *Am J Cardiol*. 2013 Apr 15;111(8):1192-7.
471. van der Meer P, Postmus D, Ponikowski P, Cleland JG, **O'Connor CM**, Cotter G, Metra M, Davison BA, Givertz MM, Mansoor GA, Teerlink JR, Massie BM, Hillege HL, Voors AA. The predictive value of short-term changes in hemoglobin concentration in patients presenting with acute decompensated heart failure. *J Am Coll Cardiol*. 2013 May 14;61(19):1973-81.
472. Watkins LL, Koch GG, Sherwood A, Blumenthal JA, Davidson JR, **O'Connor C**, Sketch MH. Association of anxiety and depression with all-cause mortality in individuals with coronary heart disease. *J Am Heart Assoc*. 2013 Mar 19;2(2):e000068.
473. Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Ofili EO, **O'Connor CM**, Felker GM, Goldsmith SR, Bart BA, McNulty SE, Ibarra JC, Lin G, Oh JK, Patel MR, Kim RJ, Tracy RP, Velazquez EJ, Anstrom KJ, Hernandez AF, Mascette AM, Braunwald E; RELAX Trial. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. *JAMA*. 2013 Mar 27;309(12):1268-77.
474. Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, Maggioni AP, McMurray JJ, **O'Connor C**, Pfeffer MA, Solomon SD, Sun Y, Tendera M, van Veldhuisen DJ; RED-HF Committees; RED-HF Investigators. Treatment of anemia with darbepoetin alfa in systolic heart failure. *N Engl J Med*. 2013 Mar 28;368(13):1210-9.
475. Wolfe F, Bolster MB, **O'Connor CM**, Michaud K, Lyles KW, Colón-Emeric CS. Bisphosphonate use is associated with reduced risk of myocardial infarction in patients with rheumatoid arthritis. *J Bone Miner Res*. 2013 May;28(5):984-991.
476. Jiang W, Velazquez EJ, Kuchibhatla M, Samad Z, Boyle SH, Kuhn C, Becker RC, Ortel TL, Williams RB, Rogers JG, **O'Connor C**. Effect of escitalopram on mental stress-induced myocardial ischemia: results of the REMIT trial. *JAMA*. 2013 May 22;309(20):2139-49.
477. **O'Connor CM**. Do we really need more biomarkers? *JACC Heart Fail*. 2013 Jun;1(3):270-1. doi: 10.1016/j.jchf.2013.04.001.
478. Eapen ZJ, Reed SD, Li Y, Kociol RD, Armstrong PW, Starling RC, McMurray JJ, Massie BM, Swedberg K, Ezekowitz JA, Fonarow GC, Teerlink JR, Metra M, Whellan DJ, **O'Connor CM**, Califf RM, Hernandez AF. Do Countries or Hospitals With Longer Hospital Stays for Acute Heart Failure Have Lower Readmission Rates? Findings From ASCEND-HF. *Circ Heart Fail*. 2013 Jun 14.
479. Hudson L, Morales A, Mauro AC, Whellan D, Adams KF, **O'Connor CM**, Hershberger RE. Family History of Dilated Cardiomyopathy among Patients with Heart Failure from the HF-ACTION Genetic Ancillary Study. *Clin Transl Sci*. 2013 Jun;6(3):179-83.
480. Gottlieb SS, Stebbins A, Voors AA, Hasselblad V, Ezekowitz JA, Califf RM, **O'Connor CM**, Starling RC, Hernandez AF. Effects of Nesiritide and Predictors of Urine Output in Acute Decompensated Heart Failure: Results From ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure). *J Am Coll Cardiol*. 2013 Sep 24;62(13):1177-83.
481. Eapen ZJ, Reed SD, Li Y, Kociol RD, Armstrong PW, Starling RC, McMurray JJ, Massie BM, Swedberg K, Ezekowitz JA, Fonarow GC, Teerlink JR, Metra M, Whellan DJ, **O'Connor CM**,

- Califf RM, Hernandez AF. Do Countries or Hospitals With Longer Hospital Stays for Acute Heart Failure Have Lower Readmission Rates?: Findings From ASCEND-HF. *Circ Heart Fail.* 2013 Jul 1;6(4):727-32..
482. Mentz RJ, Lazzarini V, Fiuzat M, Metra M, **O'Connor CM**, Felker GM. Is there a rationale for antiplatelet therapy in acute heart failure? *Circ Heart Fail.* 2013 Jul 1;6(4):869-76.
483. Ahmad T, **O'Connor C**. Therapeutic Implications of Biomarkers in Chronic Heart Failure. *Clin Pharmacol Ther.* 2013 Jul 15. doi: 10.1038/clpt.2013.139. [Epub ahead of print]
484. Howlett JG, Ezekowitz JA, Podder M, Hernandez AF, Diaz R, Dickstein K, Dunlap ME, Corbalán R, Armstrong PW, Starling RC, **O'Connor CM**, Califf RM, Fonarow GC; on behalf of the ASCEND-HF Investigators. Global Variation in Quality of Care Among Patients Hospitalized With Acute Heart Failure in an International Trial: Findings From the Acute Study Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). *Circ Cardiovasc Qual Outcomes.* 2013 Sep 1;6(5):534-42. Jul 30.
485. Fiuzat M, **O'Connor CM**, Gueyffier F, Mascette AM, Geller NL, Mebazaa A, Voors AA, Adams KF, Piña IL, Neyses L, Muntendam P, Felker GM, Pitt B, Zannad F, Bristow MR. Biomarker-guided therapies in heart failure: a forum for unified strategies. *J Card Fail.* 2013 Aug;19(8):592-9.
486. Zannad F, Stough WG, Regnault V, Gheorghiade M, Deliargyris E, Gibson CM, Agewall S, Berkowitz SD, Burton P, Calvo G, Goldstein S, Verheugt FW, Koglin J, **O'Connor CM**. Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challenges. *Int J Cardiol.* 2013 Sep 1;167(5):1772-82.
487. Aleong, R, Sauer W Davis G, , Murphy G, Port JD, Anand I, Fiuzat M, **O'Connor CM**, Abraham WT, Liggett SB, Bristow, M. Prevention of Atrial Fibrillation by Bucindolol is Dependent on the Beta-1 389 Arg/Gly Adrenergic Receptor Polymorphism. *JACC: HF.* 2013;1:338-44
488. Mentz RJ, Bittner V, Schulte PJ, Fleg JL, Piña IL, Keteyian SJ, Moe G, Nigam A, Swank AM, Onwuanyi AE, Fitz-Gerald M, Kao A, Ellis SJ, Kraus WE, Whellan DJ, **O'Connor CM**. Race, exercise training, and outcomes in chronic heart failure: Findings from Heart Failure - A Controlled Trial Investigating Outcomes in Exercise Training (HF-ACTION). *Am Heart J.* 2013 Sep;166(3):488-495.e1.
489. Reed SD, Kaul P, Li Y, Eapen ZJ, Davidson-Ray L, Schulman KA, Massie BM, Armstrong PW, Starling RC, **O'Connor CM**, Hernandez AF, Califf RM. Medical Resource Use, Costs, and Quality of Life in Patients With Acute Decompensated Heart Failure: Findings From ASCEND-HF. *J Card Fail.* 2013 Sep;19(9):611-20.
490. Mentz RJ, Felker GM, Ahmad T, Peacock WF, Pitt B, Fiuzat M, Maggioni AP, Gheorghiade M, Ando Y, Pocock SJ, Zannad F, **O'Connor CM**. Learning from recent trials and shaping the future of acute heart failure trials. *Am Heart J.* 2013 Oct;166(4):629-35.
491. Jiang W, **O'Connor CM**, Velazquez EJ. Therapy for mental stress-induced myocardial ischemia -- Reply. *JAMA.* 2013 Oct 2;310(13):1401-2. No abstract available.
492. McCullough PA, Barnard D, Clare R, Ellis SJ, Fleg JL, Fonarow GC, Franklin BA, Kilpatrick RD, Kitzman DW, **O'Connor CM**, Piña IL, Thadani U, Thohan V, Whellan DJ; for the HF-ACTION Investigators. Anemia and Associated Clinical Outcomes in Patients With Heart Failure Due to Reduced Left Ventricular Systolic Function. *Clin Cardiol.* 2013 Oct;36(10):611-20.
493. Carson P, Wertheimer J, Miller A, **O'Connor CM**, Piña IL, Selzman C, Sueta C, She L, Greene D, Lee KL, Jones RH, Velazquez EJ; for the STICH investigators. Surgical Treatment for

- Ischemic Heart Failure (STICH) Trial: Mode of Death Results. *JACC Heart Fail.* 2013 Oct;1(5).
494. Felker GM, Fiuzat M, Thompson V, Shaw LK, Neely ML, Adams KF, Whellan DJ, Donahue MP, Ahmad T, Kitzman DW, Piña IL, Zannad F, Kraus WE, **O'Connor CM**. Soluble ST2 in Ambulatory Patients With Heart Failure: Association With Functional Capacity and Long-Term Outcomes. *Circ Heart Fail.* 2013 Nov 1;6(6):1172-9.
  495. Chen HH, Anstrom KJ, Givertz MM, Stevenson LW, Semigran MJ, Goldsmith SR, Bart BA, Bull DA, Stehlik J, Lewinter MM, Konstam MA, Huggins GS, Rouleau JL, O'Meara E, Tang WH, Starling RC, Butler J, Deswal A, Felker GM, **O'Connor CM**, Bonita RE, Margulies KB, Cappola TP, Ofili EO, Mann DL, Dávila-Román VG, McNulty SE, Borlaug BA, Velazquez EJ, Lee KL, Shah MR, Hernandez AF, Braunwald E, Redfield MM; for the NHLBI Heart Failure Clinical Research Network. Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Renal Dysfunction: The ROSE Acute Heart Failure Randomized Trial. *JAMA.* 2013 Nov 18.
  496. Boyle SH, Samad Z, Becker RC, Williams R, Kuhn C, Ortel TL, Kuchibhatla M, Prybol K, Rogers J, **O'Connor C**, Velazquez EJ, Jiang W. Depressive symptoms and mental stress-induced myocardial ischemia in patients with coronary heart disease. *Psychosom Med.* 2013 Nov;75(9):822-31.
  497. Meyer S, van der Meer P, Massie BM, **O'Connor CM**, Metra M, Ponikowski P, Teerlink JR, Cotter G, Davison BA, Cleland JG, Givertz MM, Bloomfield DM, Fiuzat M, Dittrich HC, Hillege HL, Voors AA. Sex-specific acute heart failure phenotypes and outcomes from PROTECT. *Eur J Heart Fail.* 2013 Dec;15(12):1374-81.
  498. Fiuzat M, Schulte PJ, Felker GM, Ahmad T, Neely M, Adams KF, Donahue MP, Kraus WE, Piña IL, Whellan DJ, **O'Connor CM**. Relationship between Galectin-3 Levels and Mineralocorticoid Receptor Antagonist Use in Heart Failure: Analysis from the HF-ACTION Study. *J Card Fail.* 2014 Jan;20(1):38-44.
  499. Dobre D, Borer JS, Fox K, Swedberg K, Adams KF, Cleland JG, Cohen-Solal A, Gheorghide M, Gueyffier F, **O'Connor CM**, Fiuzat M, Patak A, Piña IL, Rosano G, Sabbah HN, Tavazzi L, Zannad F. Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties. *Eur J Heart Fail.* 2014 Jan;16(1):76-85
  500. Wilcox JE, Fonarow GC, Zhang Y, Albert NM, Curtis AB, Gheorghide M, Heywood JT, Mehra MR, **O'Connor CM**, Reynolds D, Walsh MN, Yancy CW. Clinical effectiveness of cardiac resynchronization and implantable cardioverter-defibrillator therapy in men and women with heart failure: findings from IMPROVE HF. *Circ Heart Fail.* 2014 Jan;7(1):146-53.
  501. Givertz MM, Postmus D, Hillege HL, Mansoor GA, Massie BM, Davison BA, Ponikowski P, Metra M, Teerlink JR, Cleland JG, Dittrich HC, **O'Connor CM**, Cotter G, Voors AA. Renal Function Trajectories and Clinical Outcomes in Acute Heart Failure. *Circ Heart Fail.* 2014 Jan;7(1):59-67.
  502. Mentz RJ, Broderick S, Shaw LK, Fiuzat M, **O'Connor CM**. Heart Failure with Preserved Ejection Fraction: Comparison of Patients With and Without Angina Pectoris (From the Duke Databank for Cardiovascular Disease). *J Am Coll Cardiol.* 2014 Jan 28;63(3):251-8.
  503. Cleland JG, Chiswell K, Teerlink JR, Stevens S, Fiuzat M, Givertz MM, Davison BA, Mansoor GA, Ponikowski P, Voors AA, Cotter G, Metra M, Massie BM, **O'Connor CM**. Predictors of Post-Discharge Outcomes from Information Acquired Shortly After Admission for Acute Heart Failure: A Report from the PROTECT Study. *Circ Heart Fail.* 2014 Jan;7(1):76-87.

504. Damman K, Valente MA, Voors AA, **O'Connor CM**, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. *Eur Heart J*. 2014 Feb;35(7):455-69..
505. **O'Connor C**. Design of design papers. *JACC Heart Fail*. 2014 Feb;2(1):95-6. Epub 2014 Jan 25. No abstract available.
506. Ersboll M, Al Enezi F, Samad Z, Sedberry B, Boyle SH, **O'Connor C**, Jiang W, Velazquez EJ; REMIT Investigators. Impaired Resting Myocardial Annular Velocities Are Independently Associated With Mental Stress-Induced Ischemia in Coronary Heart Disease. *JACC Cardiovasc Imaging*. 2014 Apr;7(4):351-61. Epub 2014 Mar 7.
507. Ahmad T, Fiuzat M, Mark DB, Neely B, Neely M, Kraus WE, Kitzman DW, Whellan DJ, Donahue M, Zannad F, Piña IL, Adams K, **O'Connor CM**, Felker GM. The Effects of Exercise on Cardiovascular Biomarkers in patients with chronic heart failure. *Am Heart J*. 2014 Feb;167(2):193-202.e1.
508. Toma M, Ezekowitz JA, Bakal JA, **O'Connor CM**, Hernandez AF, Sardar MR, Zolty R, Massie BM, Swedberg K, Armstrong PW, Starling RC. The relationship between left ventricular ejection fraction and mortality in patients with acute heart failure: insights from the ASCEND-HF Trial. *Eur J Heart Fail*. 2014 Mar;16(3):334-41.
509. Valente MA, Voors AA, Damman K, Van Veldhuisen DJ, Massie BM, **O'Connor CM**, Metra M, Ponikowski P, Teerlink JR, Cotter G, Davison B, Cleland JG, Givertz MM, Bloomfield DM, Fiuzat M, Dittrich HC, Hillege HL. Diuretic response in acute heart failure: clinical characteristics and prognostic significance. *Eur Heart J*. 2014 May 14;35(19):1284-93. Epub 2014 Feb 28.
510. Mentz RJ, Kjeldsen K, Rossi GP, Voors AA, Cleland JG, Anker SD, Gheorghide M, Fiuzat M, Rossignol P, Zannad F, Pitt B, **O'Connor C**, Felker GM. Decongestion in acute heart failure. *Eur J Heart Fail*. 2014 May;16(5):471-8. Epub 2014 Mar 5.
511. Kalogeropoulos AP, Tang WH, Hsu A, Felker GM, Hernandez AF, Troughton RW, Voors AA, Anker SD, Metra M, McMurray JJ, Massie BM, Ezekowitz JA, Califf RM, **O'Connor CM**, Starling RC, Butler J. High sensitivity C-reactive protein in acute heart failure: Insights from the ASCEND-HF trial. *J Card Fail*. 2014 May;20(5):319-26. Epub 2014 Feb 11.
512. Vavalle JP, Phillips HR, Holleran SA, Wang A, **O'Connor CM**, Smith PK, Hughes GC, Harrison JK, Patel MR. Analysis of geographic variations in the diagnosis and treatment of patients with aortic stenosis in North Carolina. *Am J Cardiol*. 2014 Jun 1;113(11):1874-8. Epub 2014 Mar 22.
513. Ahmad T, **O'Connor CM**, et al. Biomarkers of Myocardial Stress and Fibrosis as Predictors of Mode of Death in Patients with Chronic Heart Failure. *JACC Heart Fail*. 2014 Jun;2(3):260-8.
514. **O'Connor CM**. Editorial Mentorship. *JACC Heart Fail*. 2014 Jun;2(3):321-2.
515. Troughton RW, Frampton CM, Brunner-La Rocca HP, Pfisterer M, Eurlings LW, Erntell H, Persson H, **O'Connor CM**, Moertl D, Karlström P, Dahlström U, Gaggin HK, Januzzi JL, Berger R, Richards AM, Pinto YM, Nicholls MG. Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. *Eur Heart J*. Jun 14;35(23):1559-67. Epub 2014 Mar 6.
516. Mentz RJ, Cotter G, Cleland JG, Stevens SR, Chiswell K, Davison BA, Teerlink JR, Metra M, Voors AA, Grinfeld L, Ruda M, Mareev V, Lotan C, Bloomfield GM, Fiuzat M, Givertz MM, Ponikowski P, Massie BM, **O'Connor CM**. International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in

- patients enrolled in Eastern Europe and Russia in the PROTECT trial. *Eur J Heart Fail*. 2014 June;16(6):614-24. Epub 2014 Apr 25.
517. Taylor RS, Piepoli MF, Smart N, Coats AJ, Ellis S, **O'Connor CM**, Warren FC, Whellan D, Ciana O; ExTraMATCH II Collaborators. Exercise training for chronic heart failure (ExTraMATCH II): Protocol for an individual participant data meta-analysis. *Int J Cardiol*. 2014 July 1;174(3):683-7. Epub 2014 April 26.
518. Li Y, Levy WC, Neilson MP, Ellis SJ, Whellan DJ, Schulman KA, **O'Connor CM**, Reed SD. Associations between Seattle Heart Failure Model scores and medical resource use and costs: findings from HF-ACTION. *J Card Fail*. 2014 Aug;20(8):541-7. doi. 10.1016/j.cardfail.2014.05.009. Epub 2014 Jun 2.
519. Jones LW, Douglas PS, Khouri MG, Mackey JR, Wojdyla D, Kraus WE, Whellan DJ, **O'Connor CM**. Safety and efficacy of aerobic training in patients with cancer who have heart failure: an analysis of the HF-ACTION randomized trial. *J Clin Oncol*. 2014 Aug 10;32(23):2496-502. doi. 10.1200/JCO.2013.53.5724. Epub 2014 Jul 7.
520. Mentz RJ, Broderick S, Shaw LK, Chiswell K, Fiuzat M, **O'Connor CM**. Persistent angina pectoris in ischaemic cardiomyopathy: increased rehospitalization and major adverse cardiac events. *Eur J Heart Fail*. 2014 Aug;16(8):854-60. doi. 10.1002/ejhf.130. Epub 2014 June 27.
521. Ahmad T, Fiuzat M, Pencina MJ, Geller NL, Zannad F, Cleland JG, Snider JV, Blankenberg S, Adams KF, Redberg RF, Kim JB, Mascette A, Mentz RJ, **O'Connor CM**, Felker GM, Januzzi JL. *JACC Heart Fail*. 2014 Oct;2(5):477-88. doi. 10.1016/j.jchf.2014.02.005. Epub 2014 Jun 11.
522. van Deursen VM, Hernandez AF, Stebbins A, Hasselblad V, Ezekowitz JA, Califf RM, Gottlieb SS, **O'Connor CM**, Starling RC, Tang WH, McMurray JJ, Dickstein K, Voors AA. Nesiritide, renal function, and associated outcomes during hospitalization for acute and decompensated heart failure: results from the Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF). *Circulation*. 2014 Sept 16;130(12):958-65. doi. 10.1161/Circulation.AHA.113.003046. Epub 2014 Jul 29.
523. Felker GM, Ahmad T, Anstrom KJ, Adams KF, Cooper LS, Ezekowitz JA, Fiuzat M, Houston-Miller N, Januzzi JL, Leifer ES, Mark DB, Desvigne-Nickens P, Paynter G, Piña IL, Whellan DJ, **O'Connor CM**. Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure. *JACC Heart Fail*. 2014 Oct;2(5):457-65. doi. 10.1016/j.jchf.2014.05.007. Epub 2014 Sept 3.
524. Patel CB, DeVore AD, Felker GM, Wojdyla DM, Hernandez AF, Milano CA, **O'Connor CM**, Rogers JG. Characteristics and outcomes of patients with heart failure and discordant findings by right-sided heart catheterization and cardiopulmonary exercise testing. *Am J Cardiol*. 2014 Oct 1;114(7):1059-64. doi. 10.1016/j.amjcard.2014.07.022. Epub 2014 Jul 18.
525. Rogers JG, **O'Connor CM**. The changing landscape of advanced heart failure therapeutics. *J Am Coll Cardiol*. 2014 Oct 7;64(14):1416-7. doi. 10.1016/j.jacc.2014.04.085. No abstract available.
526. Ahmad T, Fiuzat M, Pencina MJ, Geller NL, Zannad F, Cleland JG, Snider JV, Blankenberg S, Adams KF, Redberg RF, Kim JB, Mascette A, Mentz RJ, **O'Connor CM**, Felker GM, Januzzi JL. Charting a roadmap for heart failure biomarker studies. *JACC Heart Fail*. 2014 Oct;2(5):477-88. doi. 10.1016/j.jchf.2014.02.005. Epub 2014 Jun 11.
527. Ahmad T, Pencina MJ, Schulte PJ, O'Brien E, Whellan DJ, Piñal L, Kitzman DW, Lee KL, **O'Connor CM**, Felker GM. Clinical implications of chronic heart failure phenotypes by cluster

- analysis. *J Am Coll Cardiol*. 2014 Oct 28;64(17):1765-74. doi. 10.1016/j.jacc.2014.07.979. Epub 2014 Oct 21.
528. Mentz RJ, Tulskey JA, Granger BB, Anstrom KJ, Adams PA, Dodson GC, Fiuzat M, Johnson KS, Patel CB, Steinhauser KE, Taylor DH, **O'Connor CM**, Rogers JG. *Am Heart J*. 2014 Nov;168(5):645-651.e1. doi. 10.1016/j.ahj.2014.07.018. Epub 2014 Jul 30.
529. Mentz RJ, Kelly JP, von Lueder TG, Voors AA, Lam CS, Cowie MR, Kjeldsen K, Jankowska EA, Atar D, Butler J, Fiuzat M, Zannad F, Pitt B, **O'Connor CM**. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. *J Am Coll Cardiol*. 2014 Dec 2;64(21):2281-93. doi. 10.1016/j.jacc.2014.2014.08.036. Epub 2014 Nov 24. Review
530. Das D, Bakal JA, Westerhout CM, Hernandez AF, **O'Connor CM**, Atar D, McMurray JJ, Armstrong PW, Ezekowitz JA. The association between meteorological events and acute heart failure: new insights from ASCEND-HF. *Int J Cardiol*. 2014 Dec 20;177(3):819-24. doi. 10.1016/j.ijcar.2014.11.066. Epub 2014 Nov 6.
531. Patel PA, Heizer G, **O'Connor CM**, Schulte PJ, Dickstein K, Ezekowitz JA, Armstrong PW, Hasselblad V, Mills RM, McMurray JJ, Starling RC, Tang WH, Califf RM, Hernandez AF. *Circ Heart Fail*. 2014 Nov;7(6):918-25. doi. 10.1161/Circ Heart Fail.113...00872. Epub 2014 Oct 3.
532. van Diepen S, Podder M, Hernandez AF, Westerhout CM, Armstrong PW, McMurray JJ, Eapen ZJ, Califf RM, Starling RC, **O'Connor CM**, Ezekowitz JA. Acute decompensated heart failure patients admitted to critical care units: insights from ASCEND-HF. *Int J Cardiol*. 2014 Dec 20;177(3):840-6. doi. 10.1016/j.ijcard.2014.11.007. Epub 2014 Nov 7.
533. **O'Connor CM**. Precision and predictive medicine: lessons learned from our oncology colleagues. *JACC Heart Fail*. 2014 Dec;2(6):671. doi. 10.1016/j.jchf.2014.10.004. Epub 2014 Dec 1. No abstract available.
534. Samad Z, Boyle S, Ersboll M, Vora AN, Zhang Y, Becker RC, Williams R, Kuhn C, Ortel TL, Rogers JG, **O'Connor CM**, Velazquez EJ, Jiang W; REMIT Investigators. Sex differences in platelet reactivity and cardiovascular and psychological response to mental stress in patients with stable ischemic heart disease: insights from the REMIT study. *J Am Coll Cardiol*. 2014 Oct 21;64(16):1669-78. doi. 10.1016/j.jacc.2014.04.087. Erratum in: *J Am Coll Cardiol*. 2014 Dec 9;64(22):2438
535. Cotter G, Metra M, Davison BA, Senger S, Bourge RC, Cleland JG, Jondeau G, Krum H, **O'Connor CM**, Parker JD, Torre-Amione G, van Veldhuisen DJ, Milo O, Kobrin I, Rainisio M, McMurray JJ, Teerlink JR; VERITAS Investigators. Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the VERITAS study. *Eur J Heart Fail*. 2014 Dec;16(12):1362-71. doi. 10.1002/ehf.186. Epub 2014 Nov 5.
536. Tang WH, Dupont M, Hernandez AF, Voors AA, Hsu AP, Felker GM, Butler J, Metra M, Anker SD, Troughton RW, Gottlieb SS, McMurray JJ, Armstrong PW, Massie BM, Califf RM, **O'Connor CM**. Comparative assessment of short-term adverse events in acute heart failure with cystatin C and other estimates of renal function: results from the ASCEND-HF trial. *JACC Heart Fail*. 2015 Jan;3(1):40-9. doi. 10.1016/j.jchf.2014.06.014. Epub 2014 Nov 11.
537. Zeitler EP, Piccini JP, Hellkamp AS, Whellan DJ, Jackson KP, Ellis SJ, Kraus WE, Keteyian SJ, Kitzman DW, Ewald GA, Fleg JL, Piña IL, **O'Connor CM**; HF-ACTION Investigators. Exercise training and pacing status in patients with heart failure: results from HF-ACTION. *J Card Fail*. 2015 Jan;21(1):60-7. doi. 10.1016/j.cardfail.2014.10.004. Epub Oct 15.
538. Metra M, Mentz RJ, Chiswell K, Bloomfield DM, Cleland JG, Cotter G, Davison BA, Dittrich HC, Fiuzat M, Givertz MM, Lazzarini V, Mansoor GA, Massie BM, Ponikowski P, Teerlink JF, Voors



- AA, **O'Connor CM**. Acute heart failure in elderly patients: worse outcomes and differential utility of standard prognostic variables. Insights from the PROTECT trial. *Eur J Heart Fail*. 2015 Jan;17(1):109-18. doi. 10.1002/ejhf.207. Epub 2014 Nov 27.
539. Mentz RJ, Stevens SR, DeVore AD, Lala A, Vader JM, AbouEzzeddine OF, Khazanie P, Redfield MM, Stevenson LW, **O'Connor CM**, Goldsmith SR, Bart BA, Anstrom KJ, Hernandez AF, Braunwald E, Felker GM. Decongestion strategies and Renin-Angiotensin-aldosterone system activation in acute heart failure. *JACC Heart Fail*. 2015 Feb;3(2):97-107. doi. 10.1016/j.jchf.2014.09.003. Epub 2014 Oct 31.
540. **O'Connor CM**, Conflict of interest and transparency: are the headlights misaligned? *JACC Heart Fail*. 2015 Jan;3(1):94. doi. 10.1016/j.jchf.2014.10.001. No abstract available.
541. Metra M, Cotter G, El-Khorazaty J, Davison BA, Milo O, Carubelli V, Bourge RC, Cleland JG, Jondeau G, Krum H, **O'Connor CM**, Parker JD, Torre-Amione G, van Veldhuisen DJ, Rainisio M, Kobrin I, McMurray JJ, Teerlink JR. Acute Heart Failure in the Elderly: Differences in Clinical Characteristics, Outcomes, and Prognostic Factors in the VERITAS Study. *J Card Fail*. 2015 Mar;21(3):179-88. doi. 10.1016/j.cardfail.2014.12.012. Epub 2015 Jan 5.
542. DeVore AD, Hasselblad V, Mentz RJ, **O'Connor CM**, Armstrong PW, McMurray JJ, Ezekowitz JA, Tang WH, Starling RC, Voors AA, Califf RM, Hernandez AF. Loop diuretic adjustments after a hospitalization for heart failure: insights from ASCEND-HF. *Eur J Heart Fail*. 2015 Mar;17(3):340-6. doi. 10.1002/ejhf.235. Epub 2015 Jan 23.
543. **O'Connor CM**. War and peace: the role of medical journals in the discussion of conflict. *JACC Heart Fail*. 2015 Feb;3(2):192. doi. 10.1016/j.jchf.2014.11.002.
544. Dardas T, Li Y, Reed SD, **O'Connor CM**, Whellan DJ, Ellis SJ, Schulman KA, Kraus WE, Forman DE, Levy WC. Incremental and independent value of cardiopulmonary exercise test measures and the Seattle Heart Failure Model for prediction of risk in patients with heart failure. *J Heart Lung Transplant*. 2015 Mar 26. pii: S1053-2498(15)01113-4. [Epub ahead of print]
545. Buggey J, Mentz RJ, Pitt B, Eisenstein EL, Anstrom KJ, Velazquez EJ, **O'Connor CM**. A reappraisal of loop diuretic choice in heart failure patients. *Am Heart J*. 2015 Mar;169(3):323-333. doi. 10.1015/j.ahj.2014.12.009. Epub 2015 Jan 6. Review.
546. **O'Connor CM**. Hop, Skip, and Jump: Do We Need Phase II Cardiovascular Clinical Trials? *JACC Heart Fail*. 2015 Mar;3(3):273-4. doi. 10.1016/j.jchf.2014.12.003. No abstract available.
547. Yun H, Delzell E, Saag KG, Kilgore ML, Morrissey MA, Muntner P, Matthews R, Guo L, Wright N, Smith W, Colón-Emeric C, **O'Connor CM**, Lyles KW, Curtis JR. Fractures and mortality in relation to different osteoporosis treatments. *Clin Exp Rheumatol*. 2015 May-Jun;33(3):302-9. Epub 2014 Jul 28.
548. Butler J, Fonarow GC, **O'Connor C**, Adams K, Bonow RO, Cody RJ, Collins SP, Dunnmon P, Dinh W, Fiuzat M, Georgiopoulou VV, Grant S, Kim SY, Kupfer S, Lefkowitz M, Mentz RJ, Misselwitz F, Pitt B, Roessig L, Schelbert E, Shah M, Solomon S, Stockbridge N, Yancy C, Gheorghiadu M. Improving cardiovascular clinical trials conduct in the United States: recommendation from clinicians, researchers, sponsors, and regulators. *Am Heart J*. 2015 Mar;169(3):305-14. doi: 10.1016/j.ahj.2014.12.001. Epub 2014 Dec 17.
549. Whellan DJ, Kraus WE, Kitzman DW, Rooney B, Keteyian SJ, Piña IL, Ellis SJ, Ghali JK, Lee KL, Cooper LS, **O'Connor CM**. Authorship in a multicenter clinical trial: The Heart Failure-A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) Authorship and Publication (HAP) scoring system results. *Am Heart J*. 2015 Apr;169(4):457-63.e6. doi: 10.1016/j.ahj.2014.11.022. Epub 2015 Jan 10. Review.

550. Jiang W, Boyle SH, Ortel TL, Samad Z, Velazquez EJ, Harrison RW, Wilson J, Kuhn C, Williams RB, **O'Connor CM**, Becker RC. Platelet aggregation and mental stress induced myocardial ischemia: Results from the Responses of Myocardial Ischemia to Escitalopram Treatment (REMIT) study. *Am Heart J*. 2015 Apr;169(4):496-507.e1. Epub 2014 Dec 17.
551. **O'Connor CM**. Reading RVUs: How can we meet the informational needs of cardiologists? *JACC Heart Fail*. 2015 Apr;3(4):340-1.
552. Kelly JP, Mentz RJ, Mebazaa A, Voors AA, Butler J, Roessig L, Fiuzat M, Zannad F, Pitt B, **O'Connor CM**, Lam CS. Patient selection in heart failure with preserved ejection fraction clinical trials. *J Am Coll Cardiol*. 2015 Apr 28;65(16):1668-82. Review.
553. Rosendorff C, Lackland DT, Allison M, Aronow WS, Black HR, Blumenthal RS, Cannon CP, de Lemos JA, Elliott WJ, Findeiss L, Gersh BJ, Gore JM, Levy D, Long JB, **O'Connor CM**, O'Gara PT, Ogedegbe O, Oparil S, White WB; American Heart Association, American College of Cardiology, and American Society of Hypertension. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. *J Am Coll Cardiol*. 2015 May 12;65(18):1998-2038. Epub 2015 Mar 31.
554. Davison BA, Metra M, Cotter G, Massie BM, Cleland JG, Dittrich HC, Edwards C, Filippatos G, Givertz MM, Greenberg B, Ponikowski P, Voors AA, **O'Connor CM**, Teerlink JR; PROTECT and RELAX-AHF Executive Committees. Worsening Heart Failure Following Admission for Acute Heart Failure: A Pooled Analysis of the PROTECT and RELAX-AHF Studies. *JACC Heart Fail*. 2015 May;3(5):395-403.
555. Mentz RJ, Buggey J, Fiuzat M, Ersbøll MK, Schulte PJ, DeVore AD, Eisenstein EL, Anstrom KJ, **O'Connor CM**, Velazquez EJ. Torsemide versus furosemide in heart failure patients: insights from duke university hospital. *J Cardiovasc Pharmacol*. 2015 May;65(5):438-43.
556. Mentz RJ, Babyak MA, Bittner V, Fleg JL, Keteyian SJ, Swank AM, Piña IL, Kraus WE, Whellan DJ, **O'Connor CM**, Blumenthal JA; HF-ACTION Investigators. Prognostic significance of depression in blacks with heart failure: insights from heart failure: a controlled trial investigating outcomes of exercise training. *Circ Heart Fail*. 2015 May;8(3):497-503. Epub 2015 Apr 21.
557. Farzaneh-Far A, Shaw LK, Dunning A, Oldan JD, **O'Connor CM**, Borges-Neto S. Comparison of the prognostic value of regadenoson and adenosine myocardial perfusion imaging. *J Nucl Cardiol*. 2015 May 19. [Epub ahead of print]
558. Hess PL, Shaw LK, Vemulapalli S, Pagnanelli R, **O'Connor CM**, Borges-Neto S. An alternative method to examine the predictive value of mechanical dyssynchrony. *J Nucl Cardiol*. 2015 May 21. [Epub ahead of print]
559. **O'Connor CM**. Medical editors' grand rounds: a discussion of timely topics and editorial emergencies. *JACC Heart Fail*. 2015 May;3(5):422-3.
560. Givertz MM, Anstrom KJ, Redfield MM, Deswal A, Haddad H, Butler J, Tang WH, Dunlap ME, LeWinter MM, Mann DL, Felker GM, **O'Connor CM**, Goldsmith SR, Ofili EO, Saltzberg MT, Margulies KB, Cappola TP, Konstam MA, Semigran MJ, McNulty SE, Lee KL, Shah MR, Hernandez AF; NHLBI Heart Failure Clinical Research Network\*. Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study. *Circulation*. 2015 May 19;131(20):1763-71. Epub 2015 Apr 14.

561. Ahmad T, O'Brien EC, Schulte PJ, Stevens SR, Fiuzat M, Kitzman DW, Adams KF, Kraus WE, Piña IL, Donahue MP, Zannad F, Whellan DJ, **O'Connor CM**, Felker GM. Evaluation of the Incremental Prognostic Utility of Increasingly Complex Testing in Chronic Heart Failure. *Circ Heart Fail*. 2015 Jul;8(4):709-16.
562. Boyle SH, Matson WR, Velazquez EJ, Samad Z, Williams RB Jr, Sharma S, Thomas B, Wilson JL, **O'Connor C**, Jiang W. Metabolomics analysis reveals insights into biochemical mechanisms of mental stress-induced left ventricular dysfunction. *Metabolomics*. 2015 Jun 1;11(3):571-582.
563. **O'Connor CM**. Time for Recognition. *JACC Heart Fail*. 2015 Jun;3(6):508-9.
564. Mentz RJ, Metra M, Cotter G, Milo O, McKendry C, Chiswell K, Davison BA, Cleland JG, Bloomfield DM, Dittrich HC, Fiuzat M, Ponikowski P, Givertz MM, Voors AA, Teerlink JR, **O'Connor CM**. Early vs. late worsening heart failure during acute heart failure hospitalization: insights from the PROTECT trial. *Eur J Heart Fail*. 2015 Jul;17(7):697-706.
565. Harinstein ME, Butler J, Greene SJ, Fonarow GC, Stockbridge NL, **O'Connor CM**, Pfeiffer MA, Mehra MR, Solomon SD, Yancy CW, Fiuzat M, Mentz RJ, Collins SP, McMurray JJ, Vaduganathan M, Dunnmon PM, Rosano GM, Dinh W, Misselwitz F, Bonow RO, Gheorghiane M. Site selection for heart failure clinical trials in the USA. *Heart Fail Rev*. 2015 Jul;20(4):375-83. doi: 10.1007/s10741-015-9473-z.
566. Xiong GL, Prybol K, Boyle SH, Hall R, Streilein RD, Steffens DC, Krishnan R, Rogers JG, **O'Connor CM**, Jiang W; SADHART-CHF Investigators Inflammation Markers and Major Depressive Disorder in Patients With Chronic Heart Failure: Results From the Sertraline Against Depression and Heart Disease in Chronic Heart Failure Study. *Psychosom Med*. 2015 Jul 16. [Epub ahead of print]
567. Garber AM, Mentz RJ, Al-Khalidi HR, Shaw LK, Fiuzat M, **O'Connor CM**, Velazquez EJ. Clinical predictors and outcomes of patients with left ventricular thrombus following ST-segment elevation myocardial infarction. *J Thromb Thrombolysis*. 2015 Jul 23. [Epub ahead of print]
568. **O'Connor CM**. Why We Respect Randomized Controlled Clinical Trials in Heart Failure. *JACC Heart Fail*. 2015 Jul;3(7):576-7.
569. Abualnaja S, Podder M, Hernandez AF, McMurray JJ, Starling RC, **O'Connor CM**, Califf RM, Armstrong PW, Ezekowitz JA. Acute Heart Failure and Atrial Fibrillation: Insights From the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) Trial. *J Am Heart Assoc*. 2015 Aug 24;4(8). pii: e002092. doi: 10.1161/JAHA.115.002092.
570. Ter Maaten JM, Dunning AM, Valente MA, Damman K, Ezekowitz JA, Califf RM, Starling RC, van der Meer P, **O'Connor CM**, Schulte PJ, Testani JM, Hernandez AF, Tang WH, Voors AA. Diuretic response in acute heart failure-an analysis from ASCEND-HF. *Am Heart J*. 2015 Aug;170(2):313-321.e4. doi: 10.1016/j.ahj.2015.05.003. Epub 2015 May 9.
571. Kelly JP, Mentz RJ, Hasselblad V, Ezekowitz JA, Armstrong PW, Zannad F, Felker GM, Califf RM, **O'Connor CM**, Hernandez AF. Worsening heart failure during hospitalization for acute heart failure: Insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF). *Am Heart J*. 2015 Aug;170(2):298-305. doi: 10.1016/j.ahj.2015.04.007. Epub 2015 Apr 15.
572. Khazanie P, Heizer GM, Hasselblad V, Armstrong PW, Califf RM, Ezekowitz J, Dickstein K, Levy WC, McMurray JJ, Metra M, Tang WH, Teerlink JR, Voors AA, **O'Connor CM**, Hernandez AF, Starling R. Predictors of clinical outcomes in acute decompensated heart failure: Acute

- Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models. *Am Heart J.* 2015 Aug;170(2):290-297.e1. doi: 10.1016/j.ahj.2015.04.006. Epub 2015 Apr 11.
573. Ter Maaten JM, Valente MA, Metra M, Bruno N, **O'Connor CM**, Ponikowski P, Teerlink JR, Cotter G, Davison B, Cleland JG, Givertz MM, Bloomfield DM, Dittrich HC, van Veldhuisen DJ, Hillege HL, Damman K, Voors AA. A combined clinical and biomarker approach to predict diuretic response in acute heart failure. *Clin Res Cardiol.* 2016 Feb;105(2):145-53. Epub 2015 Aug 18.
574. **O'Connor CM**. The Globalization of Heart Failure Research. *JACC Heart Fail.* 2015 Aug;3(8):657-8.
575. **O'Connor CM**, Ahmad T. The Role of Sodium and Chloride in Heart Failure: Does It Take Two to Tango? *J Am Coll Cardiol.* 2015 Aug 11;66(6):667-9.
576. Ovchinnikova ES, Schmitter D, Vegter EL, Ter Maaten JM, Valente MA, Liu LC, van der Harst P, Pinto YM, de Boer RA, Meyer S, Teerlink JR, **O'Connor CM**, Metra M, Davison BA, Bloomfield DM, Cotter G, Cleland JG, Mebazaa A, Laribi S, Givertz MM, Ponikowski P, van der Meer P, van Veldhuisen DJ, Voors AA, Berezikov E. Signature of circulating microRNAs in patients with acute heart failure. *Eur J Heart Fail.* 2015 Sep 8. doi: 10.1002/ejhf.332. [Epub ahead of print]
577. Felker GM, Mentz RJ, Adams KF, Cole RT, Egnaczyk GF, Patel CB, Fiuzat M, Gregory D, Wedge P, **O'Connor CM**, Udelson JE, Konstam MA. Tolvaptan in Patients Hospitalized With Acute Heart Failure: Rationale and Design of the TACTICS and the SECRET of CHF Trials. *Circ Heart Fail.* 2015 Sep;8(5):997-1005.
578. **O'Connor CM**. What Is a Life Worth?: A Tribute to Dr. William Little, a Pioneer in the Understanding of Heart Failure With Preserved Ejection Fraction. *JACC Heart Fail.* 2015 Sep;3(9):734-5.
579. Xiong GL, Prybol K, Boyle SH, Hall R, Streilein RD, Steffens DC, Krishnan R, Rogers JG, **O'Connor CM**, Jiang W; SADHART-CHF Investigators. Inflammation Markers and Major Depressive Disorder in Patients With Chronic Heart Failure: Results From the Sertraline Against Depression and Heart Disease in Chronic Heart Failure Study. *Psychosom Med.* 2015 Sep;77(7):808-15.
580. Mentz RJ, Velazquez EJ, Metra M, McKendry C, Chiswell K, Fiuzat M, Givertz MM, Voors AA, Teerlink JR, **O'Connor CM**. Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial. *Future Cardiol.* 2015 Sep;11(5):585-95. doi: 10.2217/fca.15.56. Epub 2015 Sep 25.
581. Samad Z, Shaw LK, Phelan M, Erbsoll M, Risum N, Al-Khalidi HR, Glower DD, Milano CA, Alexander JH, **O'Connor CM**, Wang A, Velazquez EJ. Management and outcomes in patients with moderate or severe functional mitral regurgitation and severe left ventricular dysfunction. *Eur Heart J.* 2015 Oct 21;36(40):2733-41. Epub 2015 Aug 1.
582. Grodin JL, Perez AL, Wu Y, Hernandez AF, Butler J, Metra M, Felker GM, Voors AA, McMurray JJ, Armstrong PW, Califf RM, Starling RC, **O'Connor CM**, Tang WH. Circulating Kidney Injury Molecule-1 Levels in Acute Heart Failure: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). *JACC Heart Fail.* 2015 Oct;3(10):777-85.
583. **O'Connor CM**. Physician-Leaders: A Call for Cardiovascular Specialists to Step Up. *JACC Heart Fail.* 2015 Oct;3(10):843-4.

584. **O'Connor CM**. Bundle Up for Value-Based Heart Failure Care. *JACC Heart Fail*. 2015 Nov;3(11):931-2. doi: 10.1016/j.jchf.2015.09.003. No abstract available.
585. Cooper LB, Mentz RJ, Sun JL, Schulte PJ, Fleg JL, Cooper LS, Piña IL, Leifer ES, Kraus WE, Whellan DJ, Keteyian SJ, **O'Connor CM**. Psychosocial Factors, Exercise Adherence, and Outcomes in Heart Failure Patients: Insights From Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION). *Circ Heart Fail*. 2015 Nov;8(6):1044-51. Erratum in: *Circ Heart Fail*. 2016 Mar;9(3):e000014.
586. Brunner-La Rocca HP, Eurlings L, Richards AM, Januzzi JL, Pfisterer ME, Dahlström U, Pinto YM, Karlström P, Erntell H, Berger R, Persson H, **O'Connor CM**, Moertl D, Gaggin HK, Frampton CM, Nicholls MG, Troughton RW. Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials. *Eur J Heart Fail*. 2015 Dec;17(12):1252-61. Epub 2015 Sep 30.
587. Banks AZ, Mentz RJ, Stebbins A, Mikus CR, Schulte PJ, Fleg JL, Cooper LS, Leifer ES, Badenhop DT, Keteyian SJ, Piña IL, Kitzman DW, Fiuzat M, Whellan DJ, Kraus WE, **O'Connor CM**. Response to Exercise Training and Outcomes in Patients With Heart Failure and Diabetes Mellitus: Insights From the HF-ACTION Trial. *J Card Fail*. 2015 Dec 11. pii: S1071-9164(15)01216-6 [Epub ahead of print]
588. Cotter G, Davison BA, Milo O, Bourge RC, Cleland JG, Jondeau G, Krum H, **O'Connor CM**, Metra M, Parker JD, Torre-Amione G, van Veldhuisen DJ, Kobrin I, Rainisio M, Senger S, Edwards C, McMurray JJ, Teerlink JR; VERITAS Investigators. Predictors and Associations With Outcomes of Length of Hospital Stay in Patients With Acute Heart Failure: Results From VERITAS. *J Card Fail*. 2015 Dec 22. pii: S1071-9164(15)01248-8. [Epub ahead of print]
589. **O'Connor CM**. Heart Failure "End Result Cards": Solid B. *JACC Heart Fail*. 2015 Dec;3(12):1001-2. doi: 10.1016/j.jchf.2015.10.004. No abstract available.
590. Samsky MD, Dunning A, DeVore AD, Schulte PJ, Starling RC, Wilson Tang WH, Armstrong PW, Ezekowitz JA, Butler J, McMurray JJ, Teerlink JR, Voors AA, Metra M, Mentz RJ, **O'Connor CM**, Patel CB, Hernandez AF. Liver function tests in patients with acute heart failure and associated outcomes: insights from ASCEND-HF. *Eur J Heart Fail*. 2015 Dec 28. doi: 10.1002/ejhf.440. [Epub ahead of print]
591. Mentz RJ, **O'Connor CM**. Pathophysiology and clinical evaluation of acute heart failure. *Nat Rev Cardiol*. 2016 Jan;13(1):28-35. Epub 2015 Sep 15. Review.
592. Bruno N, Ter Maaten JM, Ovchinnikova ES, Vegter EL, Valente MA, van der Meer P, de Boer RA, van der Harst P, Schmitter D, Metra M, **O'Connor CM**, Ponikowski P, Teerlink JR, Cotter G, Davison B, Cleland JG, Givertz MM, Bloomfield DM, Dittrich HC, Pinto YM, van Veldhuisen DJ, Hillege HL, Berezikov E, Voors AA. MicroRNAs relate to early worsening of renal function in patients with acute heart failure. *Int J Cardiol*. 2016 Jan 15;203:564-9. Epub 2015 Nov 11.
593. **O'Connor CM**. Why Dr. Robert Califf's Nomination for Commissioner of the Food and Drug Administration Is Good for Heart Failure Patients. *JACC Heart Fail*. 2016 Jan;4(1):90-1. doi: 10.1016/j.jchf.2015.11.004. No abstract available.
594. Ahmad T, Kelly JP, McGarrah RW, Hellkamp AS, Fiuzat M, Testani JM, Wang TS, Verma A, Samsky MD, Donahue MP, Ilkayeva OR, Bowles DE, Patel CB, Milano CA, Rogers JG, Felker GM, **O'Connor CM**, Shah SH, Kraus WE. Prognostic Implications of Long-Chain Acylcarnitines in Heart Failure and Reversibility With Mechanical Circulatory Support. *J Am Coll Cardiol*. 2016 Jan 26;67(3):291-9. doi: 10.1016/j.jacc.2015.10.079.

595. Wong YW, Mentz RJ, Felker GM, Ezekowitz J, Pieper K, Heizer G, Hasselblad V, Metra M, **O'Connor CM**, Armstrong PW, Starling RC, Hernandez AF. Nesiritide in patients hospitalized for acute heart failure: does timing matter? Implication for future acute heart failure trials. *Eur J Heart Fail*. 2016 Jan 27. doi: 10.1002/ejhf.487. [Epub ahead of print]
596. Fiuzat M, Oldenberg O, Whellan DJ, Woehrle H, Punjabi NM, Anstrom KJ, Blase AB, Benjafield AV, Lindenfeld J, **O'Connor CM**. Lessons learned from a clinical trial: Design, rationale, and insights from The Cardiovascular Improvements with Minute Ventilation-targeted Adaptive Sero-Ventilation (ASV) Therapy in Heart Failure (CAT-HF) Study. *Contemp Clin Trials*. 2016 Jan 19;47:158-164. doi: 10.1016/j.cct.2016.01.001. [Epub ahead of print]
597. Tang WH, Wu Y, Grodin JL, Hsu AP, Hernandez AF, Butler J, Metra M, Voors AA, Felker GM, Troughton RW, Mills RM, McMurray JJ, Armstrong PW, **O'Connor CM**, Starling RC. Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure. *JACC Heart Fail*. 2016 Jan;4(1):68-77. 2015 Dec 2.
598. Demissei BG, Cleland JG, **O'Connor CM**, Metra M, Ponikowski P, Teerlink JR, Davison B, Givertz MM, Bloomfield DM, Dittrich H, van Veldhuisen DJ, Hillege HL, Voors AA, Cotter G. Procalcitonin-based indication of bacterial infection identifies high risk acute heart failure patients. *Int J Cardiol*. 2016 Feb 1;204:164-71. doi: 10.1016/j.ijcard.2015.11.141. Epub 2015 Nov 26.
599. Ahmad T, Desai N, Wilson F, Schulte P, Dunning A, Jacoby D, Allen L, Fiuzat M, Rogers J, Felker GM, **O'Connor C**, Patel CB. Clinical Implications of Cluster Analysis-Based Classification of Acute Decompensated Heart Failure and Correlation with Bedside Hemodynamic Profiles. *PLoS One*. 2016 Feb 3;11(2):e0145881
600. Fiuzat M, Wojdyla D, Pina I, Adams K, Whellan D, **O'Connor CM**. Heart Rate or Beta-blocker Dose? Association with Outcomes in Ambulatory Heart Failure Patients with Systolic Dysfunction: Results from the HF-ACTION Trial. *JACC Heart Fail*. 2016 Feb;4(2):109-15.
601. **O'Connor CM**. Death of the Heart Failure Clinical Investigator: Molecules and Receptors Win Nobel Prizes, Clinical Investigation Improves Survival. *JACC Heart Fail*. 2016 Feb;4(2):162-3.
602. Keteyian SJ, Patel M, Kraus WE, Brawner CA, McConnell TR, Piña IL, Leifer ES, Fleg JL, Blackburn G, Fonarow GC, Chase PJ, Piner L, Vest M, **O'Connor CM**, Ehrman JK, Walsh MN, Ewald G, Bensimhon D, Russell SD; HF-ACTION Investigators. Variables Measured During Cardiopulmonary Exercise Testing as Predictors of Mortality in Chronic Systolic Heart Failure. *J Am Coll Cardiol*. 2016 Feb 23;67(7):780-9.
603. Mentz RJ, Hasselblad V, DeVore AD, Metra M, Voors AA, Armstrong PW, Ezekowitz JA, Tang WH, Schulte PJ, Anstrom KJ, Hernandez AF, Velazquez EJ, **O'Connor CM**. Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). *Am J Cardiol*. 2016 Feb 1;117(3):404-11. Epub 2015 Nov 18.
604. **O'Connor CM**. I Lost a Friend From HFpEF: William Anlyan, MD, Chancellor Emeritus and Duke University Trustee. *JACC Heart Fail*. 2016 Mar;4(3):230-1. doi: 10.1016/j.jchf.2016.01.007.
605. Demissei BG, Valente MA, Cleland JG, **O'Connor CM**, Metra M, Ponikowski P, Teerlink JR, Cotter G, Davison B, Givertz MM, Bloomfield DM, Dittrich H, van der Meer P, van Veldhuisen DJ, Hillege HL, Voors AA. Optimizing clinical use of biomarkers in high-risk acute heart failure patients. *Eur J Heart Fail*. 2016 Mar;18(3):269-80. doi: 10.1002/ejhf.443. Epub 2015 Dec 3.
606. Perez AL, Grodin JL, Wu Y, Hernandez AF, Butler J, Metra M, Felker GM, Voors AA, McMurray JJ, Armstrong PW, Starling RC, **O'Connor CM**, Tang WH. Increased mortality with elevated

plasma endothelin-1 in acute heart failure: an ASCEND-HF biomarker substudy. *Eur J Heart Fail*. 2016 Mar;18(3):290-7. Epub 2015 Dec 14.

607. Navarese EP, Kolodziejczak M, Kereiakes DJ, Tantry US, **O'Connor C**, Gurbel PA. Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome: A Narrative Review. *Ann Intern Med*. 2016 Mar 22. doi: 10.7326/M15-2994. [Epub ahead of print]
608. Ambrosy AP, Hernandez AF, Armstrong PW, Butler J, Dunning A, Ezekowitz JA, Felker GM, Greene SJ, Kaul P, McMurray JJ, Metra M, **O'Connor CM**, Reed SD, Schulte PJ, Starling RC, Tang WH, Voors AA, Mentz RJ. The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF. *Eur J Heart Fail*. 2016 Mar;18(3):306-13. Epub 2015 Oct 14.
609. Ezekowitz JA, Podder M, Hernandez AF, Armstrong PW, Starling RC, **O'Connor CM**, Califf RM. Arrival by ambulance in acute heart failure: insights into the mode of presentation from Acute Studies of Nesiritide in Decompensated Heart Failure (ASCEND-HF). *BMJ Open*. 2016 Mar 17;6(3):e010201.
610. Whellan DJ, Stebbins A, Hernandez AF, Ezekowitz JA, McMurray JJ, Mather PJ, Hasselblad V, **O'Connor CM**. Dichotomous Relationship between Age and 30-Day Death or Rehospitalization in Heart Failure Patients Admitted with Acute Decompensated Heart Failure: Results From the ASCEND-HF Trial. *J Card Fail*. 2016 Mar 4. pii: S1071-9164(16)00072-5.
611. Cooper LB, Mentz RJ, Stevens SR, Felker GM, Lombardi C, Metra M, Stevenson LW, **O'Connor CM**, Milano CA, Patel CB, Rogers JG. Hemodynamic Predictors of Heart Failure Morbidity and Mortality: Fluid or Flow? *J Card Fail*. 2016 Mar;22(3):182-9. doi: 10.1016/j.cardfail.2015.11.012.
612. **O'Connor CM**. Why Negative Trials Are Positive for Heart Failure Patients. *JACC Heart Fail*. 2016 Apr;4(4):329-30. doi: 10.1016/j.jchf.2016.02.010.
613. Metra M, Mentz RJ, Hernandez AF, Heizer GM, Armstrong PW, Clausell N, Corbalan R, Costanzo MR, Dickstein K, Dunlap ME, Ezekowitz JA, Howlett JG, Komajda M, Krum H, Lombardi C, Fonarow GC, McMurray JJ, Nieminen MS, Swedberg K, Voors AA, Starling RC, Teerlink JR, **O'Connor CM**. Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF Trial). *Am J Cardiol*. 2016 Jun 1;117(11):1771-8. doi: 10.1016/j.amjcard.2016.03.002.
614. **O'Connor CM**. Social Media: Can It Reduce Heart Failure Events? *JACC Heart Fail*. 2016 Jun;4(6):514-5. doi: 10.1016/j.jchf.2016.04.006.
615. Reeves GR, Whellan DJ, Patel MJ, **O'Connor CM**, Duncan P, Eggebeen JD, Morgan TM, Hewston LA, Pastva AM, Kitzman DW. Comparison of Frequency of Frailty and Severely Impaired Physical Function in Patients  $\geq 60$  Years Hospitalized With Acute Decompensated Heart Failure Versus Chronic Stable Heart Failure With Reduced and Preserved Left Ventricular Ejection Fraction. *Am J Cardiol*. 2016 Jun 15;117(12):1953-8. doi: 10.1016/j.amjcard.2016.03.046.
616. **O'Connor CM**. The Year in Heart Failure Review 2015 to 2016. *JACC Heart Fail*. 2016 Jul;4(7):603-604. doi: 10.1016/j.jchf.2016.05.005.
617. Biegus J, Hillege HL, Postmus D, Valente MA, Bloomfield DM, Cleland JG, Cotter G, Davison BA, Dittrich HC, Fiuzat M, Givertz MM, Massie BM, Metra M, Teerlink JR, Voors AA, **O'Connor CM**, Ponikowski P. Abnormal liver function tests in acute heart failure: relationship with clinical characteristics and outcome in the PROTECT study. *Eur J Heart Fail*. 2016 Jul;18(7):830-9. doi: 10.1002/ejhf.532.PMID:27170455

618. Kelly JP, Dunning A, Schulte PJ, Fiuzat M, Leifer ES, Fleg JL, Cooper LS, Keteyian SJ, Kitzman DW, Pina IL, Kraus WE, Whellan DJ, **O'Connor CM**, Mentz RJ. Statins and Exercise Training Response in Heart Failure Patients: Insights From HF-ACTION. *JACC Heart Fail.* 2016 Aug;4(8):617-24. doi: 10.1016/j.jchf.2016.05.006.
619. **O'Connor CM**. Can Academic Cardiology Divisions Survive? *JACC Heart Fail.* 2016 Aug;4(8):687-8. doi: 10.1016/j.jchf.2016.06.001.
620. Ter Maaten JM, Damman K, Hanberg JS, Givertz MM, Metra M, **O'Connor CM**, Teerlink JR, Ponikowski P, Cotter G, Davison B, Cleland JG, Bloomfield DM, Hillege HL, van Veldhuisen DJ, Voors AA, Testani JM. Hypochloremia, Diuretic Resistance, and Outcome in Patients With Acute Heart Failure. *Circ Heart Fail.* 2016 Aug;9(8). pii: e003109. doi: 10.1161/Circ HF.116.003109.
621. Kelly JP, Cooper LB, Gallup D, Anstrom KJ, Chen HH, Redfield MM, **O'Connor CM**, Mentz RJ, Hernanadez AF, Felker GM. Implications of Using Different Definitions on Outcomes in Worsening Heart Failure. *Circ Heart Fail.* 2016 Aug;9(8). pii: e003048. doi: 10.1161/Circ Heart Fail.116.003048. PMID:27514750
622. Davison BA, Metra M, Senger S, Edwards C, Milo O, Bloomfield DM, Cleland JG, Dittrich HC, Givertz MM, **O'Connor CM**, Massie BM, Ponikowski P, Teerlink JR, Voors AA, Cotter G. Patient journey after admission for acute heart failure: length of stay, 30-day readmission and 90-day mortality. *Eur J Heart Fail.* 2016 Aug;18(8):1041-50. doi: 10.1002/ejhf.540.
623. Luo N, Rogers JG, Dodson GC, Patel CB, Galanos AN, Milano CA, **O'Connor CM**, Mentz RJ. Usefulness of Palliative Care to Complement the Management of Patients on Left Ventricular Assist Devices. *Am J Cardiol.* 2016 Sep 1;118(5):733-8. doi: 10.1016/j.amjcard.2016.06.010.
624. **O'Connor CM**. The Mentor's Mentor: The Life of Galen Wagner. *JACC Heart Fail.* 2016 Sep;4(9):759. doi: 10.1016/j.jchf.2016.07.009.
625. Greene SJ, Hernandez AF, Sun JL, Metra M, Butler J, Ambrosy AP, Ezekowitz JA, Starling RC, Teerlink JR, Schulte PJ, Voors AA, Armstrong PW, **O'Connor CM**, Mentz RJ. Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). *Circ Heart Fail.* 2016 Sep;9(9). pii: e002986. doi: 10.1161/Circ Heart Fail.116.002986.PMID: 27623769 [PubMed - in process]
626. Vegter EL, Schmitter D, Hagemeyer Y, Ovchinnikova ES, van der Harst P, Teerlink JR, **O'Connor CM**, Metra M, Davison BA, Bloomfield D, Cotter G, Cleland JG, Givertz MM, Ponikowski P, van Veldhuisen DJ, van der Meer P, Berezhikov E, Voors AA, Khan MA. Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failure. *Int J Cardiol.* 2016 Sep 11;224:231-239. doi: 10.1016/j.ijcard.2016.09.010. [Epub ahead of print] PMID: 27661412
627. Felker GM, Mentz RJ, Cole R, Adams KF, Egnaczyk GF, Fiuzat M, Patel CB, Echols M, Khouri MG, Tauras JM, Gupta D, Monds P, Roberts R, **O'Connor CM**. Efficacy and Safety of Tolvaptan in Patients Hospitalized with Acute Heart Failure. *J Am Coll Cardiol.* 2016 Sep 13. pii: S0735-1097(16)35321-9. doi: 10.1016/j.jacc.2016.09.004. [Epub ahead of print] PMID: 27654854
628. Kitai T, Grodin JL, Mentz RJ, Hernandez AF, Butler J, Metra M, McMurray JJ, Armstrong PW, Starling RC, **O'Connor CM**, Swedberg K, Tang WH. Insufficient reduction in heart rate during hospitalization despite beta-blocker treatment in acute decompensated heart failure: insights



- from the ASCEND-HF trial. *Eur J Heart Fail*. 2016 Sep 16. doi: 10.1002/ejhf.629. [Epub ahead of print] PMID: 27634557
629. Matsue Y, Ter Maaten JM, Struck J, Metra M, O'Connor CM, Ponikowski P, Teerlink JR, Cotter G, Davison B, Cleland JG, Givertz MM, Bloomfield DM, Dittrich HC, van Veldhuisen DJ, van der Meer P, Damman K, Voors AA. Clinical Correlates and Prognostic Value of Proenkephalin in Acute and Chronic Heart Failure. *J Card Fail*. 2016 Sep 20. pii: S1071-9164(16)31141-1. doi: 10.1016/j.cardfail.2016.09.007. [Epub ahead of print]
630. Matsue Y, van der Meer P, Damman K, Metra M, **O'Connor CM**, Ponikowski P, Teerlink JR, Cotter G, Davison B, Cleland JG, Givertz MM, Bloomfield DM, Dittrich HC, Gansevoort RT, Bakker SJ, van der Harst P, Hillege HL, van Veldhuisen DJ, Voors AA. Blood urea nitrogen-to-creatinine ratio in the general population and in patients with acute heart failure. *Heart*. 2016 Sep 22. pii: heartjnl-2016-310112. doi: 10.1136/heartjnl-2016-310112. [Epub ahead of print] PMID: 27658757
631. **O'Connor CM**. The International Olympic Games: Heart Teams and Heart Failure. *JACC Heart Fail*. 2016 Oct;4(10):826-827. doi: 10.1016/j.jchf.2016.08.004
632. Tromp J, Ter Maaten J, Damman K, **O'Connor CM**, Metra M, Dittrich HC, Ponikowski P, Teerlink JR, Cotter G, Davison B, Cleland JG, Givertz MM, Bloomfield DM, van der Wal MH, Jaarsma T, van Veldhuisen DJ, Hillege HL, Voors AA, van der Meer P. Serum Potassium Levels and Outcome in Acute Heart Failure (Data from the PROTECT and COACH Trials). *Am J Cardiol*. 2016 Oct 8. pii: S0002-9149(16)31610-1. doi: 10.1016/j.amjcard.2016.09.038. [Epub ahead of print]
633. Cotter G, Davison BA, Milo O, Bourge RC, Cleland JG, Jondeau G, Krum H, **O'Connor CM**, Metra M, Parker JD, Torre-Amione G, van Veldhuisen DJ, Kobrin I, Rainisio M, Senger S, Edwards C, McMurray JJ, Teerlink JR; VERITAS Investigators. Predictors and Associations With Outcomes of Length of Hospital Stay in Patients With Acute Heart Failure: Results From VERITAS. *J Card Fail*. 2016 Oct;22(10):815-22. doi: 10.1016/j.cardfail.2015.12.017.
634. Parikh KS, Coles A, Schulte PJ, Kraus WE, Fleg JL, Keteyian SJ, Piña IL, Fiuzat M, Whellan DJ, **O'Connor CM**, Mentz RJ. Relation of Angina Pectoris to Outcomes, Quality of Life, and Response to Exercise Training in Patients With Chronic Heart Failure (from HF-ACTION). *Am J Cardiol*. 2016 Oct 15;118(8):1211-1216. doi: 10.1016/j.amjcard.2016.07.040.
635. Tromp J, Meyer S, Mentz RJ, **O'Connor CM**, Metra M, Dittrich HC, Ponikowski P, Teerlink JR, Cotter G, Davison B, Cleland JG, Givertz MM, Bloomfield DM, van Veldhuisen DJ, Hillege HL, Voors AA, van der Meer P. Acute heart failure in the young: Clinical characteristics and biomarker profiles. *Int J Cardiol*. 2016 Oct 15;221:1067-72. doi: 10.1016/j.ijcard.2016.06.339.
636. **O'Connor CM**. Peer Review of Peer Review: Somewhere Over the Rainbow. *JACC Heart Fail*. 2016 Nov;4(11):907-908. doi: 10.1016/j.jchf.2016.09.005.
637. Demissei BG, Postmus D, Liu LC, Cleland JG, **O'Connor CM**, Metra M, Ponikowski P, Teerlink JR, Cotter G, Davison BA, Edwards C, Givertz MM, Bloomfield DM, Dittrich HC, Voors AA, Hillege HL. Risk-based evaluation of efficacy of rolofylline in patients hospitalized with acute heart failure - Post-hoc analysis of the PROTECT trial. *Int J Cardiol*. 2016 Nov 15;223:967-975. doi: 10.1016/j.ijcard.2016.08.271.
638. Vegter EL, Schmitter D, Hagemeyer Y, Ovchinnikova ES, van der Harst P, Teerlink JR, **O'Connor CM**, Metra M, Davison BA, Bloomfield D, Cotter G, Cleland JG, Givertz MM, Ponikowski P, van Veldhuisen DJ, van der Meer P, Berezikov E, Voors AA, Khan MA. Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failure. *Int J Cardiol*. 2016 Dec 1;224:231-239. doi: 10.1016/j.ijcard.2016.09.010.

639. **O'Connor CM**. Not Your Mother's FDA. *JACC Heart Fail*. 2016 Dec;4(12):978. doi: 10.1016/j.jchf.2016.10.001.
640. Sun JL, Boyle SH, Samad Z, Babyak MA, Wilson JL, Kuhn C, Becker RC, Ortel TL, Williams RB, Rogers JG, **O'Connor CM**, Velazquez EJ, Jiang W. Mental stress-induced left ventricular dysfunction and adverse outcome in ischemic heart disease patients. *Eur J Prev Cardiol*. 2017 Jan 1:2047487316686435. doi: 10.1177/2047487316686435. [Epub ahead of print]
641. Ambrosy AP, Cerbin LP, Armstrong PW, Butler J, Coles A, DeVore AD, Dunlap ME, Ezekowitz JA, Felker GM, Fudim M, Greene SJ, Hernandez AF, **O'Connor CM**, Schulte P, Starling RC, Teerlink JR, Voors AA, Mentz RJ. Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes: Findings From the ASCEND-HF Trial. *JACC Heart Fail*. 2017 Jan;5(1):1-13. doi: 10.1016/j.jchf.2016.09.012.
642. Sherwood A, Blumenthal JA, Koch GG, Hoffman BM, Watkins LL, Smith PJ, **O'Connor CM**, Adams KF Jr, Rogers JG, Sueta C, Chang PP, Johnson KS, Schwartz J, Hinderliter AL. Effects of Coping Skills Training on Quality of Life, Disease Biomarkers, and Clinical Outcomes in Patients With Heart Failure: A Randomized Clinical Trial. *Circ Heart Fail*. 2017 Jan;10(1). pii: e003410. doi: 10.1161/Circ Heart Fail.116.003410.
643. Verma AK, Schulte PJ, Bittner V, Keteyian SJ, Fleg JL, Piña IL, Swank AM, Fitz-Gerald M, Ellis SJ, Kraus WE, Whellan DJ, **O'Connor CM**, Mentz RJ. Socioeconomic and partner status in chronic heart failure: Relationship to exercise capacity, quality of life, and clinical outcomes. *Am Heart J*. 2017 Jan;183:54-61. doi: 10.1016/j.ahj.2016.10.007.
644. Streng KW, Ter Maaten JM, Cleland JG, **O'Connor CM**, Davison BA, Metra M, Givertz MM, Teerlink JR, Ponikowski P, Bloomfield DM, Dittrich HC, Hillege HL, van Veldhuisen DJ, Voors AA, van der Meer P. Associations of Body Mass Index With Laboratory and Biomarkers in Patients With Acute Heart Failure. *Circ Heart Fail*. 2017 Jan;10(1). pii: e003350. doi: 10.1161/Circ Heart Fail.116.003350.
645. **O'Connor CM**. 21st Century Cures: A Step Forward for Patients With Heart Failure. *JACC Heart Fail*. 2017 Feb;5(2):154. doi: 10.1016/j.jchf.2016.12.004.
646. Feigal JP, Boyle SH, Samad Z, Velazquez EJ, Wilson JL, Becker RC, Williams RB Jr, Kuhn CM, Ortel TL, Rogers JG, **O'Connor CM**, Jiang W. Associations between positive emotional well-being and stress-induced myocardial ischemia: Well-being scores predict exercise-induced ischemia. *J Psychosom Res*. 2017 Feb;93:14-18. doi: 10.1016/j.jpsychores.2016.11.012.
647. Kitai T, Grodin JL, Mentz RJ, Hernandez AF, Butler J, Metra M, McMurray JJ, Armstrong PW, Starling RC, **O'Connor CM**, Swedberg K, Tang WH. Insufficient reduction in heart rate during hospitalization despite beta-blocker treatment in acute decompensated heart failure: insights from the ASCEND-HF trial. *Eur J Heart Fail*. 2017 Feb;19(2):241-249. doi: 10.1002/ejhf.629.
648. Levy WC, Li Y, Reed SD, Zile MR, Shadman R, Dardas T, Whellan DJ, Schulman KA, Ellis SJ, Neilson M, **O'Connor CM**; HFACTION Investigators. Does the Implantable Cardioverter-Defibrillator Benefit Vary With the Estimated Proportional Risk of Sudden Death in Heart Failure Patients? *JACC Clin Electrophysiol*. 2017 Mar;3(3):291-298. doi: 10.1016/j.jacep.2016.09.006.
649. **O'Connor CM**. Is Salt Bad for You? *JACC Heart Fail*. 2017 Mar;5(3):238-239. doi: 10.1016/j.jchf.2017.01.003.
650. Reeves GR, Whellan DJ, Duncan P, **O'Connor CM**, Pastva AM, Eggebeen JD, Hewston LA, Morgan TM, Reed SD, Rejeski WJ, Mentz RJ, Rosenberg PB, Kitzman DW; REHAB-HF Trial

- Investigators. Rehabilitation Therapy in Older Acute Heart Failure Patients (REHAB-HF) trial: Design and rationale. *Am Heart J*. 2017 Mar;18(5):130-139. doi: 10.1016/j.ahj.2016.12.012.
651. Felker GM, Mentz RJ, Cole RT, Adams KF, Egnaczyk GF, Fiuzat M, Patel CB, Echols M, Khouri MG, Tauras JM, Gupta D, Monds P, Roberts R, **O'Connor CM**. Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure. *J Am Coll Cardiol*. 2017 Mar 21;69(11):1399-1406. doi: 10.1016/j.jacc.2016.09.004.
652. **O'Connor CM**, Whellan DJ, Fiuzat M, Punjabi NM, Tasissa G, Anstrom KJ, Benjafield AV, Woehrle H, Blase AB, Lindenfeld J, Oldenberg O. Cardiovascular Outcomes With Minute Ventilation-Targeted Adaptive Servo-Ventilation Therapy in Heart Failure: The CAT-HF Trial. *J Am Coll Cardiol*. 2017 Mar 28;69(12):1577-1587. doi: 10.1016/j.jacc.2017.01.041.
653. Luo N, Merrill P, Parikh KS, Whellan DJ, Piña IL, Fiuzat M, Kraus WE, Kitzman DW, Keteyian SJ, **O'Connor CM**, Mentz RJ. Exercise Training in Patients With Chronic Heart Failure and Atrial Fibrillation. *J Am Coll Cardiol*. 2017 Apr 4;69(13):1683-1691. doi: 10.1016/j.jacc.2017.01.032.
654. Ambrosy AP, Cerbin LP, DeVore AD, Greene SJ, Kraus WE, **O'Connor CM**, Piña IL, Whellan DJ, Wojdyla D, Wu A, Mentz RJ. Aerobic exercise training and general health status in ambulatory heart failure patients with a reduced ejection fraction-Findings from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION)trial. *Am Heart J*. 2017 Apr;186:130-138. doi: 10.1016/j.ahj.2016.12.017.
655. Sun JL, Boyle SH, Samad Z, Babyak MA, Wilson JL, Kuhn C, Becker RC, Ortel TL, Williams RB, Rogers JG, **O'Connor CM**, Velazquez EJ, Jiang W. Mental stress-induced left ventricular dysfunction and adverse outcome in ischemic heart disease patients. *Eur J Prev Cardiol*. 2017 Apr;24(6):591-599. doi: 10.1177/2047487316686435.
656. Reeves GR, Whellan DJ, **O'Connor CM**, Duncan P, Eggebeen JD, Morgan TM, Hewston LA, Pastva A, Patel MJ, Kitzman DW. A Novel Rehabilitation Intervention for Older Patients With Acute Decompensated Heart Failure: The REHAB-HF Pilot Study. *JACC Heart Fail*. 2017 May;5(5):359-366. doi: 10.1016/j.jchf.2016.12.019.
657. **O'Connor CM**. High Heart Failure Readmission Rates: Is It the Health System's Fault? *JACC Heart Fail*. 2017 May;5(5):393. doi: 10.1016/j.jchf.2017.03.011.
658. **O'Connor CM**. Development of Acute Decompensated Heart Failure Therapies: Is the Journey Over? *JACC Heart Fail*. 2017 Jun;5(6):464-465. doi: 10.1016/j.jchf.2017.04.010.
659. Demissei BG, Postmus D, Cleland JG, **O'Connor CM**, Metra M, Ponikowski P, Teerlink JR, Cotter G, Davison BA, Givertz MM, Bloomfield DM, van Veldhuisen DJ, Dittrich HC, Hillege HL, Voors AA. Plasma biomarkers to predict or rule out early post-discharge events after hospitalization for acute heart failure. *Eur J Heart Fail*. 2017 Jun;19(6):728-738. doi: 10.1002/ejhf.766.
660. Cleland JGF, Teerlink JR, Davison BA, Shoaib A, Metra M, Senger S, Milo O, Cotter G, Bourge RC, Parker JD, Jondeau G, Krum H, **O'Connor CM**, Torre-Amione G, van Veldhuisen DJ, McMurray JJV; VERITAS Investigators. Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failure-does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studies (VERITAS). *Eur J Heart Fail*. 2017 Jun;19(6):739-747. doi: 10.1002/ejhf.786.
661. Sharma A, Demissei BG, Tromp J, Hillege HL, Cleland JG, **O'Connor CM**, Metra M, Ponikowski P, Teerlink JR, Davison BA, Givertz MM, Bloomfield DM, Dittrich H, van Veldhuisen DJ, Cotter G, Ezekowitz JA, Khan MAF, Voors AA. A network analysis to compare biomarker

profiles in patients with and without diabetes mellitus in acute heart failure. *Eur J Heart Fail*. 2017 Jun 21. doi: 10.1002/ejhf.912.

662. Greene SJ, Hernandez AF, Dunning A, Ambrosy AP, Armstrong PW, Butler J, Cerbin LP, Coles A, Ezekowitz JA, Metra M, Starling RC, Teerlink JR, Voors AA, **O'Connor CM**, Mentz RJ. Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure: From the ASCEND-HF Trial. *J Am Coll Cardiol*. 2017 Jun 27;69(25):3029-3039. doi: 10.1016/j.jacc.2017.04.043.
663. Liu LCY, Valente MAE, Postmus D, **O'Connor CM**, Metra M, Dittrich HC, Ponikowski P, Teerlink JR, Cotter G, Davison B, Cleland JGF, Givertz MM, Bloomfield DM, van Veldhuisen DJ, Hillege HL, van der Meer P, Voors AA. Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT Trial : Differential Response in Acute Heart Failure. *Cardiovasc Drugs Ther*. 2017 Jun 27. doi: 10.1007/s10557-017-6726-1.
664. **O'Connor CM**. A Decade With Editorial Mentors: The Day They Dropped the Mic. *JACC Heart Fail*. 2017 Jul;5(7):541-542. doi: 10.1016/j.jchf.2017.05.009.
665. Tromp J, Khan MAF, Mentz RJ, **O'Connor CM**, Metra M, Dittrich HC, Ponikowski P, Teerlink JR, Cotter G, Davison B, Cleland JGF, Givertz MM, Bloomfield DM, Van Veldhuisen DJ, Hillege HL, Voors AA, van der Meer P. Biomarker Profiles of Acute Heart Failure Patients With a Mid-Range Ejection Fraction. *JACC Heart Fail*. 2017 Jul;5(7):507-517. doi: 10.1016/j.jchf.2017.04.007.
666. Rogers JG, Patel CB, Mentz RJ, Granger BB, Steinhauser KE, Fiuzat M, Adams PA, Speck A, Johnson KS, Krishnamoorthy A, Yang H, Anstrom KJ, Dodson GC, Taylor DH Jr, Kirchner JL, Mark DB, **O'Connor CM**, Tulsy JA. Palliative Care in Heart Failure: The PAL-HF Randomized, Controlled Clinical Trial. *J Am Coll Cardiol*. 2017 Jul 18;70(3):331-341. doi: 10.1016/j.jacc.2017.05.030.
667. **O'Connor CM**. Does Institutional Memory Matter? *JACC Heart Fail*. 2017 Aug;5(8):616. doi: 10.1016/j.jchf.2017.07.001.
668. Felker GM; Anstrom KJ; Adams K; Ezekowitz J; Fiuzat M; Houston-Miller N; Januzzi J; Mark D; Piña I; Passmore G; Whellan D; Yang H; Cooper LS; Leifer E; Desvigne-Nickens P; **O'Connor CM**. Effect of Natriuretic Peptide–Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. *JAMA*. 2017 Aug 22;318(8):713-720. doi:10.1001/jama.2017.10565.
669. **O'Connor CM**. America and Apple Pie: How Do We Change the American Health Care System? *JACC Heart Fail*. 2017 Sep;5(9):686-687. doi: 10.1016/j.jchf.2017.07.006.
670. **O'Connor CM**. Q&A With the JACC: Heart Failure Editor-in-Chief: Marking the 5-Year Milestone. *JACC Heart Fail*. 2017 Oct;5(10):758-759. doi: 10.1016/j.jchf.2017.08.006.
671. Sharma A, Stevens SR, Lucas J, Fiuzat M, Adams KF, Whellan DJ, Donahue MP, Kitzman DW, Piña IL, Zannad F, Kraus WE, **O'Connor CM**, Felker GM. Utility of Growth Differentiation Factor-15, A Marker of Oxidative Stress and Inflammation, in Chronic Heart Failure: Insights From the HF-ACTION Study. *JACC Heart Fail*. 2017 Oct;5(10):724-734. doi: 10.1016/j.jchf.2017.07.013.
672. Sharma A, Demissei BG, Tromp J, Hillege HL, Cleland JG, **O'Connor CM**, Metra M, Ponikowski P, Teerlink JR, Davison BA, Givertz MM, Bloomfield DM, Dittrich H, van Veldhuisen DJ, Cotter G, Ezekowitz JA, Khan MAF, Voors AA. A network analysis to compare biomarker

profiles in patients with and without diabetes mellitus in acute heart failure. *Eur J Heart Fail*. 2017 Oct;19(10):1310-1320. doi: 10.1002/ejhf.912.

673. Alenezi F, Brummett BH, Boyle SH, Samad Z, Babyak MA, Alzaeim N, Wilson J, Romano MMD, Sun JL, Ersboll M, **O'Connor CM**, Velazquez EJ, Jiang W. Usefulness of Myocardial Annular Velocity Change During Mental Stress to Predict Cardiovascular Outcome in Patients With Coronary Artery Disease (From the Responses of Mental Stress-Induced Myocardial Ischemia to Escitalopram Treatment Trial). *Am J Cardiol*. 2017 Nov 1;120(9):1495-1500. doi: 10.1016/j.amjcard.2017.07.039.
674. **O'Connor CM**. Goodbye Mihai: We Will Miss You. *JACC Heart Fail*. 2017 Nov;5(11):848-849. doi: 10.1016/j.jchf.2017.09.007.
675. Pastva AM, Duncan PW, Reeves GR, Nelson MB, Whellan DJ, **O'Connor CM**, Eggebeen JD, Hewston LA, Taylor KM, Mentz RJ, Rosenberg PB, Kitzman DW. Strategies for supporting intervention fidelity in the rehabilitation therapy in older acute heart failure patients (REHAB-HF) trial. *Contemp Clin Trials*. 2018 Jan;64:118-127. doi: 10.1016/j.cct.2017.10.014.
676. **O'Connor CM**. I Don't Care How Low My BNP Is, I Want to Feel Good. *JACC Heart Fail*. 2018 Jan;6(1):82-83. doi: 10.1016/j.jchf.2017.11.004.
677. **O'Connor CM**, Psotka MA, Fiuzat M, Lindenfeld J, Abraham WT, Bristow MR, Canos D, Harrington RA, Hillebrenner M, Jessup M, Malik FI, Solomon SD, Stockbridge N, Tchong JE, Unger EF, Whellan DJ, Zuckerman B, Califf RM. Improving Heart Failure Therapeutics Development in the United States: The Heart Failure Collaboratory. *J Am Coll Cardiol*. 2018 Jan 30;71(4):443-453. doi: 10.1016/j.jacc.2017.11.048.
678. Armstrong PW, Roessig L, Patel MJ, Anstrom KJ, Butler J, Voors AA, Lam CSP, Ponikowski P, Temple T, Pieske B, Ezekowitz J, Hernandez AF, Koglin J, **O'Connor CM**. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial. *JACC Heart Fail*. 2018 Feb;6(2):96-104. doi: 10.1016/j.jchf.2017.08.013. Epub 2017 Oct 11.
679. Cotter G, Metra M, Davison BA, Jondeau G, Cleland JGF, Bourge RC, Milo O, **O'Connor CM**, Parker JD, Torre-Amione G, van Veldhuisen DJ, Kobrin I, Rainisio M, Senger S, Edwards C, McMurray JJV, Teerlink JR; VERITAS Investigators. Systolic blood pressure reduction during the first 24 h in acute heart failure admission: friend or foe? *Eur J Heart Fail*. 2018 Feb;20(2):317-322. doi: 10.1002/ejhf.889.
680. Fudim M, **O'Connor CM**, Dunning A, Ambrosy AP, Armstrong PW, Coles A, Ezekowitz JA, Greene SJ, Metra M, Starling RC, Voors AA, Hernandez AF, Michael Felker G, Mentz RJ. Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND-HF. *Eur J Heart Fail*. 2018 Feb;20(2):304-314. doi: 10.1002/ejhf.1020.
681. **O'Connor CM**. Smartphone, Mom, and HFpEF. *JACC Heart Fail*. 2018 Feb;6(2):176. doi: 10.1016/j.jchf.2017.12.010.
682. Bhatt AS, Cooper LB, Ambrosy AP, Clare RM, Coles A, Joyce E, Krishnamoorthy A, Butler J, Felker GM, Ezekowitz JA, Armstrong PW, Hernandez AF, **O'Connor CM**, Mentz RJ. Interaction of Body Mass Index on the Association Between N-Terminal-Pro-b-Type Natriuretic Peptide and Morbidity and Mortality in Patients With Acute Heart Failure: Findings From ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). *J Am Heart Assoc*. 2018 Feb 3;7(3). pii: e006740. doi: 10.1161/JAHA.117.006740.

683. Hicks KA, Mahaffey KW, Mehran R, Nissen SE, Wiviott SD, Dunn B, Solomon SD, Marler JR, Teerlink JR, Farb A, Morrow DA, Targum SL, Sila CA, Hai MTT, Jaff MR, Joffe HV, Cutlip DE, Desai AS, Lewis EF, Gibson CM, Landray MJ, Lincoff AM, White CJ, Brooks SS, Rosenfield K, Domanski MJ, Lansky AJ, McMurray JJV, Tcheng JE, Steinhubl SR, Burton P, Mauri L, **O'Connor CM**, Pfeffer MA, Hung HMJ, Stockbridge NL, Chaitman BR, Temple RJ; Standardized Data Collection for Cardiovascular Trials Initiative (SCTI). 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. *Circulation*. 2018 Feb 27;137(9):961-972. doi: 10.1161/Circulation.AHA.117.033502. *J Am Coll Cardiol*. 2018 Mar 6;71(9):1021-1034. doi: 10.1016/j.jacc.2017.12.048.
684. **O'Connor CM**. Heart Failure Health Care 2018: Challenges and Opportunities. *JACC Heart Fail*. 2018 Mar;6(3):262-263. doi: 10.1016/j.jchf.2018.01.013.
685. Pokorney SD, Al-Khatib SM, Sun JL, Schulte P, **O'Connor CM**, Teerlink JR, Armstrong PW, Ezekowitz JA, Starling RC, Voors AA, Velazquez EJ, Hernandez AF, Mentz RJ. Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND-HF. *Eur J Heart Fail*. 2018 Mar;20(3):525-532. doi: 10.1002/ehf.1078.
686. Cerbin LP, Ambrosy AP, Greene SJ, Armstrong PW, Butler J, Coles A, DeVore AD, Ezekowitz JA, Hernandez AF, Metra M, Starling RC, Tang W, Teerlink JR, Voors AA, Wu A, **O'Connor CM**, Mentz RJ. Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure: Insights From ASCEND-HF Trial. *JACC Heart Fail*. 2018 Apr;6(4):298-307. doi: 10.1016/j.jchf.2018.01.018.
687. Vaduganathan M, Patel RB, Mentz RJ, Subacius H, Chatterjee NA, Greene SJ, Ambrosy AP, Maggioni AP, Udelson JE, Swedberg K, Konstam MA, **O'Connor CM**, Butler J, Gheorghiu M, Zannad F. Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial). *Am J Cardiol*. 2018 Apr 11. pii: S0002-9149(18)30851-8. doi: 10.1016/j.amjcard.2018.03.362. *Am J Cardiol*. 2018 Jul 15;122(2):255-260. doi: 10.1016/j.amjcard.2018.03.362.
688. **O'Connor CM**, Bristow MR. Changing the Research Culture in the United States. *JACC Heart Fail*. 2018 Apr;6(4):344-345. doi: 10.1016/j.jchf.2018.03.001.
689. Ahmad T, Lund LH, Rao P, Ghosh R, Warier P, Vaccaro B, Dahlström U, **O'Connor CM**, Felker GM, Desai NR. Machine Learning Methods Improve Prognostication, Identify Clinically Distinct Phenotypes, and Detect Heterogeneity in Response to Therapy in a Large Cohort of Heart Failure Patients. *J Am Heart Assoc*. 2018 Apr 12;7(8). pii: e008081. doi: 10.1161/JAHA.117.008081.
690. Rubio-Gracia J, Demissei BG, Ter Maaten JM, Cleland JG, **O'Connor CM**, Metra M, Ponikowski P, Teerlink JR, Cotter G, Davison BA, Givertz MM, Bloomfield DM, Dittrich H, Damman K, Pérez-Calvo JI, Voors AA. Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. *Int J Cardiol*. 2018 May 1;258:185-191. doi: 10.1016/j.ijcard.2018.01.067.
691. **O'Connor CM**. What's One More Day? *JACC Heart Fail*. 2018 May;6(5):438. doi: 10.1016/j.jchf.2018.03.015.
692. Metra M, Cotter G, Senger S, Edwards C, Cleland JG, Ponikowski P, Cursack GC, Milo O, Teerlink JR, Givertz MM, **O'Connor CM**, Dittrich HC, Bloomfield DM, Voors AA, Davison BA. Prognostic Significance of Creatinine Increases During an Acute Heart Failure Admission in Patients With and Without Residual Congestion: A Post Hoc Analysis of the PROTECT Data. *Circ Heart Fail*. 2018 May;11(5):e004644. doi: 10.1161/Circ Heart Fail.117.004644.

693. Ambrosy AP, Bhatt AS, Stebbins AL, Wruck LM, Fudim M, Greene SJ, Kraus WE, **O'Connor CM**, Piña IL, Whellan DJ, Mentz RJ. Prevalent digoxin use and subsequent risk of death or hospitalization in ambulatory heart failure patients with a reduced ejection fraction-Findings from the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) randomized controlled trial. *Am Heart J*. 2018 May;199:97-104. doi: 10.1016/j.ahj.2018.02.004.
694. Ahmad T, Jackson K, Rao VS, Tang WHW, Brisco-Bacik MA, Chen HH, Felker GM, Hernandez AF, **O'Connor CM**, Sabbisetti VS, Bonventre JV, Wilson FP, Coca SG, Testani JM. Worsening Renal Function in Patients With Acute Heart Failure Undergoing Aggressive Diuresis Is Not Associated With Tubular Injury. *Circulation*. 2018 May 8;137(19):2016-2028. doi: 10.1161/Circulation.AHA.117.030112.
695. Ambrosy AP, Mentz RJ, Fiuzat M, Cleland JGF, Greene SJ, **O'Connor CM**, Teerlink JR, Zannad F, Solomon SD. The role of angiotensin receptor-neprilysin inhibitors in cardiovascular disease-existing evidence, knowledge gaps, and future directions. *Eur J Heart Fail*. 2018 Jun;20(6):963-972. doi: 10.1002/ejhf.1159.
696. **O'Connor CM**. Dying With Dignity and Heart Failure: A Lesson From Barbara Bush. *JACC Heart Fail*. 2018 Jun;6(6):536-537. doi: 10.1016/j.jchf.2018.04.011.
697. Cooper LB, Yap J, Tay WT, Teng TK, MacDonald M, Anand IS, Sharma A, **O'Connor CM**, Kraus WE, Mentz RJ, Lam CS; HF-ACTION and ASIAN-HF Investigators. Multi-ethnic comparisons of diabetes in heart failure with reduced ejection fraction: insights from the HF-ACTION trial and the ASIAN-HF registry. *Eur J Heart Fail*. 2018 Jun 26. doi: 10.1002/ejhf.1223.
698. Daubert MA, Whellan DJ, Woehrle H, Tasissa G, Anstrom KJ, Lindenfeld J, Benjafield A, Blase A, Punjabi N, Fiuzat M, Oldenburg O, **O'Connor CM**. Treatment of sleep-disordered breathing in heart failure impacts cardiac remodeling: Insights from the CAT-HF Trial. *Am Heart J*. 2018 Jul;201:40-48. doi: 10.1016/j.ahj.2018.03.026.
699. **O'Connor CM**. Cardiovascular Drug Pricing: Less Innovation for More Access? *JACC Heart Fail*. 2018 Jul;6(7):613-614. doi: 10.1016/j.jchf.2018.05.016.
700. Mentz RJ, **O'Connor CM**, Granger BB, Yang H, Patel CB, Steinhauser KE, Fiuzat M, Johnson KS, Anstrom KJ, Dodson GC, Taylor DH Jr, Mark DB, Tulskey JA, Rogers JG. Palliative care and hospital readmissions in patients with advanced heart failure: Insights from the PAL-HF trial. *Am Heart J*. 2018 Jul 20. pii: S0002-8703(18)30219-9. doi: 10.1016/j.ahj.2018.07.010.
701. Piccini JP, Pokorney SD, Anstrom KJ, Oldenburg O, Punjabi NM, Fiuzat M, Tasissa G, Whellan DJ, Lindenfeld J, Benjafield A, Woehrle H, Blase A, **O'Connor CM**. Adaptive Servo-Ventilation reduces Atrial Fibrillation Burden in Patients with Heart Failure and Sleep Apnea. *Heart Rhythm*. 2018 Jul 27. pii: S1547-5271(18)30719-7. doi: 10.1016/j.hrthm.2018.07.027.
702. Fudim M, Loungani R, Doerfler SM, Coles A, Greene SJ, Cooper LB, Fiuzat M, **O'Connor CM**, Rogers JG, Mentz RJ. Worsening renal function during decongestion among patients hospitalized for heart failure: Findings from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) trial. *Am Heart J*. 2018 Jul 29;204:163-173. doi: 10.1016/j.ahj.2018.07.019.
703. Parikh KS, Sharma K, Fiuzat M, Surks HK, George JT, Honarpour N, Depre C, Desvigne-Nickens P, Nkulikiyinka R, Lewis GD, Gomberg-Maitland M, **O'Connor CM**, Stockbridge N, Califf RM, Konstam MA, Januzzi JL Jr, Solomon SD, Borlaug BA, Shah SJ, Redfield MM, Felker GM. Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Trials. *JACC Heart Fail*. 2018 Aug;6(8):619-632. doi: 10.1016/j.jchf.2018.06.008.

704. **O'Connor CM**. HFpEF: From Early Observations to Worldwide Awareness. *JACC Heart Fail*. 2018 Aug;6(8):718-719. doi: 10.1016/j.jchf.2018.07.001.
705. Jiang W, Whellan DJ, Adams KF, Babyak MA, Boyle SH, Wilson JL, Patel CB, Rogers JG, Harris WS, **O'Connor CM**. Long-Chain Omega-3 Fatty Acid Supplements in Depressed Heart Failure Patients: Results of the OCEAN Trial. *JACC Heart Fail*. 2018 Aug 7. pii: S2213-1779(18)30226-9. doi: 10.1016/j.jchf.2018.03.011.
706. Parikh KS, Fiuzat M, Davis G, Neely M, Blain-Nelson P, Whellan DJ, Abraham WT, Adams KF Jr, Felker GM, Liggett SB, **O'Connor CM**, Bristow MR. Dose Response of  $\beta$ -Blockers in Adrenergic Receptor Polymorphism Genotypes. *Circ Genom Precis Med*. 2018 Aug;11(8):e002210. doi: 10.1161/CIRCGEN.117.002210.
707. Tahhan, AS, Vaduganathan M, Greene SJ, Fonarow, GC, Fiuzat M, Mariell Jessup M, Lindenfeld J, **O'Connor CM**, Butler J. Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials. *JAMA Cardiol*. 2018 Aug 22. doi: 10.1001/jamacardio.2018.2559.
708. Luo N, **O'Connor CM**, Cooper LB, Sun JL, Coles A, Reed SD, Whellan DJ, Piña IL, Kraus WE, Mentz RJ. Relationship between changing patient-reported outcomes and subsequent clinical events in patients with chronic heart failure: insights from HF-ACTION. *Eur J Heart Fail*. 2018 Aug 31. doi: 10.1002/ejhf.1299
709. **O'Connor CM**. Politically Correct Heart Failure Research in America to Avoid Geographic Variation. *JACC Heart Fail*. 2018 Sep;6(9):805-806. doi: 10.1016/j.jchf.2018.07.010.
710. Cooper LB, Yap J, Tay WT, Teng TK, MacDonald M, Anand IS, Sharma A, **O'Connor CM**, Kraus WE, Mentz RJ, Lam CS; HF-ACTION and ASIAN-HF Investigators. Multi-ethnic comparisons of diabetes in heart failure with reduced ejection fraction: insights from the HF-ACTION trial and the ASIAN-HF registry. *Eur J Heart Fail*. 2018 Sep; 20(9):1281-1289. doi: 10.1002/ejhf.1223.
711. Greene SJ, Mentz RJ, Fiuzat M, Butler J, Solomon SD, Ambrosy AP, Mehta C, Teerlink JR, Zannad F, **O'Connor CM**. Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure. *Circulation*. 2018 Sep 4; 138(10):1039-1053. doi: 10.1161/CIRCULATIONAHA.118.034668.
712. Ambrosy AP, Mulder H, Coles A, Kraus WE, Lam CSP, McCullough PA, Pina I, Tromp J, Whellan DJ, **O'Connor CM**, Mentz RJ. Renal Function and Exercise Training in Ambulatory Heart Failure Patients with a Reduced Ejection Fraction. *Am J Cardiol*. 2018 Sep 15; 122(6):999-1007. doi: 10.1016/j.amjcard.2018.06.011.
713. **O'Connor CM**. Depression in Heart Failure: Beyond a SADHART. *JACC Heart Fail*. 2018 Oct;6(10):885-886. doi: 10.1016/j.jchf.2018.08.004.
714. Tahhan AS, Vaduganathan M, Greene SJ, Fonarow GC, Fiuzat M, Jessup M, Lindenfeld J, **O'Connor CM**, Butler J. Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials: A Systematic Review. *JAMA Cardiol*. 2018 Oct 1;3(10):1011-1019. doi: 10.1001/jamacardio.2018.2559.
715. Jiang W, Whellan DJ, Adams KF, Babyak MA, Boyle SH, Wilson JL, Patel CB, Rogers JG, Harris WS, **O'Connor CM**. Long-Chain Omega-3 Fatty Acid Supplements in Depressed Heart Failure Patients: Results of the OCEAN Trial. *JACC Heart Fail*. 2018 Oct;6(10):833-843. doi: 10.1016/j.jchf.2018.03.011.



716. Greene SJ, Hernandez AF, Sun JL, Butler J, Armstrong PW, Ezekowitz JA, Zannad F, Ferreira JP, Coles A, Metra M, Voors AA, Califf RM, **O'Connor CM**, Mentz RJ. Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points. *Circ Cardiovasc Qual Outcomes*. 2018 Oct;11(10):e004783. doi: 10.1161/CIRCOUTCOMES.118.004783.
717. Mentz RJ, **O'Connor CM**, Granger BB, Yang H, Patel CB, Steinhauser KE, Fiuzat M, Johnson KS, Anstrom KJ, Dodson GC, Taylor DH Jr, Mark DB, Tulsy JA, Rogers JG. Palliative care and hospital readmissions in patients with advanced heart failure: Insights from the PAL-HF trial. *Am Heart J*. 2018 Oct; 204:202-204. doi: 10.1016/j.ahj.2018.07.010.
718. Fudim M, Loungani R, Doerfler SM, Coles A, Greene SJ, Cooper LB, Fiuzat M, **O'Connor CM**, Rogers JG, Mentz RJ. Worsening renal function during decongestion among patients hospitalized for heart failure: Findings from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) trial. *Am Heart J*. 2018 Oct; 204:163-173. doi: 10.1016/j.ahj.2018.07.019.
719. Fudim M, Parikh KS, Dunning A, DeVore AD, Mentz RJ, Schulte PJ, Armstrong PW, Ezekowitz JA, Tang WHW, McMurray JJV, Voors AA, Drazner MH, **O'Connor CM**, Hernandez AF, Patel CB. Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF). *Am J Cardiol*. 2018 Nov 1; 122(9):1506-1512. doi: 10.1016/j.amjcard.2018.07.023.
720. Fudim M, **O'Connor CM**, Mulder H, Coles A, Bhatt AS, Ambrosy AP, Kraus WE, Piña IL, Whellan DJ, Mentz RJ. Loop diuretic adjustments in patients with chronic heart failure: Insights from HF-ACTION. *Am Heart J*. 2018 Nov; 205:133-141. doi: 10.1016/j.ahj.2018.06.017.
721. **O'Connor CM**. COAPTING Heart Failure Physicians, Interventional Cardiologists, and CardioThoracic Surgeons: A New Opportunity for Patients. *JACC Heart Fail*. 2018 Nov;6(11):967-968. doi: 10.1016/j.jchf.2018.09.007.
722. Mark DB, Cowper PA, Anstrom KJ, Sheng S, Daniels MR, Knight JD, Baloch KN, Davidson-Ray L, Fiuzat M, Januzzi JL Jr, Whellan DJ, Piña IL, Ezekowitz JA, Adams KF, Cooper LS, **O'Connor CM**, Felker GM. Economic and Quality-of-Life Outcomes of Natriuretic Peptide-Guided Therapy for Heart Failure. *J Am Coll Cardiol*. 2018 Nov 27; 72(21):2551-2562. doi: 10.1016/j.jacc.2018.08.2184.
723. **O'Connor CM**. Aviation Emergencies for Heart Failure Cardiologists: A New Twist to the Heart Team. *JACC Heart Fail*. 2018 Dec;6(12):1047-1048. doi: 10.1016/j.jchf.2018.10.018.
724. **O'Connor CM**. JACC: Heart Failure Peer Review Hall of Fame 2018. *JACC Heart Fail*. 2019 Jan;7(1):81. doi: 10.1016/j.jchf.2018.12.001.
725. Piccini JP, Pokorney SD, Anstrom KJ, Oldenburg O, Punjabi NM, Fiuzat M, Tasissa G, Whellan DJ, Lindenfeld J, Benjafield A, Woehrle H, Blase A, **O'Connor CM**. Adaptive servo-ventilation reduces atrial fibrillation burden in patients with heart failure and sleep apnea. *Heart Rhythm*. 2019 Jan;16(1):91-97. doi: 10.1016/j.hrthm.2018.07.027.
726. Luo N, **O'Connor CM**, Cooper LB, Sun JL, Coles A, Reed SD, Whellan DJ, Piña IL, Kraus WE, Mentz RJ. Relationship between changing patient-reported outcomes and subsequent clinical events in patients with chronic heart failure: insights from HF-ACTION. *Eur J Heart Fail*. 2019 Jan; 21(1):63-70. doi: 10.1002/ejhf.1299.
727. Daubert MA, Adams K, Yow E, Barnhart HX, Douglas PS, Rimmer S, Norris C, Cooper L, Leifer E, Desvigne-Nickens P, Anstrom K, Fiuzat M, Ezekowitz J, Mark DB, **O'Connor CM**, Januzzi J, Felker GM. NT-proBNP Goal Achievement Is Associated With Significant Reverse Remodeling

- and Improved Clinical Outcomes in HFREF. *JACC Heart Fail.* 2019 Feb; 7(2):158-168. doi: 10.1016/j.jchf.2018.10.014.
728. **O'Connor CM.** Recognizing Heart Failure Awareness Week. *JACC Heart Fail.* 2019 Feb;7(2):173. doi: 10.1016/j.jchf.2018.12.013.
729. Vaduganathan M, Tahhan AS, Alrohaibani A, Greene SJ, Fonarow GC, Vardeny O, Lindenfeld J, Jessup M, Fiuzat M, **O'Connor CM**, Butler J. Do Women and Men Respond Similarly to Therapies in Contemporary Heart Failure Clinical Trials? *JACC Heart Fail.* 2019 Mar;7(3):267-271. doi: 10.1016/j.jchf.2018.12.016.
730. Lindenfeld J, **O'Connor CM.** Heart Failure in Women. *JACC Heart Fail.* 2019 Mar;7(3):274-275. doi: 10.1016/j.jchf.2019.01.012.
731. **O'Connor CM.** Heart Failure Fake News: How Do We Distinguish the Truth? *JACC Heart Fail.* 2019 Apr;7(4):363. doi: 10.1016/j.jchf.2019.02.004.
732. Tehrani BN, Truesdell AG, Sherwood MW, Desai S, Tran HA, Epps KC, Singh R, Psotka M, Shah P, Cooper LB, Rosner C, Raja A, Barnett SD, Saulino P, deFilippi CR, Gurbel PA, Murphy CE, **O'Connor CM.** Standardized Team-Based Care for Cardiogenic Shock. *J Am Coll Cardiol.* 2019 Apr 9;73(13):1659-1669. doi: 10.1016/j.jacc.2018.12.084.
733. Psotka MA, Ammon SE, Fiuzat M, Bozkurt B, Chung ES, Cole RT, Greene SJ, Kraus D, Ky B, McIlvennan CK, Shah P, Teerlink JR, Walsh MN, Jessup M, **O'Connor CM.** Heart Failure Site-Based Research in the United States: Results of the Heart Failure Society of America Research Network Survey. *JACC Heart Fail.* 2019 May;7(5):431-438. doi: 10.1016/j.jchf.2019.02.008.
734. **O'Connor CM.** Guideline-Directed Medical Therapy Clinics: A Call to Action for the Heart Failure Team. *JACC Heart Fail.* 2019 May;7(5):442-443. doi: 10.1016/j.jchf.2019.04.001.
735. Butler J, Lam CSP, Anstrom KJ, Ezekowitz J, Hernandez AF, **O'Connor CM**, Pieske B, Ponikowski P, Shah SJ, Solomon SD, Voors AA, Wu Y, Carvalho F, Bamber L, Blaustein RO, Roessig L, Armstrong PW. Rationale and Design of the VITALITY-HFpEF Trial. *Circ Heart Fail.* 2019 May;12(5):e005998. doi: 10.1161/CIRCHEARTFAILURE.119.005998.
736. **O'Connor CM.** Better Quality of Life Over More Quantity of Life: How We View Time Trade-Off. *JACC Heart Fail.* 2019 Jun;7(6):531-532. doi: 10.1016/j.jchf.2019.05.001.
737. Warraich HJ, **O'Connor CM**, Yang H, Granger BB, Johnson KS, Mark DB, Anstrom KJ, Patel CB, Steinhilber KE, Tulskey JA, Taylor DH Jr, Rogers JG, Mentz RJ. African Americans With Advanced Heart Failure Are More Likely to Die in a Health Care Facility Than at Home or in Hospice: An Analysis From the PAL-HF Trial. *J Card Fail.* 2019 May 31. pii: S1071-9164(19)30345-8. doi: 10.1016/j.cardfail.2019.05.013.
738. Felker GM, Borentain M, Cleland JG, DeSouza MM, Kessler PD, **O'Connor CM**, Seiffert D, Teerlink JR, Voors AA, McMurray JJV. Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure. *Eur J Heart Fail.* 2019 Jun 6. doi: 10.1002/ejhf.1504.
739. Reddy YNV, Borlaug BA, **O'Connor CM**, Gersh BJ. Novel approaches to the management of chronic systolic heart failure: future directions and unanswered questions. *Eur Heart J.* 2019 Jun 14. pii: ehz364. doi: 10.1093/eurheartj/ehz364.
740. **O'Connor CM**, Fiuzat M, Mulder H, Coles A, Ahmad T, Ezekowitz JA, Adams KF, Pina IL, Anstrom KJ, Cooper LS, Mark DB, Whellan DJ, Januzzi Jr JL, Leifer, ES, Felker GM. Clinical Factors Related to Morbidity and Mortality in High-Risk Heart Failure Patients: The GUIDE-IT

- Predictive Model and Risk Score. *Eur J Heart Fail*. 2019 Jun;21(6):770-778. doi: 10.1002/ejhf.1450. Epub 2019 Mar 27.
741. Ambrosy AP, Mentz RJ, Fiuzat M, Cleland JGF, Greene SJ, **O'Connor CM**, Teerlink JR, Zannad F, Solomon SD. Erratum to 'The role of angiotensin receptor-neprilysin inhibitors in cardiovascular disease-existing evidence, knowledge gaps, and future directions' [*Eur J Heart Fail* 2018;20:963-972]. *Eur J Heart Fail*. 2019 Jun;21(6):819. doi: 10.1002/ejhf.1480.
742. Yang S, Starks MA, Hernandez AF, Turner EL, Califf RM, **O'Connor CM**, Mentz RJ, Choudhury KR. Impact of baseline covariate imbalance on bias in treatment effect estimation in cluster randomized trials: Race as an example. *Contemp Clin Trials*. 2019 Jun 19. pii: S1551-7144(18)30730-4. doi: 10.1016/j.cct.2019.04.016.
743. **O'Connor CM**. N-of-1 Clinical Trials. *JACC Heart Fail*. 2019 Jul;7(7):630-631. doi: 10.1016/j.jchf.2019.05.004.
744. Beldhuis IE, Streng KW, van der Meer P, Maaten JMT, **O'Connor CM**, Metra M, Dittrich HC, Ponikowski P, Cotter G, Cleland JGF, Davison BA, Givertz MM, Teerlink JR, Bloomfield DM, Voors AA, Damman K. Trajectories of Changes in Renal Function in Patients with Acute Heart Failure. *J Card Fail*. 2019 Jul 15. pii: S1071-9164(19)30070-3. doi: 10.1016/j.cardfail.2019.07.004.
745. **O'Connor CM**. Why Should We Publish All Clinical Trials? *JACC Heart Fail*. 2019 Aug;7(8):730. doi: 10.1016/j.jchf.2019.06.009.
746. Psotka MA, Fiuzat M, Carson PE, Kao DP, Cerkvenik J, Schaber DE, Verta P, Kazmierski RT, Shinnar M, Stockbridge N, Unger EF, Zuckerman B, Butler J, Felker GM, Konstam MA, Lindenfeld J, Solomon SD, Teerlink JR, **O'Connor CM**, Abraham WT. Design of a "Lean" Case Report Form for Heart Failure Therapeutic Development. *JACC Heart Fail*. 2019 Nov;7(11):913-921. doi: 10.1016/j.jchf.2019.07.001.
747. Januzzi JL Jr, Ahmad T, Mulder H, Coles A, Anstrom KJ, Adams KF, Ezekowitz JA, Fiuzat M, Houston-Miller N, Mark DB, Piña IL, Passmore G, Whellan DJ, Cooper LS, Leifer ES, Desvigne-Nickens P, Felker GM, **O'Connor CM**. Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction. *J Am Coll Cardiol*. 2019 Sep 3;74(9):1205-1217. doi: 10.1016/j.jacc.2019.06.055.
748. **O'Connor CM**. Heart Failure Physician Burnout: How Can We Help? *JACC Heart Fail*. 2019 Sep;7(9):821. doi: 10.1016/j.jchf.2019.07.004.
749. DeVore AD, Yow E, Krucoff MW, Sherwood MW, Shaw LK, Chiswell K, **O'Connor CM**, Ohman EM, Velazquez EJ. Percutaneous coronary intervention outcomes in patients with stable coronary disease and left ventricular systolic dysfunction. *ESC Heart Fail*. 2019 Sep 27. doi: 10.1002/ehf2.12510.
750. **O'Connor CM**. Acute Decompensated Heart Failure: Is There a Path Forward? *JACC Heart Fail*. 2019 Oct;7(10):911-912. doi: 10.1016/j.jchf.2019.08.005.
751. Psotka MA, Fonarow GC, Allen LA, Joynt Maddox KE, Fiuzat M, Heidenreich P, Hernandez AF, Konstam MA, Yancy CW, **O'Connor CM**. The Hospital Readmissions Reduction Program: Nationwide Perspectives and Recommendations. *JACC Heart Fail*. 2019 Oct 5. pii: S2213-1779(19)30675-4. doi: 10.1016/j.jchf.2019.07.012.
752. Greene SJ, DeVore AD, Sheng S, Fonarow GC, Butler J, Califf RM, Hernandez AF, Matsouaka RA, Samman Tahhan A, Thomas KL, Vaduganathan M, Yancy CW, Peterson ED, **O'Connor CM**, Mentz RJ. Representativeness of a Heart Failure Trial by Race and Sex: Results From

- ASCEND-HF and GWTG-HF. *JACC Heart Fail.* 2019 Nov;7(11):980-992. doi: 10.1016/j.jchf.2019.07.011.
753. Beusekamp JC, Tromp J, Cleland JGF, Givertz MM, Metra M, **O'Connor CM**, Teerlink JR, Ponikowski P, Ouwerkerk W, van Veldhuisen DJ, Voors AA, van der Meer P. Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality. *JACC Heart Fail.* 2019 Nov;7(11):970-979. doi: 10.1016/j.jchf.2019.07.010.
754. **O'Connor CM**, deFilippi C. PARAGON-HF - Why We Do Randomized, Controlled Clinical Trials. *N Engl J Med.* 2019 Oct 24;381(17):1675-1676. doi: 10.1056/NEJMe1912402.
755. **O'Connor CM**. A Call for Change: Level of Statistical Significance. *JACC Heart Fail.* 2019 Nov;7(11):993-994. doi: 10.1016/j.jchf.2019.09.005.
756. Caraballo C, Desai NR, Mulder H, Alhanti B, Wilson FP, Fiuzat M, Felker GM, Piña IL, **O'Connor CM**, Lindenfeld J, Januzzi JL, Cohen LS, Ahmad T. Clinical Implications of the New York Heart Association Classification. *J Am Heart Assoc.* 2019 Dec 3;8(23):e014240. doi: 10.1161/JAHA.119.014240. Epub 2019 Nov 27.
757. Regan JA, Kitzman DW, Leifer ES, Kraus WE, Fleg JL, Forman DE, Whellan DJ, Wojdyla D, Parikh K, **O'Connor CM**, Mentz RJ. Impact of Age on Comorbidities and Outcomes in Heart Failure With Reduced Ejection Fraction. *JACC Heart Fail.* 2019 Dec;7(12):1056-1065. doi: 10.1016/j.jchf.2019.09.004.
758. **O'Connor CM**. N-1 and Sequencing Clinical Heart Failure Trials: Charting the Path for Future Clinical Care. *JACC Heart Fail.* 2019 Dec;7(12):1089-1090. doi: 10.1016/j.jchf.2019.10.006.
759. Pandhi P, Ter Maaten JM, Emmens JE, Struck J, Bergmann A, Cleland JG, Givertz MM, Metra M, **O'Connor CM**, Teerlink JR, Ponikowski P, Cotter G, Davison B, van Veldhuisen DJ, Voors AA. Clinical value of pre-discharge bio-adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission. *Eur J Heart Fail.* 2019 Dec 3. doi: 10.1002/ejhf.1693.
760. Pieske B, Patel MJ, Westerhout CM, Anstrom KJ, Butler J, Ezekowitz J, Hernandez AF, Koglin J, Lam CSP, Ponikowski P, Roessig L, Voors AA, **O'Connor CM**, Armstrong PW; VICTORIA Study Group. Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial. *Eur J Heart Fail.* 2019 Dec;21(12):1596-1604. doi: 10.1002/ejhf.1664.
761. Butler J, Packer M, Greene SJ, Fiuzat M, Anker SD, Anstrom KJ, Carson PE, Cooper LB, Fonarow GC, Hernandez AF, Januzzi JL Jr, Jessup M, Kalyani RR, Kaul S, Kosiborod M, Lindenfeld J, McGuire DK, Sabatine MS, Solomon SD, Teerlink JR, Vaduganathan M, Yancy CW, Stockbridge N, **O'Connor CM**. Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues. *Circulation.* 2019 Dec 17;140(25):2108-2118. doi: 10.1161/CIRCULATIONAHA.119.042155.
762. **O'Connor CM**. The Heart Failure High Five: Medical Therapy and Policy: 2019. *JACC Heart Fail.* 2020 Jan;8(1):81-82. doi: 10.1016/j.jchf.2019.11.008.
763. Psotka MA, Fonarow GC, Allen LA, Joynt Maddox KE, Fiuzat M, Heidenreich P, Hernandez AF, Konstam MA, Yancy CW, **O'Connor CM**. The Hospital Readmissions Reduction Program: Nationwide Perspectives and Recommendations: A JACC: Heart Failure Position Paper. *JACC Heart Fail.* 2020 Jan;8(1):1-11. doi: 10.1016/j.jchf.2019.07.012. Epub 2019 Oct 9.

764. Masson R, Ambrosy AP, Kheder K, Fudim M, Clare RM, Coles A, Hernandez AF, Starling RC, Ezekowitz JA, **O'Connor CM**, Mentz RJ. A Novel In-hospital Congestion Score to Risk Stratify Patients Admitted for Worsening Heart Failure (from ASCEND-HF). *J Cardiovasc Transl Res*. 2020 Jan 13. doi: 10.1007/s12265-020-09954-x.
765. Carubelli V, Zhang Y, Metra M, Lombardi C, Felker GM, Filippatos G, **O'Connor CM**, Teerlink JR, Simmons P, Segal R, Malfatto G, La Rovere MT, Li D, Han X, Yuan Z, Yao Y, Li B, Lau LF, Bianchi G, Zhang J; Istaroxime ADHF Trial Group. Treatment with 24 hour istaroxime infusion in patients hospitalised for acute heart failure: a randomised, placebo-controlled trial. *Eur J Heart Fail*. 2020 Jan 23. doi: 10.1002/ejhf.1743.
766. **O'Connor CM**. Open Access in Heart Failure: Ready or Not, Here We Come. *JACC Heart Fail*. 2020 Feb;8(2):151-152. doi: 10.1016/j.jchf.2020.01.001.
767. **O'Connor CM**. Suicide in HF Patients: A Call for Recognition. *JACC Heart Fail*. 2020 Mar;8(3):243-244. doi: 10.1016/j.jchf.2020.01.008.
768. Bhatt AS, Ambrosy AP, Dunning A, DeVore AD, Butler J, Reed S, Voors A, Starling R, Armstrong PW, Ezekowitz JA, Metra M, Hernandez AF, **O'Connor CM**, Mentz RJ. The burden of non-cardiac comorbidities and association with clinical outcomes in an acute heart failure trial - insights from ASCEND-HF. *Eur J Heart Fail*. 2020 Mar 25. doi: 10.1002/ejhf.1795.
769. Damluji AA, Rodriguez G, Noel T, Davis L, Dahya V, Tehrani B, Epps K, Sherwood M, Sarin E, Walston J, Bandeen-Roche K, Resar JR, Brown TT, Gerstenblith G, **O'Connor CM**, Batchelor W. Sarcopenia and health-related quality of life in older adults after transcatheter aortic valve replacement. *Am Heart J*. 2020 Apr 4;224:171-181. doi: 10.1016/j.ahj.2020.03.021.
770. **O'Connor CM**. Heart Failure Multidisciplinary Teams and New Zealand Rugby: What Can We Learn From the "All Blacks" Rugby Team? *JACC Heart Fail*. 2020 Apr;8(4):341-342. doi: 10.1016/j.jchf.2020.02.003.
771. Truby LK, **O'Connor CM**, Fiuzat M, Stebbins A, Coles A, Patel CB, Granger B, Pagidipati N, Agarwal R, Rymer J, Lowenstern A, Douglas PS, Tulskey J, Rogers JG, Mentz RJ. Sex Differences in Quality of Life and Clinical Outcomes in Patients With Advanced Heart Failure: Insights From the PAL-HF Trial. *Circ Heart Fail*. 2020 Apr;13(4):e006134. doi: 10.1161/CIRCHEARTFAILURE.119.006134. Epub 2020 Apr 9.
772. Fiuzat M, Ezekowitz J, Alemayehu W, Westerhout CM, Sbolli M, Cani D, Whellan DJ, Ahmad T, Adams K, Piña IL, Patel CB, Anstrom KJ, Cooper LS, Mark D, Leifer ES, Felker GM, Januzzi JL, **O'Connor CM**. Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial: A Secondary Analysis of a Randomized Clinical Trial. *JAMA Cardiol*. 2020 Apr 22:e200640. doi: 10.1001/jamacardio.2020.0640.
773. Bilchick KC, Wang Y, Curtis JP, Cheng A, Dharmarajan K, Shadman R, Dardas TF, Anand I, Lund LH, Dahlström U, Sartipy U, Maggioni A, **O'Connor C**, Levy WC. Modeling defibrillation benefit for survival among cardiac resynchronization therapy defibrillator recipients. *Am Heart J*. 2020 Apr;222:93-104. doi: 10.1016/j.ahj.2019.12.017. Epub 2019 Dec 27.
774. Fiuzat M, Lowy N, Stockbridge N, Sbolli M, Latta F, Lindenfeld J, Lewis E, MD, MPH; Abraham WT, Teerlink J, Walsh MN, Heidenreich P, Bozkurt B, Starling RC, Solomon S, Felker GM, Butler J, Yancy C, Stevenson LW, **O'Connor C**, Unger E, Temple R, McMurray J. Endpoints in Heart Failure Drug Development: History and Future. *JACC Heart Fail*. 2020 Jun;8(6):429-440. doi: 10.1016/j.jchf.2019.12.011. Epub 2020 Apr 8.

775. Abraham WT, Fiuzat M, Psotka MA, **O'Connor CM**. Heart Failure Collaboratory Statement on Clinical Trials in the Landscape of COVID-19. *JACC Heart Fail*. 2020 May;8(5):423-425. doi: 10.1016/j.jchf.2020.03.005.
776. Ibrahim NE, Burnett JC Jr, Butler J, Camacho A, Felker GM, Fiuzat M, **O'Connor CM**, Solomon SD, Vaduganathan M, Zile MR, Januzzi JL Jr. Natriuretic Peptides as Inclusion Criteria in Clinical Trials: A JACC: Heart Failure Position Paper. *JACC Heart Fail*. 2020 May;8(5):347-358. doi: 10.1016/j.jchf.2019.12.010. Epub 2020 Mar 11.
777. Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam CSP, Ponikowski P, Voors AA, Jia G, McNulty SE, Patel MJ, Roessig L, Koglin J, **O'Connor CM**; VICTORIA Study Group. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. *N Engl J Med*. 2020 May 14;382(20):1883-1893. doi: 10.1056/NEJMoa1915928.
778. Cooper LB, Psotka MA, Sinha S, Nallamotheu BK, deFilippi CR, Batchelor W, **O'Connor CM**, Damluji AA. Specificity of administrative coding for older adults with acute heart failure hospitalizations. *Am Heart J*. 2020 May;223:1-2. doi: 10.1016/j.ahj.2020.02.004.
779. Butler J, Khan MS, Anker SD, Fonarow GC, Kim RJ, Nodari S, **O'Connor CM**, Pieske B, Pieske-Kraigher E, Sabbah HN, Senni M, Voors AA, Udelson JE, Carr J, Gheorghide M, Filippatos G. Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. *J Card Fail*. 2020 May;26(5):429-437. doi: 10.1016/j.cardfail.2020.02.001.
780. Sbolli M, Fiuzat M, Cani D, **O'Connor C**. Depression and heart failure: the lonely comorbidity. *Eur J Heart Fail*. 2020 May 29. doi: 10.1002/ejhf.1865.
781. **O'Connor CM**. Heart Failure Editorial Emergencies in the COVID-19 Era. *JACC Heart Fail*. 2020 Jun;8(6):518. doi: 10.1016/j.jchf.2020.04.002.
782. Psotka M, Latta F, Cani C, Fiuzat M, Sbolli M, Barnett S, Metra M, **O'Connor CM**. Publication Rates of Heart Failure Clinical Trials Remain Low. *J Am Coll Cardiol*. 2020 Jun, 75 (25) 3151-3161.
783. **O'Connor CM**. COVID-10 Fatigue: Not So Fast. *JACC Heart Fail*. 2020 Jul;8(7):592-594. doi: 10.1016/j.jchf.2020.06.001.
784. Abraham WT, Fiuzat M, Psotka MA, **O'Connor CM**. Heart Failure Collaboratory Statement on Remote Monitoring and Social Distancing in the Landscape of COVID-19. *JACC Heart Fail*. 2020 Aug;8(8):692-694. doi: 10.1016/j.jchf.2020.06.006.
785. Tehrani BN, Damluji AA, Sherwood MW, Rosner C, Truesdell AG, Epps KC, Howard E, Barnett SD, Raja A, deFilippi CR, Murphy CE, **O'Connor CM**, Batchelor WB. Tehrani BN, Damluji AA, Sherwood MW, Rosner C, Truesdell AG, Epps KC, Howard E, Barnett SD, Raja A, deFilippi CR, Murphy CE, O'Connor CM, Batchelor WB. Transradial access in acute myocardial infarction complicated by cardiogenic shock: Stratified analysis by shock severity. *Catheter Cardiovasc Interv*. 2020 Aug 3. doi: 10.1002/ccd.29098.
786. Reza N, Tahhan AS, Mahmud N, DeFilippis EM, Alrohaibani A, Vaduganathan M, Greene SJ, Ho AH, Fonarow GC, Butler J, **O'Connor C**, Fiuzat M, Vardeny O, Piña IL, Lindenfeld J, Jessup M. Representation of Women Authors in International Heart Failure Guidelines and Contemporary Clinical Trials. *Circ Heart Fail*. 2020 Aug;13(8):e006605. doi: 10.1161/CIRCHEARTFAILURE.119.006605.
787. Damluji AA, Fabbro M 2nd, Epstein RH, Rayer S, Wang Y, Moscucci M, Cohen MG, Carroll JD, Messenger JC, Resar JR, Cohen DJ, Sherwood MW, **O'Connor CM**, Batchelor W.

Transcatheter Aortic Valve Replacement in Low-Population Density Areas: Assessing Healthcare Access for Older Adults with Severe Aortic Stenosis. *Circ Cardiovasc Qual Outcomes*. 2020 Aug;13(8):e006245. doi: 10.1161/CIRCOUTCOMES.119.006245.

788. Psotka MA, Fiuzat M, Solomon SD, Chauhan C, Felker GM, Butler J, Teerlink JR, Sinha SS, **O'Connor CM**, Konstam MA. Challenges and Potential Improvements to Patient Access to Pharmaceuticals: Examples From Cardiology. *Circulation*. 2020 Aug 25;142(8):790-798. doi: 10.1161/CIRCULATIONAHA.119.044976.
789. **O'Connor CM**, Francis C. The Journey of an American Black Cardiologist. *JACC Heart Fail*. 2020 Sep;8(9):780-781. doi: 10.1016/j.jchf.2020.08.001.
790. Angraal S, Caraballo C, Kahn P, Bhatnagar A, Singh B, Wilson FP, Fiuzat M, **O'Connor CM**, Allen LA, Desai NR, Mamtani R, Ahmad T. Geographical affiliation with top 10 NIH-funded academic medical centers and differences between mortality from cardiovascular disease and cancer. *Am Heart J*. 2020 Sep 18;230:54-58. doi: 10.1016/j.ahj.2020.08.014.
791. **O'Connor CM**. Convalescence From COVID Research: Lessons From the Heart Failure Community. *JACC Heart Fail*. 2020 Oct;8(10):870-871. doi: 10.1016/j.jchf.2020.08.005.
792. Lanfear DE, Luzum JA, She R, Gui H, Donahue MP, **O'Connor CM**, Adams KF, Sanders-van Wijk S, Zeld N, Maeder MT, Sabbah HN, Kraus WE, Brunner-La Rocca HP, Li J, Williams LK. Polygenic Score for Beta-Blocker Survival Benefit in European Ancestry Patients with Reduced Ejection Fraction Heart Failure. *Circ Heart Fail*. 2020 Oct 4. doi: 10.1161/CIRCHEARTFAILURE.119.007012.
793. Abraham WT, Psotka MA, Fiuzat M, Filippatos G, Lindenfeld J, Mehran R, Ambardekar AV, Carson PE, Jacob R, Januzzi JL Jr, Konstam MA, Krucoff MW, Lewis EF, Piccini JP, Solomon SD, Stockbridge N, Teerlink JR, Unger EF, Zeitler EP, Anker SD, **O'Connor CM**. Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel from the Heart Failure Collaboratory and Academic Research Consortium (HF-ARC). *Eur J Heart Fail*. 2020 Oct 5. doi: 10.1002/ejhf.2018.
794. Armstrong PW, Anstrom KJ, **O'Connor CM**; VICTORIA Study Group. Plasma Volume Status and Its Association With In-Hospital and Postdischarge Outcomes in Decompensated Heart Failure. *J Card Fail*. 2020 Oct 7:S1071-9164(20)31468-8. doi: 10.1016/j.cardfail.2020.09.478.
795. Perego C, Sbolli M, Specchia C, Fiuzat M, McCaw ZR, Metra M, Oriecua C, Peveri G, Wei LJ, **O'Connor CM**, Psotka MA. Utility of Restricted Mean Survival Time Analysis for Heart Failure Clinical Trial Evaluation and Interpretation. *JACC Heart Fail*. 2020 Oct 2:S2213-1779(20)30455-8. doi: 10.1016/j.jchf.2020.07.005.
796. Armstrong PW, Lam CSP, Anstrom KJ, Ezekowitz J, Hernandez AF, **O'Connor CM**, Pieske B, Ponikowski P, Shah SJ, Solomon SD, Voors AA, She L, Vlainic V, Carvalho F, Bamber L, Blaustein RO, Roessig L, Butler J; VITALITY-HfpEF Study Group. Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial. *JAMA*. 2020 Oct 20;324(15):1512-1521. doi: 10.1001/jama.2020.15922.
797. Ezekowitz JA, **O'Connor CM**, Troughton RW, Alemayehu WG, Westerhout CM, Voors AA, Butler J, Lam CSP, Ponikowski P, Emdin M, Patel MJ, Pieske B, Roessig L, Hernandez AF, Armstrong PW. N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study. *JACC Heart Fail*. 2020 Nov;8(11):931-939. doi: 10.1016/j.jchf.2020.08.008.

798. **O'Connor CM**. Personalized Therapeutic Approach: Gun Control for Shotgun Therapy. *JACC Heart Fail*. 2020 Nov;8(11):954-955. doi: 10.1016/j.jchf.2020.09.002.
799. Lam CSP, Giczewska A, Sliwa K, Edelmann F, Refsgaard J, Bocchi E, Ezekowitz JA, Hernandez AF, **O'Connor CM**, Roessig L, Patel MJ, Pieske B, Anstrom KJ, Armstrong PW; VICTORIA Study Group. Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial. *JAMA Cardiol*. 2020 Nov 13:e206455. doi: 10.1001/jamacardio.2020.6455.
800. Psocka MA, Abraham WT, Fiuzat M, Filippatos G, Lindenfeld J, Ahmad T, Bhatt AS, Carson PE, Cleland JGF, Felker GM, Januzzi JL Jr, Kitzman DW, Leifer ES, Lewis EF, McMurray JJV, Mentz RJ, Solomon SD, Stockbridge N, Teerlink JR, Vaduganathan M, Vardeny O, Whellan DJ, Wittes J, Anker SD, **O'Connor CM**. Conduct of Clinical Trials in the Era of COVID-19: JACC Scientific Expert Panel. *J Am Coll Cardiol*. 2020 Nov 17;76(20):2368-2378. doi:10.1016/j.jacc.2020.09.544.
801. Abraham WT, Psocka MA, Fiuzat M, Filippatos G, Lindenfeld J, Mehran R, Ambardekar AV, Carson PE, Jacob R, Januzzi JL Jr, Konstam MA, Krucoff MW, Lewis EF, Piccini JP, Solomon SD, Stockbridge N, Teerlink JR, Unger EF, Zeitler EP, Anker SD, **O'Connor CM**. Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research Consortium. *JACC Heart Fail*. 2020 Dec;8(12):961-972. doi: 10.1016/j.jchf.2020.10.002.
802. Sbolli M, **O'Connor CM**. Aldosterone: Behind the Scenes of Depression and Heart Failure? *JACC Heart Fail*. 2020 Dec;8(12):1021-1023. doi: 10.1016/j.jchf.2020.10.006.
803. **O'Connor CM**, Bristow MR. Changing U.S. Heart Failure Research Culture: Part 2-Recognizing Frontline Investigators and Coordinators. *JACC Heart Fail*. 2020 Dec;8(12):1050-1051. doi: 10.1016/j.jchf.2020.10.010.
804. Farsky PS, White J, Al-Khalidi HR, Sueta CA, Rouleau JL, Panza JA, Velazquez EJ, **O'Connor CM**; Working Group and Surgical Treatment for Ischemic Heart failure Trial Investigators. Optimal medical therapy with or without surgical revascularization and long-term outcomes in ischemic cardiomyopathy. *J Thorac Cardiovasc Surg*. 2021 Jan 7:S0022-5223(20)33449-8. doi: 10.1016/j.jtcvs.2020.12.094.
805. Bhatt AS, Abraham WT, Lindenfeld J, Bristow M, Carson PE, Felker GM, Fonarow GC, Greene SJ, Psocka MA, Solomon SD, Stockbridge N, Teerlink JR, Vaduganathan M, Wittes J, Fiuzat M, **O'Connor CM**, Butler J. Treatment of HF in an Era of Multiple Therapies: Statement From the HF Collaboratory. *JACC Heart Fail*. 2021 Jan;9(1):1-12. doi: 10.1016/j.jchf.2020.10.014.
806. **O'Connor CM**. A Generation Passed; A Generation Forward: Why Joseph C. Greenfield, Chairman of Medicine, Duke University, Matters Today (1931 to 2020). *JACC Heart Fail*. 2021 Jan;9(1):80-81. doi: 10.1016/j.jchf.2020.11.005.
807. Markousis-Mavrogenis G, Tromp J, Mentz RJ, **O'Connor CM**, Metra M, Ponikowski P, Teerlink JR, Cotter G, Davison B, Cleland JGF, Givertz MM, van Veldhuisen DJ, Hillege HL, Voors AA, van der Meer P. The Additive Prognostic Value of Serial Plasma Interleukin-6 Levels over Changes in Brain Natriuretic Peptide in Patients with Acute Heart Failure. *J Card Fail*. 2021 Jan 23:S1071-9164(21)00011-7. doi: 10.1016/j.cardfail.2021.01.008.
808. Perez AL, Grodin JL, Chaikijurajai T, Wu Y, Hernandez AF, Butler J, Metra M, Felker GM, Voors AA, McMurray JJ, Armstrong PW, **O'Connor C**, Starling RC, Tang WHW. Interleukin-6 and Outcomes in Acute Heart Failure: An ASCEND-HF Substudy. *J Card Fail*. 2021 Jan 23:S1071-9164(21)00009-9. doi: 10.1016/j.cardfail.2021.01.006.



809. Felker GM, McMurray JJV, Cleland JG, **O'Connor CM**, Teerlink JR, Voors AA, Belohlavek J, Böhm M, Borentain M, Bueno H, Cole RT, DeSouza MM, Ezekowitz JA, Filippatos G, Lang NN, Kessler PD, Martinez FA, Mebazaa A, Metra M, Mosterd A, Pang PS, Ponikowski P, Sato N, Seiffert D, Ye J. Effects of a Novel Nitroxyl Donor in Acute Heart Failure: The STAND-UP AHF Study. *JACC Heart Fail.* 2021 Feb;9(2):146-157. doi: 10.1016/j.jchf.2020.10.012.
810. **O'Connor CM**. Meet Me in the Middle: Lessons From the Cardiorenal Advisory Committee for Sacubitril/Valsartan in HFpEF. *JACC Heart Fail.* 2021 Feb;9(2):161-163. doi: 10.1016/j.jchf.2020.12.003.
811. Feng KY, **O'Connor CM**, Clare R, Alhanti B, Piña IL, Kraus WE, Whellan DJ, Mentz RJ. Greater Pain Severity Is Associated with Worse Outcomes in Patients with Heart Failure. *J Cardiovasc Transl Res.* 2021 Feb 9. doi: 10.1007/s12265-021-10104-0.
812. Lang NN, Ahmad FA, Cleland JG, **O'Connor CM**, Teerlink JR, Voors AA, Taubel J, Hodes AR, Anwar M, Karra R, Sakata Y, Ishihara S, Senior R, Khemka A, Prasad NG, DeSouza MM, Seiffert D, Ye JY, Kessler PD, Borentain M, Solomon SD, Felker GM, McMurray JJV. Haemodynamic effects of the nitroxyl donor cimlanod (BMS-986231) in chronic heart failure: a randomized trial. *Eur J Heart Fail.* 2021 Feb 23. doi: 10.1002/ejhf.2138.
813. Batchelor WB, Damluji AA, Yong C, Fiuzat M, Barnett SD, Kandzari DE, Sherwood MW, Epps KC, Tehrani BN, Allocco DJ, Meredith IT, Lindenfeld J, **O'Connor CM**, Mehran R. Does Study Subject Diversity Influence Cardiology Research Site Performance?: Insights from 2 U.S. National Coronary Stent Registries. *Am Heart J.* 2021 Feb 23:S0002-8703(21)00035-1. doi: 10.1016/j.ahj.2021.02.003.
814. Wan L, Samsky MD, **O'Connor CM**, Stebbins A, Alhanti B, Warraich HJ, Johnson KS, Anstrom KJ, Fiuzat M, Granger BB, Mark DB, Tulsy JA, Rogers JG, Mentz RJ. Patterns of Change in Individual Domains of the Kansas City Cardiomyopathy Questionnaire with a Palliative Care Intervention for Patients with Advanced Heart Failure: Insights from PAL-HF. *J Card Fail.* 2021 Feb 26:S1071-9164(21)00079-8. doi: 10.1016/j.cardfail.2021.02.007.
815. **O'Connor CM**. Reviewers Hall of Fame: 2020 Top Reviewers. *JACC Heart Fail.* 2021 Mar;9(3):241. doi: 10.1016/j.jchf.2021.01.004.
816. Blumer V, Greene SJ, Wu A, Butler J, Ezekowitz JA, Lindenfeld J, Alhanti B, Hernandez AF, **O'Connor CM**, Mentz RJ. Sex Differences in Clinical Course and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure. *JACC Heart Fail.* 2021 Mar 10:S2213-1779(21)00011-1. doi: 10.1016/j.jchf.2020.12.011.
817. Kaufman BG, Granger BB, Sun JL, Sanders G, Taylor DH Jr, Mark DB, Warraich H, Fiuzat M, Steinhauser K, Tulsy JA, Rogers JG, **O'Connor C**, Mentz RJ. The Cost-Effectiveness of Palliative Care: Insights from the PAL-HF Trial. *J Card Fail.* 2021 Mar 14:S1071-9164(21)00114-7. doi: 10.1016/j.cardfail.2021.02.019.
818. Brooksbank JA, Greene SJ, Harris HM, Stebbins A, Fiuzat M, Whellan DJ, Alhanti B, Kraus WE, Piña IL, **O'Connor CM**, Mentz RJ. Beta-blocker and ACE-inhibitor dosing as a function of body surface area: From the HF-ACTION trial. *Am Heart J.* 2021 Mar;233:1-4. doi: 10.1016/j.ahj.2020.11.003.
819. Bozkurt B, Fonarow GC, Goldberg LR, Guglin M, Josephson RA, Forman DE, Lin G, Lindenfeld J, **O'Connor C**, Panjrath G, Piña IL, Shah T, Sinha SS, Wolfel E; ACC's Heart Failure and Transplant Section and Leadership Council. Cardiac Rehabilitation for Patients With Heart Failure: JACC Expert Panel. *J Am Coll Cardiol.* 2021 Mar 23;77(11):1454-1469. doi: 10.1016/j.jacc.2021.01.030.

820. Blumer V, Mentz RJ, Sun JL, Butler J, Metra M, Voors AA, Hernandez AF, **O'Connor CM**, Greene SJ. Prognostic Role of Prior Heart Failure Hospitalization Among Patients Hospitalized for Worsening Chronic Heart Failure. *Circ Heart Fail*. 2021 Apr;14(4):e007871. doi: 10.1161/CIRCHEARTFAILURE.120.007871.
821. **O'Connor CM**. Heart Failure Leadership, Culture, and Governance: Lessons Learned From Tom Brady. *JACC Heart Fail*. 2021 Apr;9(4):317-318. doi: 10.1016/j.jchf.2021.02.002.
822. Bhatt AS, Fiuzat M, Lindenfeld J, **O'Connor CM**, Butler J. Reply: Improving Heart Failure Therapeutics: Thinking Outside the Pillbox? *JACC Heart Fail*. 2021 Apr;9(4):317-318. doi: 10.1016/j.jchf.2021.02.002.
823. Chouairi F, Pacor J, Miller PE, Fuery MA, Caraballo C, Sen S, Leifer ES, Felker GM, Fiuzat M, **O'Connor CM**, Januzzi JL, Friedman DJ, Desai NR, Ahmad T, Freeman JV. Effects of Atrial Fibrillation on Heart Failure Outcomes and NT-proBNP Levels in the GUIDE-IT Trial. *Mayo Clin Proc Innov Qual Outcomes*. 2021 Apr 8;5(2):447-455. doi: 10.1016/j.mayocpiqo.2021.02.005.
824. Lindenfeld J, Fiuzat M, **O'Connor C**. Promoting Diversity in Clinical Trial Leadership: A Call to Action. *JACC Heart Fail*. 2021 May;9(5):401-402. doi: 10.1016/j.jchf.2021.03.005.
825. Daubert MA, Yow E, Barnhart HX, Piña IL, Ahmad T, Leifer E, Cooper L, Desvigne-Nickens P, Fiuzat M, Adams K, Ezekowitz J, Whellan DJ, Januzzi JL, **O'Connor CM**, Felker GM. Differences in NT-proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction. *J Am Heart Assoc*. 2021 May 18;10(10):e019712. doi: 10.1161/JAHA.120.019712.
826. Mentz RJ, Mulder H, Mosterd A, Sweitzer NK, Senni M, Butler J, Ezekowitz JA, Lam CSP, Pieske B, Ponikowski P, Voors AA, Anstrom KJ, Armstrong PW, **O'Connor CM**; VICTORIA Study Group. Clinical Outcome Predictions for the VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial: VICTORIA Outcomes Model. *J Card Fail*. 2021 May 26:S1071-9164(21)00206-2. doi: 10.1016/j.cardfail.2021.05.016.
827. **O'Connor CM**, Rogers J, Lindenfeld J. Device Development in the Gray Zone: One Step Forward. *JACC Heart Fail*. 2021 Jun;9(6):463-464. doi: 10.1016/j.jchf.2021.05.001.
828. Chouairi F, Fuery MA, Mullan CW, Caraballo C, Sen S, Maulion C, Wilkinson ST, Surti T, McCullough M, Miller PE, Pacor J, Leifer ES, Felker GM, Velazquez EJ, Fiuzat M, **O'Connor CM**, Januzzi JL, Desai NR, Ahmad T. The Impact of Depression on Outcomes in Patients With Heart Failure and Reduced Ejection Fraction Treated in the GUIDE-IT Trial. *J Card Fail*. 2021 Jun 22:S1071-9164(21)00244-X. doi: 10.1016/j.cardfail.2021.06.008.
829. Mentz RJ, Mulder H, Mosterd A, Sweitzer NK, Senni M, Butler J, Ezekowitz JA, Lam CSP, Pieske B, Ponikowski P, Voors AA, Anstrom KJ, Armstrong PW, **O'Connor CM**, Hernandez AF; VICTORIA Study Group. Clinical Outcome Predictions for the VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial. *J Card Fail*. 2021 Jun 24:S1071-9164(21)00206-2. doi: 10.1016/j.cardfail.2021.05.016.
830. Mentz RJ, Whellan DJ, Reeves GR, Pastva AM, Duncan P, Upadhyya B, Nelson MB, Chen H, Reed SD, Rosenberg PB, Bertoni AG, **O'Connor CM**, Kitzman DW. Rehabilitation Intervention in Older Patients With Acute Heart Failure With Preserved Versus Reduced Ejection Fraction. *JACC Heart Fail*. 2021 Jun 29:S2213-1779(21)00231-6. doi: 10.1016/j.jchf.2021.05.007.
831. Fuery MA, Chouairi F, Januzzi JL, Moe GW, Caraballo C, McCullough M, Miller PE, Reinhardt SW, Clark K, Oseran A, Milner A, Pacor J, Kahn PA, Singh A, Ravindra N, Guha A, Vadlamani L, Kulkarni NS, Fiuzat M, Felker GM, **O'Connor CM**, Ahmad T, Ezekowitz J, Desai NR.

Intercountry Differences in Guideline-Directed Medical Therapy and Outcomes Among Patients With Heart Failure. *JACC Heart Fail.* 2021 Jul;9(7):497-505. doi: 10.1016/j.jchf.2021.02.011.

832. Whellan DJ, **O'Connor CM**. Function Follows Form. *JACC Heart Fail.* 2021 Jul;9(7):482-483. doi: 10.1016/j.jchf.2021.02.012.
833. Kitzman DW, Whellan DJ, Duncan P, Pastva AM, Mentz RJ, Reeves GR, Nelson MB, Chen H, Upadhyaya B, Reed SD, Espeland MA, Hewston L, **O'Connor CM**. Physical Rehabilitation for Older Patients Hospitalized for Heart Failure. *N Engl J Med.* 2021 Jul 15;385(3):203-216. doi: 10.1056/NEJMoa2026141.
834. Ahmad T, **O'Connor C**. Change Is the Only Constant in Heart Failure. *JACC Heart Fail.* 2021 Jul;9(7):528-529. doi: 10.1016/j.jchf.2021.06.001.
835. Anchouche K, Elharram M, Oulousian E, Razaghizad A, Avram R, Marquis-Gravel G, Randhawa VK, Nkulikiyinka R, Ni W, Fiuzat M, **O'Connor C**, Psotka MA, Fox J, Tyl B, Kao D, Sharma A. Use of Actigraphy (Wearable Digital Sensors to Monitor Activity) in Heart Failure Randomized Clinical Trials: A Scoping Review. *Can J Cardiol.* 2021 Jul 10:S0828-282X(21)00365-2. doi: 10.1016/j.cjca.2021.07.001.
836. Voors AA, Mulder H, Reyes E, Cowie MR, Lassus J, Hernandez AF, Ezekowitz JA, Butler J, **O'Connor CM**, Koglin J, Lam CSP, Pieske B, Roessig L, Ponikowski P, Anstrom KJ, Armstrong PW; VICTORIA Study Group. Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial. *Eur J Heart Fail.* 2021 Aug;23(8):1313-1321. doi: 10.1002/ejhf.2221.
837. Rosner CM, Genovese L, Tehrani BN, Atkins M, Bakhshi H, Chaudhri S, Damluji AA, de Lemos JA, Desai SS, Emaminia A, Flanagan MC, Khera A, Maghsoudi A, Mekonnen G, Muthukumar A, Saeed IM, Sherwood MW, Sinha SS, **O'Connor CM**, deFilippi CR. Myocarditis Temporally Associated With COVID-19 Vaccination. *Circulation.* 2021 Aug 10;144(6):502-505. doi: 10.1161/CIRCULATIONAHA.121.055891.
838. Ponikowski P, Alemayehu W, Oto A, Bahit MC, Noori E, Patel MJ, Butler J, Ezekowitz JA, Hernandez AF, Lam CSP, **O'Connor CM**, Pieske B, Roessig L, Voors AA, Westerhout C, Armstrong PW; VICTORIA Study Group. Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial. *Eur J Heart Fail.* 2021 Aug;23(8):1300-1312. doi: 10.1002/ejhf.2285.
839. Psotka MA, **O'Connor CM**, Teerlink JR. Empower the Future... Even Oprah Had a Mentor! *JACC Heart Fail.* 2021 Aug;9(8):604-605. doi: 10.1016/j.jchf.2021.06.006.
840. Truby LK, Regan JA, Giamberardino SN, Ilkayeva O, Bain J, Newgard CB, **O'Connor CM**, Felker GM, Kraus WE, McGarrah RW, Shah SH. Circulating long chain acylcarnitines and outcomes in diabetic heart failure: an HF-ACTION clinical trial substudy. *Cardiovasc Diabetol.* 2021 Aug 3;20(1):161. doi: 10.1186/s12933-021-01353-z.
841. Ezekowitz J, Mentz RJ, Westerhout CM, Sweitzer NK, Givertz MM, Piña IL, **O'Connor CM**, Greene SJ, McMullan C, Roessig L, Hernandez AF, Armstrong PW. Participation in a Heart Failure Clinical Trial: Perspectives and Opportunities From the VICTORIA Trial and VICTORIA Simultaneous Registry. *Circ Heart Fail.* 2021 Aug 19:CIRCHEARTFAILURE120008242. doi: 10.1161/CIRCHEARTFAILURE.120.008242.
842. Ezekowitz JA, Zheng Y, Cohen-Solal A, Melenovský V, Escobedo J, Butler J, Hernandez AF, Lam CSP, **O'Connor CM**, Pieske B, Ponikowski P, Voors AA, deFilippi C, Westerhout CM, McMullan C, Roessig L, Armstrong PW; VICTORIA Study Group. Hemoglobin and Clinical

Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA). *Circulation*. 2021 Aug 25. doi: 10.1161/CIRCULATIONAHA.121.056797.

843. Fudim M, Spates T, Sun JL, Kittipibul V, Testani JM, Starling RC, Tang WHW, Hernandez AF, Felker GM, **O'Connor CM**, Mentz RJ. Early diuretic strategies and the association with In-hospital and Post-discharge outcomes in acute heart failure. *Am Heart J*. 2021 Sep;239:110-119. doi: 10.1016/j.ahj.2021.05.011.
844. Anchouche K, Elharram M, Oulousian E, Razaghizad A, Avram R, Marquis-Gravel G, Randhawa VK, Nkulikiyinka R, Ni W, Fiuzat M, **O'Connor C**, Psocka MA, Fox J, Tyl B, Kao D, Sharma A. Use of Actigraphy (Wearable Digital Sensors to Monitor Activity) in Heart Failure Randomized Clinical Trials: A Scoping Review. *Can J Cardiol*. 2021 Sep;37(9):1438-1449. doi: 10.1016/j.cjca.2021.07.001.
845. Ezekowitz J, Mentz RJ, Westerhout CM, Sweitzer NK, Givertz MM, Piña IL, **O'Connor CM**, Greene SJ, McMullan C, Roessig L, Hernandez AF, Armstrong PW. Participation in a Heart Failure Clinical Trial: Perspectives and Opportunities From the VICTORIA Trial and VICTORIA Simultaneous Registry. *Circ Heart Fail*. 2021 Sep;14(9):e008242. doi: 10.1161/CIRCHEARTFAILURE.120.008242.
846. Ibrahim NE, **O'Connor CM**, Januzzi JL Jr. From Clinical Trials to Communities: The 5 C's of Ensuring Equitable Delivery of Heart Failure Therapies. *JACC Heart Fail*. 2021 Sep;9(9):694-696. doi: 10.1016/j.jchf.2021.08.001.
847. Feng KY, **O'Connor CM**, Clare R, Alhanti B, Piña IL, Kraus WE, Whellan DJ, Mentz RJ. Greater Pain Severity is Associated with Worse Outcomes in Patients with Heart Failure. *J Cardiovasc Transl Res*. 2021 Oct;14(5):984-991. doi: 10.1007/s12265-021-10104-0.
848. Mentz RJ, Whellan DJ, Reeves GR, Pastva AM, Duncan P, Upadhyya B, Nelson MB, Chen H, Reed SD, Rosenberg PB, Bertoni AG, **O'Connor CM**, Kitzman DW. Rehabilitation Intervention in Older Patients With Acute Heart Failure With Preserved Versus Reduced Ejection Fraction. *JACC Heart Fail*. 2021 Oct;9(10):747-757. doi: 10.1016/j.jchf.2021.05.007.
849. Greenberg B, **O'Connor CM**, Felker GM. Classifying Heart Failure in the 21<sup>st</sup> Century: Matching Taxonomy With Science. *JACC Heart Fail*. 2021 Oct;9(10):771-773. doi: 10.1016/j.jchf.2021.08.004.
850. Zeitler EP, **O'Connor CM**, Abraham W, Lindenfeld J. How Is Medical Device Innovation Currently Supported in the U.S.?: From the Heart Failure Collaboratory. *JACC Heart Fail*. 2021 Nov;9(11):855-857. doi: 10.1016/j.jchf.2021.09.005.
851. Luo N, **O'Connor CM**, Chiswell K, Anstrom KJ, Newby LK, Mentz RJ. Survival in Patients With Nonischemic Cardiomyopathy With Preserved vs Reduced Ejection Fraction. *CJC Open*. 2021 Jun 17;3(11):1333-1340. doi: 10.1016/j.cjco.2021.06.007.
852. Ezekowitz JA, Zheng Y, Cohen-Solal A, Melenovský V, Escobedo J, Butler J, Hernandez AF, Lam CSP, **O'Connor CM**, Pieske B, Ponikowski P, Voors AA, deFilippi C, Westerhout CM, McMullan C, Roessig L, Armstrong PW. Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA). *Circulation*. 2021 Nov 2;144(18):1489-1499. doi: 10.1161/CIRCULATIONAHA.121.056797.
853. Lam CSP, Mulder H, Lopatin Y, Vazquez-Tanus JB, Siu D, Ezekowitz J, Pieske B, **O'Connor CM**, Roessig L, Patel MJ, Anstrom KJ, Hernandez AF, Armstrong PW; VICTORIA Study Group. Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial. *J Am Heart Assoc*. 2021 Nov 16;10(22):e021094. doi: 10.1161/JAHA.121.021094.

854. Wan L, Samsky MD, **O'Connor CM**, Stebbins A, Alhanti B, Warraich HJ, Johnson KS, Anstrom KJ, Fiuzat M, Granger BB, Mark DB, Tulsy JA, Rogers JG, Mentz RJ. Patterns of Change in Individual Domains of the Kansas City Cardiomyopathy Questionnaire With a Palliative Care Intervention for Patients With Advanced Heart Failure: Insights from PAL-HF. *J Card Fail.* 2021 Dec;27(12):1476-1478. doi: 10.1016/j.cardfail.2021.02.007.
855. Chouairi F, Fuery MA, Mullan CW, Caraballo C, Sen S, Maulion C, Wilkinson ST, Surti T, McCullough M, Miller PE, Pacor J, Leifer ES, Felker GM, Velazquez EJ, Fiuzat M, **O'Connor CM**, Januzzi JL, Desai NR, Ahmad T. The Impact of Depression on Outcomes in Patients With Heart Failure and Reduced Ejection Fraction Treated in the GUIDE-IT Trial. *J Card Fail.* 2021 Dec;27(12):1359-1366. doi: 10.1016/j.cardfail.2021.06.008.
856. Costanzo MR, **O'Connor CM**, Ventura HO. Advanced Heart Failure: Progress and Disappointments. *JACC Heart Fail.* 2021 Dec;9(12):938-940. doi: 10.1016/j.jchf.2021.10.005.
857. Ostrominski JW, Hirji S, Bhatt AS, Butler J, Fiuzat M, Fonarow GC, Heidenreich PA, Januzzi JL Jr, Lam CSP, Maddox TM, **O'Connor CM**, Vaduganathan M. Cost and Value in Contemporary Heart Failure Clinical Guidance Documents. *JACC Heart Fail.* 2022 Jan;10(1):1-11. doi: 10.1016/j.jchf.2021.08.002.
858. Cowie MR, **O'Connor CM**. The Digital Future Is Now. *JACC Heart Fail.* 2022 Jan;10(1):67-69. doi: 10.1016/j.jchf.2021.11.003.
859. Granger BB, Tulsy JA, Kaufman BG, Clare RM, Anstrom K, Mark DB, Johnson KA, Patel CB, Fiuzat M, Steinhauser K, **O'Connor C**, Rogers JG, Mentz RJ. Polypharmacy in Palliative Care for Advanced Heart Failure: The PAL-HF Experience. *J Card Fail.* 2022 Feb;28(2):334-338. doi: 10.1016/j.cardfail.2021.08.021.
860. Ezekowitz JA, Alemayehu W, Rathwell S, Grant AD, Fiuzat M, Whellan DJ, Ahmad T, Adams K, Piña IL, Cooper LS, Januzzi JL, Leifer ES, Mark D, **O'Connor CM**, Felker GM. The influence of comorbidities on achieving an N-terminal pro-b-type natriuretic peptide target: a secondary analysis of the GUIDE-IT trial. *ESC Heart Fail.* 2022 Feb;9(1):77-86. doi: 10.1002/ehf2.13692.
861. Tobin RS, Samsky MD, Kuchibhatla M, **O'Connor CM**, Fiuzat M, Warraich HJ, Anstrom KJ, Granger BB, Mark DB, Tulsy JA, Rogers JG, Mentz RJ, Johnson KS. Race Differences in Quality of Life following a Palliative Care Intervention in Patients with Advanced Heart Failure: Insights from the Palliative Care in Heart Failure Trial. *J Palliat Med.* 2022 Feb;25(2):296-300. doi: 10.1089/jpm.2021.0220.
862. **O'Connor C**. Behavioral Benefits of COVID Lockdown for Heart Failure Patients: A New Therapeutic Intervention? *JACC Heart Fail.* 2022 Feb;10(2):142-143. doi: 10.1016/j.jchf.2021.12.001.
863. Abraham WT, Piccini JP, Duffon C, Carroll IA, Healey JS, **O'Connor CM**, Marshall D, Aleong R, van Veldhuisen DJ, Rienstra M, Wilton SB, White M, Sauer WH, Anand IS, Huebler SP, Connolly SJ, Bristow MR. Dose-limiting, adverse event-associated bradycardia with  $\beta$ -blocker treatment of atrial fibrillation in the GENETIC-AF trial. *Heart Rhythm O2.* 2021 Nov 14;3(1):40-49. doi: 10.1016/j.hroo.2021.11.005.
864. Ijaz N, Buta B, Xue QL, Mohess DT, Bushan A, Tran H, Batchelor W, deFilippi CR, Walston JD, Bandeen-Roche K, Forman DE, Resar JR, **O'Connor CM**, Gerstenblith G, Damluji AA. Interventions for Frailty Among Older Adults With Cardiovascular Disease: JACC State-of-the-Art Review. *J Am Coll Cardiol.* 2022 Feb 8;79(5):482-503. doi: 10.1016/j.jacc.2021.11.029.
865. Fiuzat M, Hamo CE, Butler J, Abraham WT, DeFilippis EM, Fonarow GC, Lindenfeld J, Mentz RJ, Psotka MA, Solomon SD, Teerlink JR, Vaduganathan M, Vardeny O, McMurray

- JJV, **O'Connor CM**. Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials: JACC Review Topic of the Week. *J Am Coll Cardiol*. 2022 Feb 8;79(5):504-510. doi: 10.1016/j.jacc.2021.11.033.
866. Cooper LB, Bruce S, Psocka M, Mentz R, Bell R, Seliger SL, **O'Connor C**, deFilippi C. Proteomic differences among patients with heart failure taking furosemide or torsemide. *Clin Cardiol*. 2022 Mar;45(3):265-272. doi: 10.1002/clc.23733.
867. **O'Connor CM**. Implementation Noise. *JACC Heart Fail*. 2022 Mar;10(3):211-212. doi: 10.1016/j.jchf.2022.01.001.
868. Saldarriaga C, Atar D, Stebbins A, Lewis BS, Abidin IZ, Blaustein RO, Butler J, Ezekowitz JA, Hernandez AF, Lam CSP, **O'Connor CM**, Pieske B, Ponikowski P, Roessig L, Voors AA, Anstrom KJ, Armstrong PW; VICTORIA Study Group. Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction. *Eur J Heart Fail*. 2022 Mar 3. doi: 10.1002/ejhf.2468.
869. Greene SJ, Ezekowitz JA, Anstrom KJ, Demyanenko V, Givertz MM, Piña IL, **O'Connor CM**, Koglin J, Roessig L, Hernandez AF, Armstrong PW, Mentz RJ. Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry. *J Card Fail*. 2022 Mar 14:S1071-9164(22)00103-8. doi: 10.1016/j.cardfail.2022.02.011.
870. Tobin RS, Cosiano MF, **O'Connor CM**, Fiuzat M, Granger BB, Rogers JG, Tulskey JA, Steinhauser KE, Mentz RJ. Spirituality in Patients With Heart Failure. *JACC Heart Fail*. 2022 Apr;10(4):217-226. doi: 10.1016/j.jchf.2022.01.014.
871. **O'Connor CM**. Editorial Privilege. *JACC Heart Fail*. 2022 Apr;10(4):290. doi: 10.1016/j.jchf.2022.02.002.
872. Rosner CM, Atkins M, Saeed IM, de Lemos JA, Khera A, Maghsoudi A, Min J, Tehrani BN, **O'Connor CM**, deFilippi CR. Patients With Myocarditis Associated With COVID-19 Vaccination. *J Am Coll Cardiol*. 2022 Apr 5;79(13):1317-1319. doi: 10.1016/j.jacc.2022.02.004.
873. Pahuja M, Leifer ES, Clarke JD, Ahmad T, Daubert MA, Mark DJ, Cooper L, Desvigne-Nickens P, Fiuzat M, Adams K, Ezekowitz J, Whellan DJ, Januzzi JL, **O'Connor CM**, Felker GM, Piña IL. Assessing race and ethnicity differences in outcomes based on GDMT and target NT-proBNP in patients with heart failure with reduced ejection fraction: An analysis of the GUIDE-IT study. *Prog Cardiovasc Dis*. 2022 Apr 28:S0033-0620(22)00039-1. doi: 10.1016/j.pcad.2022.04.010.
874. DeFilippis EM, Echols M, Adamson PB, Batchelor WB, Cooper LB, Cooper LS, Desvigne-Nickens P, George RT, Ibrahim NE, Jessup M, Kitzman DW, Leifer ES, Mendoza M, Piña IL, Psocka M, Senatore FF, Stein KM, Teerlink JR, Yancy CW, Lindenfeld J, Fiuzat M, **O'Connor CM**, Vardeny O, Vaduganathan M. Improving Enrollment of Underrepresented Racial and Ethnic Populations in Heart Failure Trials: A Call to Action From the Heart Failure Collaboratory. *JAMA Cardiol*. 2022 May 1;7(5):540-548. doi: 10.1001/jamacardio.2022.0161.
875. **O'Connor C**. Editorial Regrets and Opportunities: JACC: Heart Failure. *JACC Heart Fail*. 2022 May;10(5):363-364. doi: 10.1016/j.jchf.2022.03.005.
876. Sinha SS, Rosner CM, Tehrani BN, Maini A, Truesdell AG, Lee SB, Bagchi P, Cameron J, Damluji AA, Desai M, Desai SS, Epps KC, deFilippi C, Flanagan MC, Genovese L, Moukhachen H, Park JJ, Psocka MA, Raja A, Shah P, Sherwood MW, Singh R, Tang D, Young KD, Welch T, **O'Connor CM**, Batchelor WB. Cardiogenic Shock From Heart Failure Versus Acute Myocardial Infarction: Clinical Characteristics, Hospital Course, and 1-Year Outcomes. *Circ Heart Fail*. 2022 Jun;15(6):e009279. doi: 10.1161/CIRCHEARTFAILURE.121.009279.

877. **O'Connor C**. Thank You for the Privilege. *JACC Heart Fail*. 2022 Jun;10(6):441-443. doi: 10.1016/j.jchf.2022.04.007.
878. Butler J, Stebbins A, Melenovský V, Sweitzer NK, Cowie MR, Stehlik J, Khan MS, Blaustein RO, Ezekowitz JA, Hernandez AF, Lam CSP, Nkulikiyinka R, **O'Connor CM**, Pieske BM, Ponikowski P, Spertus JA, Voors AA, Anstrom KJ, Armstrong PW; VICTORIA Study Group. Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial. *Circ Heart Fail*. 2022 Jun;15(6):e009337. doi: 10.1161/CIRCHEARTFAILURE.121.009337.
879. Greene SJ, Ezekowitz JA, Anstrom KJ, Demyanenko V, Givertz MM, Piña IL, **O'Connor CM**, Koglin J, Roessig L, Hernandez AF, Armstrong PW, Mentz RJ. Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry. *J Card Fail*. 2022 Jul;28(7):1063-1077. doi: 10.1016/j.cardfail.2022.02.011.
880. Pandey A, Segar MW, Singh S, Reeves GR, **O'Connor C**, Piña I, Whellan D, Kraus WE, Mentz RJ, Kitzman DW. Frailty Status Modifies the Efficacy of Exercise Training Among Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the HF-ACTION Trial. *Circulation*. 2022 Jul 12;146(2):80-90. doi: 10.1161/CIRCULATIONAHA.122.059983.
881. Pierce JB, Mentz RJ, Sun JL, Alhanti B, Whellan DJ, Kraus WE, Piña IL, Fiuzat M, **O'Connor CM**, Greene SJ. Titration of medical therapy and clinical outcomes among patients with heart failure with reduced ejection fraction: Findings from the HF-ACTION trial. *Am Heart J*. 2022 Sep;251:115-126. doi: 10.1016/j.ahj.2022.05.018.
882. Senni M, Alemayehu WG, Sim D, Edelmann F, Butler J, Ezekowitz J, Hernandez AF, Lam CSP, **O'Connor CM**, Pieske B, Ponikowski P, Roessig L, Voors AA, Westerhout CM, McMullan C, Armstrong PW; VICTORIA Study Group. Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial. *Eur J Heart Fail*. 2022 Sep;24(9):1614-1622. doi: 10.1002/ejhf.2608.
883. Armstrong PW, Zheng Y, Troughton RW, Lund LH, Zhang J, Lam CSP, Westerhout CM, Blaustein RO, Butler J, Hernandez AF, Roessig L, **O'Connor CM**, Voors AA, Ezekowitz JA; VICTORIA Study Group. Sequential Evaluation of NT-proBNP in Heart Failure: Insights Into Clinical Outcomes and Efficacy of Vericiguat. *JACC Heart Fail*. 2022 Sep;10(9):677-688. doi: 10.1016/j.jchf.2022.04.015.
884. Lala A, **O'Connor CM**, Fiuzat M, Drazner MH, Mentz RJ. Recognizing Efforts that Support Clinical Trial Success: Site-Based Research Awards from the Heart Failure Collaboratory and Heart Failure Society of America. *J Card Fail*. 2022 Sep;28(9):1387-1389. doi: 10.1016/j.cardfail.2022.08.001.
885. Tehrani BN, Sherwood MW, Rosner C, Truesdell AG, Ben Lee S, Damluji AA, Desai M, Desai S, Epps KC, Flanagan MC, Howard E, Ibrahim N, Kennedy J, Moukhachen H, Psothka M, Raja A, Saeed I, Shah P, Singh R, Sinha SS, Tang D, Welch T, Young K, deFilippi CR, Speir A, **O'Connor CM**, Batchelor WB. A Standardized and Regionalized Network of Care for Cardiogenic Shock. *JACC Heart Fail*. 2022 Oct;10(10):768-781. doi: 10.1016/j.jchf.2022.04.004.
886. Sharma A, Lam CSP, Tay WT, Yap J, MacDonald MR, Razaghizad A, Cooper LB, **O'Connor C**, Whellan DJ, Anand IS, Tromp J, Mentz RJ. Cause of Death Among Patients With Diabetes and Heart Failure With Reduced Ejection Fraction. *JACC Asia*. 2022 Oct 18;2(5):648-650. doi: 10.1016/j.jacasi.2022.05.002.

887. Butler J, Usman MS, Anstrom KJ, Blaustein RO, Bonaca MP, Ezekowitz JA, Freitas C, Lam CSP, Lewis EF, Lindenfeld J, McMullan CJ, Mentz RJ, **O'Connor C**, Rosano GMC, Saldarriaga CI, Senni M, Udelson J, Voors AA, Zannad F. Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum. *Eur J Heart Fail.* 2022 Nov;24(11):2029-2036. doi: 10.1002/ejhf.2720.
888. Farsky PS, White J, Al-Khalidi HR, Sueta CA, Rouleau JL, Panza JA, Velazquez EJ, **O'Connor CM**; Working Group and Surgical Treatment for Ischemic Heart Failure Trial Investigators. Optimal medical therapy with or without surgical revascularization and long-term outcomes in ischemic cardiomyopathy. *J Thorac Cardiovasc Surg.* 2022 Dec;164(6):1890-1899.e4. doi: 10.1016/j.jtcvs.2020.12.094.
889. Psozka MA, Abraham WT, Fiuzat M, Filippatos G, Lindenfeld J, Ahmad T, Felker GM, Jacob R, Kitzman DW, Leifer ES, Lewis EF, Mentz RJ, Nkulikiyinka R, Ni W, Schaber DE, Sharma A, Solomon SD, Stockbridge N, Teerlink JR, Unger EF, Whellan DJ, Wittes J, Anker SD, **O'Connor CM**. Functional and Symptomatic Clinical Trial Endpoints: The HFC-ARC Scientific Expert Panel. *JACC Heart Fail.* 2022 Dec;10(12):889-901. doi: 10.1016/j.jchf.2022.09.012.
890. Collins KA, Reeves GR, Miller NH, Whellan DJ, **O'Connor CM**, Marcus BH, Kitzman DW, Kraus WE; HF-ACTION Investigators. Clinical Predictors of Adherence to Exercise Training Among Individuals With Heart Failure: THE HF-ACTION STUDY. *J Cardiopulm Rehabil Prev.* 2022 Dec 2. doi: 10.1097/HCR.0000000000000757.
891. Rosner CM, Lee SB, Badrish N, Maini AS, Young KD, Vorgang CM, Bagnola A, Desai SS, Hahndorf C, Looby M, Psozka MA, **O'Connor CM**, Cooper LB. Advanced Practice Provider Urgent Outpatient Clinic for Patients With Decompensated Heart Failure. *J Card Fail.* 2022 Dec 13:S1071-9164(22)01220-9. doi: 10.1016/j.cardfail.2022.11.015.
892. Harrington J, Nixon AB, Daubert MA, Yow E, Januzzi J, Fiuzat M, Whellan DJ, **O'Connor CM**, Ezekowitz J, Piña IL, Adams KF, Felker GM, Karra R. Circulating Angiokines Are Associated With Reverse Remodeling and Outcomes in Chronic Heart Failure. *J Card Fail.* 2023 Jan 8:S1071-9164(23)00003-9. doi: 10.1016/j.cardfail.2022.12.011.
893. Defilippi CR, Alemayehu WG, Voors AA, Kaye D, Blaustein RO, Butler J, Ezekowitz JA, Hernandez AF, Lam CSP, Roessig L, Seliger S, Shah P, Westerhout CM, Armstrong PW, **O'Connor CM**; VICTORIA Study Group. Assessment of Biomarkers of Myocardial injury, Inflammation, and Renal Function in Heart Failure With Reduced Ejection Fraction: The VICTORIA Biomarker Substudy. *J Card Fail.* 2023 Jan 9:S1071-9164(23)00002-7. doi: 10.1016/j.cardfail.2022.12.013.
894. Bhatt AS, Dimond M, Fiuzat M, Vaduganathan M, Vardeny O, Divanji P, Komtebedde J, Lefkowitz MP, Nkulikiyinka R, Petersson M, Roessig L, Schaber D, **O'Connor CM**, Solomon SD; Heart Failure Collaboratory. Impact of COVID-19 on Heart Failure Clinical Trials: Insights From the Heart Failure Collaboratory. *JACC Heart Fail.* 2023 Feb;11(2):254-257. doi: 10.1016/j.jchf.2022.11.024.
895. Felker GM, North R, Mulder H, Jones WS, Anstrom KJ, Patel MJ, Butler J, Ezekowitz JA, Lam C, **O'Connor CM**, Roessig L, Hernandez AF, Armstrong PW; VICTORIA Study Group. Clinical Implications of Negatively Adjudicated Heart Failure Events: Data From the VICTORIA Study. *Circulation.* 2023 Feb 21;147(8):694-696. doi: 10.1161/CIRCULATIONAHA.122.062055.
896. Johansen ND, Vaduganathan M, Zahir D, Fiuzat M, DeFilippis EM, Januzzi JL, Butler J, **O'Connor CM**, Abraham WT, Psozka MA, McMurray JJV, Dewan P, Claggett BL, Solomon SD, Modin D, Butt JH, Jensen JUS, Schou M, Torp-Pedersen C, Køber L, Gislason GH, Biering-Sørensen T. A Composite Score Summarizing Use and Dosing of Evidence-Based Medical



Therapies in Heart Failure: A Nationwide Cohort Study. *Circ Heart Fail.* 2023 Feb;16(2):e009729. doi: 10.1161/CIRCHEARTFAILURE.122.009729.

### **Textbooks:**

1. **O'Connor CM**, Stough WG, Gheorghiade M, Adams KF, Jr. Managing Acute Decompensated Heart Failure; Editors. Taylor & Francis Group Publishing, London and New York, 2005.
2. **O'Connor CM**, Fiuzat M. Conducting and Interpreting Clinical Trials in Heart Failure. Guest Editors. Heart Failure Clinics, 2011 May.

### **Chapters in Textbooks:**

1. **O'Connor CM**, Mark DB, Califf RM. Combined thrombolysis and angioplasty in acute myocardial infarction: clinical results. Eds. Califf RM, Mark DB, Wagner GS. In Acute Coronary Care in the Thrombolytic Era. Chicago: Year Book Publishers, 1987.
2. **O'Connor CM**, Campbell PT, Wall TC, Corey GR. Pericarditis. In: Conn RB, (ed). Current Diagnosis. Pennsylvania: W.B. Saunders Company, 1991;Section 5:507-510.
3. Krucoff MW, Crater SW, **O'Connor CM**, Califf RM. Patient management following percutaneous transluminal coronary revascularization. Interventional Cardiovascular Medicine: Principles and Practice, 1994: 643-658.
4. **O'Connor CM**. Stroke during acute myocardial infarction. In: Califf RM, Mark DB Wagner GS (editors). Acute Coronary Care (edition 2). Mosby Year Book, Inc., St. Louis, MO, January 1995;Chapter 52:635-650.
5. Kitzman D, **O'Connor CM**. Acute Myocardial Infarction in the Elderly. In: Acute Myocardial Infarction; Eds. Gersh BJ and Rahimtoola S., Champman and Hall Publishing Company, Inc., New York. 1996; 602-734.
6. **O'Connor CM**, Friesinger GC. Aging and the Heart. In: Comprehensive Cardiovascular Medicine; Eds. Topol EJ, Califf RM, Isner JM, Prystowsky EN, Serruys PW, Swain JL, Thomas JD, Thompson PD, and Young JB., Lippincott-Raven Publishers, Philadelphia, and New York. 1998;Chapter 34;927-950.
7. Blazing MA, Galanos AN, **O'Connor CM**. Cardiovascular disorders in the elderly. Geriatrics Review Syllabus 4<sup>th</sup> Edition. Geriatrics Review Syllabus: A Core in Geriatric Medicine 1999-2001.
8. **O'Connor CM**, Jiang W. Heart Failure and Depression. In: Tailored Heart Failure Therapy. Eds: Willenheimer R and Swedberg K. Martin Dunitz Publishers, London, 2003;pp 197-208.
9. Cotter G, Stough WG, Felker GM, Velazquez EJ, Hernandez AF, Rogers JG, Gheorghiade M, Adams KF, **O'Connor CM**. Acute Heart Failure: Nomenclature, Pathophysiology, and Outcome Measures. In: Managing Acute Decompensated Heart Failure; Eds. **O'Connor CM**, Stough WG, Gheorghiade M, Adams KF. Taylor & Francis Group, London and New York. 2005;Part I; Chapter 2. Epidemiology and Pathophysiology; 19-38.
10. Jiang W, **O'Connor CM**, Krishnan RR. Psychiatric and Psychosocial Risks in Acutely Decompensated Heart Failure. In: Managing Acute Decompensated Heart Failure; Eds. **O'Connor CM**, Stough WG, Gheorghiade M, Adams KF. Taylor & Francis Group, London

and New York. 2005;Part III: Comorbidities in the Acute Heart Failure Patient, Chapter 17. 253-272.

11. Bourque JM, Velazquez EJ, **O'Connor CM**. The Role of Myocardial Ischemia in Acute Decompensated Heart Failure: Diagnostic and Management Considerations. In: Managing Acute Decompensated Heart Failure: Eds. **O'Connor CM**, Stough WG, Gheorghiade M, Adams KF. Taylor & Francis Group, London and New York, 2005;Part III: Comorbidities in The Acute Heart Failure Patient, Chapter 20, 301-322.
12. PiñalL, Whellan DJ, **O'Connor CM**. Exercise Training in Advanced Heart Failure: A need for More Data. In: Managing Acute Decompensated Heart Failure: Eds. **O'Connor CM**, Stough WG, Gheorghiade M, Adams KF. Taylor & Francis Group, London and New York, 2005;Part IV: Treatment Strategies, Chapter 33;469-477.
13. Orlandi C, Gattis WG, **O'Connor CM**, Adams KF, Gheorghiade M. Vasopressin Antagonists. In: Managing Acute Decompensated Heart Failure: Eds. **O'Connor CM**, Stough WG, Gheorghiade M, Adams KF. Taylor & Francis Group, London and New York, 2005;Part IV: Treatment Strategies, Chapter 35;497-502.
14. Teerlink JR, **O'Connor CM**. Endothelin Receptor Antagonists in the Treatment of Acute Heart Failure. In: Managing Acute Decompensated Heart Failure: Eds. **O'Connor CM**, Stough WG, Gheorghiade M, Adams KF. Taylor & Francis Group, London and New York, 2005;Part IV: Treatment Strategies, Chapter 36;503-519.
15. Joynt KE, Krishnan KRR, **O'Connor CM**. Cardiovascular Disease and Mood Disorders. In: The Physician Guide to Depression and Bipolar Disorder: Eds. Evans DL, Charney DS, Lewis L. McGraw Hill Medical Publishing Division, New York and Chicago, 2006; Section 3;241-275.

#### **Ongoing Federally Funded Research Support:**

1 K23-HL153771-01

Sponsor: NIH/NHLBI

Project Title: Frailty and Resiliency in Older Adults with Acute Myocardial Infarction

Role: **Primary Mentor (PI: Abdulla Damluji, MD)**

Duration: 7/15/2020-7/14/2025

1 K23-HL143179-01A1

Sponsor: NIH/NHLBI

Project Title: MicroRNA Biomarkers of Allograft Rejection and Cardiac Allograft Vasculopathy in Cardiac Transplantation

Role: **Primary Mentor (PI: Palak Shah, MD)**

Duration: 07/01/2020-6/30/2025

1 R18 FD006920-01

Sponsor: FDA

Project Title: The Heart Failure Collaboratory Public-Private Partnership Between the US FDA, Inova Heart and Vascular Institute, and the Heart Failure Community

Role: **Principal Investigator**

Duration: 4/10/2020-3/31/2025

1 R01-HL154768-01

Sponsor: NIH/NHLBI

Project Title: The optimal loop diuretic: mechanistic insights from longitudinal changes in blood and urine proteins to explain efficacy and safety of torsemide vs furosemide after a heart failure hospitalization

Role: **Advisor (PI: Lauren Cooper, MD)**

Duration: 07/1/2020-6/30/2024

**Completed Federally Funded Research Support:**

R34-HL-136986-01

Sponsor: NIH/NHLBI

Project Title: B-lines Lung Ultrasound Guided ED Management of Acute Heart Failure Pilot Trial (BLUSHED-AHF)

Role: **Mentor (PI: Pang)**

Duration: 04/17/2017-02/29/2020

1R01HL105448-01A1

Sponsor: NIH/ NHLBI

Project Title: GUIDing Evidence Based Therapy Using Biomarker Intensified Treatment (GUIDE-IT)

Role: **Co-Principal Investigator (PI: Felker)**

Duration: 06/08/2012 – 04/30/2018

Sponsor: NIH/NHLBI

Project Title: Regional Clinical Centers for the Cardiovascular Cell Therapy Research Network

Role: **Advisor (PI: Povsic)**

Duration: 04/01/2012 – 03/31/2019

1U10HL110312-01

Sponsor: NIH/NHLBI

Project Title: Heart Failure Network Clinical Research Services Development Core (HF Network: CSRDC)

Role: **Principal Investigator**

Duration: 01/01/2012 – 12/31/2018

1U10HL110312-01

Sponsor: NIH/NHLBI

Project Title: Heart Failure Clinical Research Network Regional Clinical Centers (HF Network: RCC)

Role: **Co Investigator (PI: Felker)**

Duration: 01/01/2012 – 12/31/2018

5T32-HL069749-09

Sponsor: NIH/NHLBI

Project Title: Postdoctoral Training in Cardiovascular Clinical Research

Role: **Mentor (PI: Mark)**

Duration: 07/01/2013 – 06/30/2018

Sponsor: NIH/NHLBI

Project Title: Depression and Heart Failure: Biobehavioral Mechanism

Role: **Co-Investigator (PI: Sherwood)**

Duration: 04/01/2013 – 03/31/2018

Sponsor: NIH/NHLBI

Project Title: Integrating Comprehensive Mental Health Care into CV Disease Mgmt-Mainland China

Role: **Investigator (PI: Jiang)**

Duration: 04/01/2013 – 03/31/2018

R01-HL105448-01A1

Sponsor: NIH/NHLBI

Project Title: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment (GUIDE-IT) (CCC)

Role: **Co-Principal Investigator (PI: O'Connor/Felker)**

Duration: 06/08/2012 – 04/30/2017

Sponsor: NIH/NHLBI

Project Title: Biomarkers of Mental Stress induced Myocardial Ischemia and CHD Prognosis

Role: **Co-Investigator (PI: Jiang)**

Duration: 04/01/2013 – 03/31/2016

1R34MH097034-02

Sponsor: NIH/NHLBI

Project Title: 1/3-Multi-Site-Omega 3 for Co-Morbid Depression and Heart Failure Treatment (OCEAN)

Role: **Co-Investigator (PI: Jiang)**

Duration: 04/01/2013 – 03/31/2016

R01-HL105853-01

Sponsor: NIH/NHLBI

Project Title: STICHES

Role: **Co Investigator (PI: Velazquez)**

Duration: 03/21/2011 – 02/29/2016

R01-NR013428-01

Sponsor: NIH/NHLBI

Project Title: Palliative Care in Heart Failure (PAL-HF)

Role: **Co-Investigator (PI: Rogers)**

Duration: 09/27/2011 – 07/31/2015

182923

Sponsor: NIH/NHLBI

Project Title: Pilot Study of Moderate Versus Vigorous Intensity Exercise Training in Patients with Heart Failure and Diabetes Mellitus

Role: **Co-Investigator (PI: Kraus)**

Duration: 04/01/2012 – 03/31/2015

R01-HL091920

Sponsor: NIH/NHLBI

Project Title: Coping Skills Training in Heart Failure: Outcomes and Mechanisms

Role: **Co-Investigator (PI: Sherwood)**

Duration: 03/01/2009 – 02/28/2014

1 T32 GM086330-01A1

Sponsor: University of North Carolina-Chapel Hill

Project Title: T-32 Institutional Training Grant in Clinical Pharmacology:UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program

Role: **Mentor (PI: Benjamin)**

Duration: 07/01/2011 – 06/30/2013

R01-HL085704

Sponsor: NIH/NHLBI

Project Title: Responses of Myocardial Ischemia to Sertraline

Role: **Co-Principal Investigator (PI: Jiang)**

Duration: 09/01/2006 – 06/30/2012

3U01-HL063747-0651

Sponsor: NIH/NHLBI  
Project Title: HF-ACTION Supplement  
Role: **Principal Investigator**  
Duration: 09/30/2009 – 12/31/2010

R01-HL091206  
Sponsor: Case Western Reserve University / NIH  
Project Title: Recovery Post Exercise: A substudy of HF-ACTION Trial (subcontract)  
Role: **Co-Investigator**  
Duration: 07/01/2008 – 06/30/2011

1 UO1-HL08487501  
Sponsor: NIH/NHLBI  
Project Title: Heart Failure Clinical Research Network RCC  
Role: **Principal Investigator**  
Duration: 09/30/2006 – 12/30/2011

1 UO1-HL08487501  
Sponsor: NIH/NHLBI  
Project Title: Heart Failure Clinical Research Network RCC & Teaching Skills Core  
Role: **Principal Investigator**  
Duration: 09/30/2006 – 12/30/2011

Project Title: ESCAPE: Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness Ancillary Study (Supplement)  
Role: **Principal Investigator**  
Duration: 11/1/2005 – 10/31/2007

R01-MH063211  
Sponsor: NIMH  
Project Title: Safety and Efficacy of Sertraline for Depression CHF (SADHART-CHF)  
Role: **Co-Principal Investigator**  
Duration: 02/20/2003 – 01/31/2010

5 UO1-HL063747  
Sponsor: NIH/NHLBI  
Project Title: HF-ACTION: A CHF Trial investigator outcomes of exercise training  
Role: **Principal Investigator**  
Duration: 9/30/2002 – 12/31/2007

5T32-HL069749-09  
Sponsor: NIH/NHLBI  
Project Title: Postdoctoral Training in Cardiovascular Clinical Research  
Role: **Mentor (PI: Mark)**  
Duration: 07/01/2002 – 06/30/2012

UO1-HL069015  
Sponsor: NHLBI  
Project Title: Surgical Treatment for Ischemic Heart Failure Trial (STICH)  
Role: **Co-Investigator**  
Duration: 01/01/2002– 12/31/2010

Sponsor: NHLBI  
Project Title : The natriuretic peptides and troponins as prognostic indices and surrogate markers for morbidity and mortality in advanced heart failure : A Mechanistic Substudy of the Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE)

Role: **Co- Principal Investigator**

Duration: 03/2001 – 07/2004

N01-HV98177

Sponsor: NIH/NHLBI

Project Title: (ESCAPE) Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness.

Role: **Co-Investigator**

Duration: 09/29/1999 – 05/31/2004

R01-HL61784

Sponsor: NIH/NHLBI

Project Title : Stress and Congestive Heart Failure: Prognosis & Mechanisms

Role : **Co- Principal Investigator**

Duration : 09/01/1999 – 6/30/2004

### **Privately Funded Grants:**

Has served as Principal Investigator or Co-Principal Investigator for over 20 national and international clinical trials (selected trials: DUCCS 1, DUCCS 2, PRAISE 1, PRAISE 2, WIZARD, GUIDE-IT, SADHART, RITZ 4, ACTIV, IMPACT-HF, PRESERVE-HF, ASCEND-HF, TACTICS, CAT-HF and VICTORIA).

### **Ongoing Sponsored Research Support:**

Sponsor: Bayer

Project Title: VITALITY-HFpEF Biomarker Substudy

Role: **Principle Investigator**

Duration: 07/01/2019-Present

Sponsor: Merck

Project Title: VICTORIA Biomarker Substudy

Role: **Principle Investigator**

Duration: 01/01/2018-Present

Sponsor: DCRI

Project Title: Roche GUIDE-IT Sub-studies

Role: **Co-investigator**

Duration: 2012- Present

### **Completed Sponsored Research Support:**

Sponsor: Duke Clinical Research Institute

Project Title: HF ACTION Manuscripts Project

Role: **Principal Investigator**

Duration: 2011-2020

Sponsor: Roche Diagnostics

Project Title: GUIDE-IT Echo Substudy

Role: **Co-investigator (PI: Michael Felker, MD)**

Duration: 06/08/2012 – 2020

Sponsor: Roche Diagnostics

Project Title: Roche Ecclesys Market Application

Role: **Co-investigator (PI: Felker)**

Duration: 2010-2014

Sponsor: ResMed

Project Title: Cardiovascular outcomes with treatment of sleep apnea in heart failure patients (CAT-HF)

Role: **Co-Principal Investigator (PI: O'Connor/Piccini)**

Duration: 2013-2018

Sponsor: Duke Clinical Research Institute

Project Title: OPTIMIZE Manuscripts Project

Role: **Principal Investigator**

Duration: 2006-2016

Sponsor: Roche Diagnostics

Project Title: Biomarker Guided Therapy pre-IDE submission

Role: **Co-investigator (PI: Felker)**

Duration: 2009-2010

Sponsor: Critical Diagnostics

Project Title: ST2 and outcomes in ambulatory heart failure patients

Role: **Co-investigator (PI: Felker)**

Duration: 2002-2013

Sponsor: BG Medicine

Project Title: Galectin -3 and outcomes in ambulatory heart failure patients

Role: **Co-investigator (PI: Felker)**

Duration: 2002-2013

Sponsor: Boston Scientific Corporation

Project Title: HF-ACTION Exercise and ICD Therapies

Role: **Co-Investigator (PI: Piccini)**

Duration: 2002-2013

#### **Professional Awards and Special Recognitions:**

American College of Cardiology, Distinguished Scientist Award, May 2021

Gary D. Plotnick, M.D. and Michael L. Fisher, M.D. Endowed Lectureship Award, University of Maryland, April 2018

Master of the American College of Cardiology (MACC), March 2018

2018 Honor Award and Gold Key Recipient, University of Maryland

Selected for Best Doctors® 2015 Database

Irish American Healthcare & Life Sciences Top 50 Winner, 2014

Selected for Best Doctors® 2013 Database

Duke School of Medicine and Nursing 2013 Research Mentoring Award for clinical science research, April 2013

Duke Cardiology & Heart Surgery Ranked #4 in US News and World Report 2013-2014

Duke Cardiology & Heart Surgery Ranked #7 in US News and World Report 2011-2012

Joseph C. Greenfield, Jr., M.D. Research Mentor Faculty Award, June 9, 2006

Co-Chair – American College of Cardiology (ACC) Foundation Appreciation Award – 55<sup>th</sup> Annual Scientific Program – March 11-14, 2006

Council on Geriatric Cardiology, First Place Award Open Division, Third Annual Scientific Session Cardiovascular Disease in the Elderly

Epidemiology Award, University of Maryland School of Medicine

American College of Cardiology, Bristol Fellow Achievement Award

American College of Physicians Clinical Vignette Award, Marion Lab

Upjohn Achievement Award, Excellence in Preventive Medicine Goodard Medal

Outstanding Male Graduate, University of Maryland, College Park

General Honors Program, University of Maryland, College Park  
Miller Warner Newcomb Scholarship for Cancer Research

**Society Memberships and Leadership Roles:**

Member, ACC Distinguished Scientist Award (Clinical Domain), 2021  
Member, ACC Douglas P. Zipes Distinguished Young Scientist Award Selection Committee, 2021  
Member, JACC Advances Editor-in-Chief Search Committee, 2021  
Member, Special Government Employee (SGEs) – CDER and CDRH, 2020-present  
Member, FDA Cardiovascular and Renal Advisory Committee, 2020- present  
Chair, HFSA Research Committee, 2019-present  
Member, HFSA International Relations Committee, 2020  
Member, JACC: Asia Editor-in-Chief Search Committee, 2020  
Member, HFSA Leadership Recruitment Committee, 2019 - 2020  
Chair, HFSA Nominations Committee, 2019  
Member, JACC: Cardio-Oncology Editor-in-Chief Search Committee, 2019  
Member, JACC: Case Reports Editor-in-Chief Search Committee, 2019  
Co-Chair, Heart Failure Collaboratory Working Groups, 2018-present  
Co-Chair, Heart Failure Collaboratory Research Networks and Culture Committee, 2018-present  
Member, Heart Failure Collaboratory Underrepresented Populations Committee, 2018-present  
Member, Heart Failure Collaboratory Digital Device and Drugs Committee, 2018-present  
Member, Heart Failure Collaboratory Drugs and Devices Regulatory and Implementation Science Working Group, 2018-present  
Immediate Past President and Executive Committee, HFSA, 2018-2019  
Principal Investigator, Heart Failure Collaboratory, 2017-present  
Chair, HFSA Research Network, 2017 – present  
Chair, HFSA Research Network Task Force, 2017-2020  
President, HFSA, 2017-2018  
President-Elect, Heart Failure Society of American (HFSA), 2016-2017  
Member, JACC: Interventions Editor-in-Chief Search Committee, 2016 - 2017  
Member, JACC: Imaging Editor-in-Chief Search Committee. 2016 – 2017  
Fellow, Heart Failure Society of America (HFSA), 2016 – present  
Fellow, ESC-Heart Failure Association (HFHA), 2019 - present  
Member, Heart Failure Society of America (HFSA) Officer and Executive Council, 2016 – present  
Member, JACC: Basic to Translational Science Editor-in-Chief Search Committee, 2015  
Member, JACC: Electrophysiology Editor-in-Chief Search Committee, 2014, 2019  
Chair, Heart Failure Society of America (HFSA) Finance Committee, 2013-2016  
Member, Heart Failure Society of America (HFSA) Board of Directors, 2012 – present  
Member, ACC Scientific Publications Committee, 2012-present  
Member, JACC Editor-in-Chief Search Committee, 2012-2013  
Member, JACC Strategic Taskforce Committee, 2012-2022  
Member, Association of University Cardiologist, 2013 - 2016  
Treasurer, Heart Failure Society of America (HFSA), 2012-2016  
Publications Committee HFSA, 2012-2015  
Fellow, European Society of Cardiology, 2010 - Present  
Program Chair, HFSA Annual Scientific Sessions 2009-2010  
Co-Chair, American College of Cardiology Scientific Sessions, 2006  
Fellow, American College of Cardiology, 1994 – 2018  
Master of the American College of Cardiology, 2018 - Present  
Fellow, American College of Physicians, 1994 - 2016  
Fellow, American Heart Association – 1994 – Present  
Member, American Association for the Advancement of Science  
Member, American Medical Association  
Member, Committee on Cardiovascular Disease on the Council of Geriatric Cardiology  
Board Member, Duke University Cooperative Cardiovascular Studies Organization  
Panel Member, National Institute of Neurological Disorders and Stroke Special Emphasis



**National Conferences and Teaching Activities:**

Speaker, American College of Cardiology New York Cardiovascular Symposium. December 2022

Speaker, Heart Failure Society of America Annual Scientific Meeting. September 2022 (Virtual).

Speaker, American College of Cardiology Heart House Roundtable: Recent Advances and Ongoing Challenges in HFpEF. June 2022 (Virtual).

Speaker, Heart Failure Society of America Clinical Research Forum: Implementation Science. May 2022 (Virtual).

Speaker, British Society for Heart Failure Autumn Meeting. November 2021 (Virtual).

Speaker, Heart Failure Society of America Annual Scientific Meeting. September 2021 (Virtual).

Speaker, 2<sup>nd</sup> Annual FDA OND Extramural Research Science Day. September 2021 (Virtual).

Speaker, American College of Cardiology Scientific Sessions. May 2021 (Virtual).

Speaker, Canadian Society of Heart Failure Society Heart Failure Update. May 2021 (Virtual)

Speaker, Mayo Clinic Snowbird Cardiovascular Conference. March 2021 (Virtual).

Speaker, Northwestern Medicine, 16<sup>th</sup> Annual Heart Failure Holiday Symposium. December 2020 (Virtual)

Speaker, British Society for Heart Failure Autumn Meeting. November 2020 (Virtual)

Speaker, Great Wall International Congress of Cardiology. October 2020 (Virtual) Speaker and Moderator, HFSA Scientific Sessions. October 2020 (Virtual).

Speaker, Canadian Society of Heart Failure Scientific Sessions. April 2020 (Virtual).

Speaker and moderator, Heart Failure Society of America (HFSA), Scientific Sessions. September 2019. Philadelphia, PA.

Speaker and moderator, European Society of Cardiology Congress, August 2019. Paris, France.

Chair, Novel Statistical Approaches to Clinical Trials in HF, July 2019. Washington DC

Speaker and moderator, FDA Public Workshop: Endpoints in Heart Failure Drug Development, July 2019. Washington DC.

Speaker and moderator, ESC Heart Failure Scientific Sessions, May 2019, Athens, Greece.

Speaker, American College of Cardiology Scientific Sessions. March 2019, New Orleans, Louisiana.

Speaker, American Heart Association Scientific Sessions, November 2018. Los Angeles, CA.

Moderator and Speaker (4 sessions) – Heart Failure Society of America (HFSA), Scientific Sessions, 2018, Nashville, TN.

Speaker, Pitfalls in observational studies and how to avoid them. European Society of Cardiology. August 2018, Munich, Germany.

Speaker, American College of Cardiology Scientific Sessions (3 sessions). March 2017, Orlando, FL

Speaker, the Year in Heart Failure: from Prevention to Intervention. European Society of Cardiology. August 2017, Barcelona, Spain.

Chair, FDA-Inova Think-Tank Meeting on Clinical Trial Enrollment in HF Trials. March 2017, October 2017, April 2018, October 2018, April 2019, October 2019, Washington DC.

Chairman and Panelist, CardioVascular Clinical Trails (CVCT) Scientific Program and Workshop Heart Failure Drug Trails. December 2016, 2017, 2018 Washington DC

Moderator & Panelist, New York Cardiovascular (NYCV) Symposium “Cardio-Pulmonary and Electrical Failure. December, 2016, 2017, 2018 New York, NY

Speaker, Heart Failure Society of America (HFSA), Scientific Sessions: “FDA Special Session – Off-Label Drug Use – Compelling Cases” , “Meet the Experts: Q&A with Heart Failure Editors - JACC: Heart Failure”. September, 2016, Orlando, FL

Speaker, European Society of Cardiology Congress “Heart failure: scope of the problem”. August 2016, Rome, Italy

Course Director and Chairman of Heart Failure Trials, CardioVascular Clinical Trialists Forum. December 2016, Washington DC

Speaker, American College of Cardiology Scientific Sessions (4 sessions). April 2016, Chicago, IL

Speaker and Course Director, Inova Cardiovascular Symposium. April 2016, McClean, VA

Speaker and Moderator, Inova Interventional Cardiology Symposium. January 2016. McClean, VA

Keynote Speaker: Duke Cardiology/DCRI Fellows' Presentation Skills Course. January 2016, Durham, NC

Course Director and Chairman of Heart Failure Trials, CardioVascular Clinical Trialists Forum. December 2015, Washington DC

Moderator, CVCT “Phenotyping Heart Failure – Is Precision Medicine the way forward?” December 2015, Washington, DC.

Panelist, CVCT “Trial Publications: Point and Counterpoint with Major Journal Editors. December 2015, Washington, DC

Moderator, New York Cardiovascular (NYCV) Symposium. Systolic Heart Failure and Basis for Management. December 2015, NYC, New York

Speaker, NYCV Symposium. “Diastolic Dysfunction: Clinical/Hemodynamic/Comorbid Features Should Prognosis/Management Be Focused on the Comorbidities?” December 2015, NYC, New York

Speaker, Heart Failure Society of America (HFSA). “Strategy to Optimize Enrollment – Partner with Health System”; “The Best of JACC: Heart Failure”; “Acute Heart Failure - Past Trials”. September 2015 Washington, DC.

Speaker, Heart Failure Association of the ESC Scientific Sessions May 2015, Sevilla, Spain

Speaker, American College of Cardiology Scientific Sessions March 2015, San Diego, CA

Co-Director and Presenter – Cardiovascular Clinical Trialists Forum (CVCT), Washington DC, 2014

Speaker, American Heart Association Scientific Sessions November 2014, Chicago, IL

Speaker, Heart Failure Society of America’s Scientific Sessions September 2014, Las Vegas, NV

Speaker, 2nd annual Duke Advanced Heart Failure Symposium October 2014, Durham, NC

Speaker - The State of Cardiovascular Trials in the United States. “Potential Solutions for Conducting Clinical Trials in US.” February 21, 2014, Silver Spring, MD.

Speaker, 1st annual Duke Advanced Heart Failure Symposium October 2013, Durham, NC

Speaker at Roche ProCardia meeting, August 2013 Amsterdam, Netherlands

Speaker, European Society of Cardiology 2013 Scientific Sessions. August 2013 Amsterdam

Speaker and Panelist - American College of Cardiology (ACC), Scientific Session and TCT@ACC-i2. San Francisco, CA, March 2013.

Speaker – Heart Failure Society of America (HFSA), Scientific Sessions, Orlando, FL, September 2013.

Co-Director and Presenter, Cardiovascular Clinical Trialists Forum (CVCT) and Workshop, Paris, France, November 2011 - 2013

Co-Chairman and Presenter, Heart Failure Society of America (HFSA), Scientific Sessions, Seattle, WA, September 2012

Presenter, European Society of Cardiology (ESC), Munich, Germany, August 2012

Presenter, Heart Failure Management, Amelia Island, Florida, July 2012

Presenter, Heart Failure Congress, Belgrade, Serbia, May 2012

Co-Chair and Presenter, Heart Failure Biomarker Working Group, Cannes, France, 2005 – 2012

Co-Chairman and Presenter, American College of Cardiology (ACC), Scientific Sessions, Chicago, IL, March 2012

Course Co-Director and Presenter, Snowbird Cardiovascular Symposium, February 2012-2016

Co-Chairman and Presenter, Heart Failure Society of America (HFSA), Scientific Sessions, Boston, MA, 2011

Co-Chairman and Presenter, American College of Cardiology (ACC), Scientific Sessions, New Orleans, LA, March 2011

Presenter - European Society of Cardiology, Paris, France, 2011

Chair and Presenter, Heart Failure Congress – Gothenburg, Sweden, May 2011

Co-Chair - Cardiovascular Clinical Trialists Forum (CVCT) Editorial Board, 2010-2017

Co-Chairman and Presenter – Heart Failure Society of America (HFSA), Scientific Sessions, San Diego, CA, 2010

Co-Chairman and Presenter – American College of Cardiology (ACC), Scientific Sessions, Atlanta, GA, March 2010

NIH/NHLBI Working Group – Emergency Department Management of Heart Failure 2010

Chief Presenter, FDA Cardio-Renal Advisory Committee Review of Nebivolol for Heart Failure, January 2010

Co-Chair, NIH/NHLBI Working Group – Cardiac Transplantation Workshop and Guidelines Committee, 2010

Co-Chairman and Presenter – Heart Failure Society of America (HFSA), Scientific Sessions, Boston, MA, 2009

Co-Chairman and Presenter – American College of Cardiology Scientific Sessions, Chicago, IL, 2009

Program Co-Director – Medtronic Cardiac Rhythm Disease Management Conference (Medtronic CRDM Education Services), New York, NY, 2009

Chair, NHLBI Review Panel– The Resuscitation Outcomes Consortium (RDC)-UO1, 2009

Co-Chair, Heart Failure Society of America (HFSA) Scientific Sessions Program Committee, 2008-2010

FDA Working Group – Acute Heart Failure Syndromes: Clinical Trials – 2008 – 2010

Co-Chair – Annual American College of Cardiology (ACC) Structured Sessions “Heart Failure and Cardiac Arrhythmias, 2004

Co-Chair, Annual Scientific Session Program Committee of the American College of Cardiology (ACC) Foundation – 2004

Reviewer, Special Emphasis Panel (SEP) for Evaluation of Applicants in a grant “Role of Infectious Agents in Vascular Disease”, June 17, 2002.

Member, American Heart Association (AHA), Acute Cardiac Care Committee on Clinical Cardiology – 1999

Member, American Heart Association (AHA) Council on Clinical Cardiology – Committee on Cardiovascular Disease in the Elderly – 1997

Reviewer, American Heart Association (AHA) Abstracts

Reviewer, American College of Cardiology (ACC) Abstracts

Member, Advanced Heart Failure Shared Clinical Experience Network II

Consultant/Grant Reviewer: NIH RO1 Application “Post-Infarction Recovery Of Ventricular Function in the Elderly

Chairman and Presenter - Success with Heart Failure: Advancing Heart Failure Care with Device Therapy and Monitoring National Program, New York, 5/5 – 5/6/2006.

Co-Chairman - Acute Heart Failure Syndromes Planning Committee, Washington, DC, 4/8-4/9/2006

Co-Chairman – Annual Southeast Region Cardiac Symposium entitled “Collaborative Management In the Treatment of the Cardiac Patient, Charleston, SC, 3/31-4/2/2006.

Mentorship Team – Junior Faculty Development Award (Award Recipient: Adrian Hernandez, MD), project: Heart Failure and Major Noncardiac Surgery, 2005

Chairman – Symposium - New Modalities in Heart Failure Management, Orlando, Florida, 11/4-11/6/2005

Faculty Member – CME Activity “Treatment of Post Myocardial Infarction Patients and the Role of ICD Therapy, Spotlight Program Videotape, 9/19/2005.

Course Director, Success with Failure: Understanding the Evidence, New Guidelines and Future Directions in Heart Failure Management, 8/20/2005.

Co-Chairman – Collaborative Management in the Treatment of the Cardiac Patient”, Charleston, SC, 5/13-5/15/2005

Moderator, Controversies in Heart Failure Management Forum, Pinehurst, NC, 4/22/2005

Co-Chairman, Late Breaking Clinical Trials Special Session, Mechanisms and New Therapeutic Approaches, Orlando, FL, 3/8/2005.

Co-Chairman, Heart Failure Symposium: Navigating the Deadly Intersection of Coronary Artery Disease and Heart Failure, Miami, FL, 2/3 – 02/06/2005

Co-Sponsor, Bi-Annual Cardiology Symposium, Asheville, NC, 10/29/2004

Course Director, The 2<sup>nd</sup> Annual New Frontiers in Heart Failure symposium, Duke University Medical Center, 10/22 – 10/23/2004

Workshop Chairman, Acute Heart Failure Syndromes 1<sup>st</sup> International Meeting, 5/1-5/2/2004

Director, Clinical Research Training Course of the Third Year Medical Students, 2002

Co-Chairman, Hospitalization for Exacerbation of Chronic Heart Failure: Current Concepts And Future Directions, 4/20 – 4/22/2001

Faculty Member for Case-Based Workshops, New Directions in Cardiac Protection: A Case Based Approach. 2001

Director, DUCCS 1<sup>st</sup> Annual Research Symposium Clinical Research in Cardiovascular Medicine: Principles for Investigators and Coordinators. 10/19-10/21/2001

Participant, American Heart Association (AHA), How-To-Session, Timing of Post Myocardial Infarction Risk Assessment, 1999

Instructor, Clinical Research Training Course, 1998 - Present  
 New Pathophysiologic Concepts in Cardiovascular Disease: Implications for Treatment, Continuing Medical Education Core Curriculum, 1998  
 Moderator, Heart Failure, The Duke Orgain Symposium, 9/27/1997.  
 National Videoconference, Heart Failure. Improved Approaches for Optimal Management Challenges in Diagnosis and Objectives of Effective Management. New York, 11/20/1996  
 Director, The War Against Atherosclerosis Congestive Heart Failure Symposium, 6/17/1995  
 Co-Director, The Greenfield Symposium, 6/16/1995  
 Co-Director, Annual Orgain Symposium, 1993 – 1995  
 Director, Annual Cost Effective Therapy Symposium, 1992  
 Co-Chairman and Presenter, Annual Heart Failure Management Symposium, Amelia Island, FL, 07/1985 - 2011  
 Director, Intern Clinical Cardiology Conference  
 Instructor and Developed the Six Week Quantitative Methods Course for Fellows and Housestaff  
 Supervisor, Fellow Research  
 Participant, Housestaff Journal Club  
 Participant, Cardiology Research Conference  
 Activity Director, CME Supported Internet Program. Blocking Angiotensin II. The Goal for Cardiovascular Disease Treatment Strategies.  
 Chair and Moderator, American College of Cardiology Scientific Sessions, Diagnosis and Therapy Session  
 Moderator, The Practice of Secondary Prevention Symposium  
 Preceptor, Primary Care Residency Training Program  
 Instructor, Med 255/Pharm 225 Lecture Series

#### **Professional Research Committee and Roles**

Member, FDA Cardiovascular and Renal Drugs Advisory Committee (CRDAC) Meeting: omecamtiv mecarbil for HF. (December 2022)  
 Member, FDA Cardiovascular and Renal Drugs Advisory Committee (CRDAC) Meeting: for tenapanor hydrochloride in chronic kidney disease (CKD) on dialysis. (November 2022)  
 Member, FDA Cardiovascular and Renal Drugs Advisory Committee (CRDAC) Meeting: daprodustat for anemia due to chronic kidney disease in adult patients. (October 2022)  
 Member, FDA Cardiovascular and Renal Drugs Advisory Committee (CRDAC) Meeting: hypoxia inducible factor prolyl hydroxylase inhibitor, Hifenzon (roxadustat) tablets (July 2021)  
 Member, FDA Circulatory System Devices Panel of the Medical Devices Advisory Committee. (April 2021)  
 Member, FDA Cardiovascular and Renal Drugs Advisory Committee (CRDAC) Meeting: spironolactone for the treatment of HFpEF. (December 2020).  
 Member, FDA Cardiovascular and Renal Drugs Advisory Committee (CRDAC) Meeting: angiotensin receptor-neprilysin inhibitor, ENTRESTO (sacubitril and valsartan) tablets (December 2020)  
 Steering Committee Member, VICTOR Trial, Merck (2021 - current)  
 Steering Committee Member, PROTECT IV Trial, Abiomed (2021 - current)  
 Steering Committee Member, Istaroxime development program, Windtree Therapeutics  
 Steering Committee and Publications Committee Member, VICTORIA Trial, Merck (2015-2020)  
 Steering Committee Member, Bayer (VITALITY-HFpEF) Trial (2016-2020)  
 Steering Committee Member, BMS / Cardioxyl Development Program (2016-2019)  
 Executive Committee and Co-Chair, Vericiguat Development Program  
 Chair, GENETIC-AF Trial Data Safety Monitoring Board  
 Chair, Abbvie ABT-494 Data Safety Adjudication Committee  
 Chair, Quintiles / Intarcia Data Safety Monitoring Board  
 Executive Committee, TRUE-HF Trial  
 Trial PI and Chair, Steering Committee – CAT-HF Trial  
 Member, DCRI / TACTICS Trial Steering Committee  
 ARCA Trial Planning Committee – Genetic AF Trial  
 Member, NHLBI / GUIDE IT Trial Executive Committee  
 Chair, NHLBI Data Safety Monitoring Board, trial of depression and intervention post CABG - 2004

Chairman, Pharmacovigilance Steering Committee - 2002  
 US Representative, International Steering Committee, Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) - 2001  
 Chair, PROTECT Publications Committee  
 Co-Chair, HF-ACTION Publications Committee  
 Co-Chair, ASCEND Publications Committee  
 Member, Novartis Advisory Committee – Relaxin Development Program  
 Member, RED-HF - Steering Committee  
 Member, Planning Committee for CSP#484 “Heart Failure in Patients with Preserved Systolic Function  
 Member, NIH Funded SMART Heart Trial Advisory Board  
 Member, Warfarin and Antiplatelet Therapy in Chronic Heart Failure Steering Committee  
 Member, Advisory Council to Improve Outcomes Nationwide in Heart Failure  
 Member, Care Standards Committee of Heart Failure Society of America (HFSA)  
 Member, Rapid Data & Safety Committee  
 Member, NHLBI ENRICHD Steering Committee  
 Member, NHLBI ENRICHD Eligibility, Recruitment, Adherence, and Retention Subcommittee  
 Member, NHLBI Beta Blocker Evaluation of Survival Trial (BEST) Endpoints Committee

**Editorial Board Memberships and Peer Reviewer:**

American Heart Journal  
 American Journal of Cardiology  
 American Family Physician  
 Cardiac Chronicle  
 CardioSource WorldNews  
 Journal of Cardiopulmonary Rehabilitation  
 HeartDrug  
 European Journal of Heart Failure  
 European Heart Journal  
 New England Journal of Medicine  
 Journal of Cardiac Failure  
 Journal of the American College of Cardiology  
 Journal of the American Medical Association

**Mentored Cardiology Fellows and Faculty:**

Name: Mike Unks, M.D.  
 Training Period: 1993-1994  
 Research Project: Endomyocardial biopsy/cardiomyopathy  
 Current Position: Private Practice, Asheville Cardiology

Name: Mike Cuffe, M.D.  
 Training Period: 1993-1994  
 Research Project: Heart failure and depression  
 Current Position: President and CEO of Physician Services for HCA

Name: William Hathaway, M.D.  
 Training Period: 1993-1995  
 Research Project: Peripartum Cardiomyopathy  
 Current Position: Private Practice, Asheville Cardiology

Name: Mark Thel, M.D.  
 Training Period: 1995-1997  
 Research Project: Cardiopulmonary arrest in congestive heart failure patients  
 Current Position: Chattanooga Heart Institute, Chattanooga, Tennessee

Name: Wei Jiang, M.D.  
Training Period: 1993-1997  
Research Project: Depression in heart failure  
Current Position: Associate Professor of Psychiatry, Duke University Medical Center, Durham, NC

Name: David DeNofrio, M.D.  
Training Period: 1994-1995  
Research Project: Adriamycin induced cardiotoxicity/myocarditis  
Current Position: Assistant Professor of Medicine, Tufts University, Boston, MA

Name: Mark Drazner, M.D.  
Training Period: 1995-1996  
Research Project: Sick-euthyroid syndrome in acute myocardial infarction  
Current Position: Professor of Medicine, University of Texas Med. Ctr., Dallas, Texas

Name: Brad Bart, M.D.  
Training Period: 1996-1998  
Research Project: Clinical determinants of mortality in ischemic/nonischemic cardiomyopathy  
Current Position: Associate Professor of Medicine, Director, Nuclear Cardiac Imaging Hennepin County Medical Center, Minneapolis, MN

Name: Wendy Gattis Stough, PharmD.  
Training Period: 1996-2005  
Research Project: Clinical pharmacology/heart failure  
Current Position: Assistant Professor of Medicine, Campbell University Expert Medical Communications, Raleigh, NC

Name: Carlos Del-Carlo, M.D.  
Training Period: 1998-1999  
Research Project: Cardiac troponins in congestive heart failure  
Current Position: Assistant Professor of Medicine, Sao Paulo, Brazil

Name: Eric Velazquez, M.D.  
Training Period: 1999-2001  
Research Project: Ischemic cardiomyopathy  
Current Position: Professor of Medicine, Duke University Medical Center, Durham, NC

Name: David Whellan, M.D.  
Training Period: 1998-2002  
Research Project: Cardiac rehabilitation/cost benefit of implementing a heart failure program  
Current Position: Professor of Medicine, Jefferson Heart Institute, Philadelphia, PA

Name: Monica Shah, M.D.  
Training Period: 1999-2001  
Research Project: Cardiac hemodynamics in predicting survival  
Current Position: Physician Project Officer, NHLBI, Washington, DC

Name: Michael Felker, M.D.  
Training Period: 2000-2002  
Research Project: Nonischemic cardiomyopathy, acute heart failure, biomarkers  
Current Position: Professor of Medicine, Duke University Medical Center

Name: Benjamin Trichon, M.D.  
Training Period: 2001-2003

Research Project: Mitral regurgitation and heart failure  
 Current Position: Private Practice, Asheville, NC

Name: Mark Donahue, M.D.  
 Training Period: 2001-2003  
 Research Project: Genetic modifiers of heart failure  
 Current Position: Assistant Professor of Medicine, Duke University Medical Center and Durham VAMC

Name: Jamie Bourque, M.D.  
 Training Period: 2001-2003  
 Research Project: Long-term outcome of patients with ischemic cardiomyopathy through Myocardial viability determination by radionuclide SPECT imaging  
 Current Position: Assistant Professor of Medicine, University of Virginia

Name: Adrian Hernandez, M.D.  
 Training Period: 2002-2004  
 Research Project: Evaluate heart failure outcomes in large registries  
 Current Position: Professor of Medicine, Duke University Medical Center

Name: Jonathan Yager, M.D.  
 Training Period: 2002-2004  
 Research Project: End of life heart failure  
 Current Position: Cardiac Care Associates, Fairfax, VA

Name: Karen Joynt, M.D.  
 Training Period: 2002-2004  
 Research Project: Cardiovascular disease and depression, heart failure disease management  
 Current Position: Assistant Professor of Medicine, Harvard School of Public Health

Name: Michael Kiernan, M.D.  
 Training Period: 2004-2007  
 Research Project: Evaluate heart failure biomarker BNP and its utility in predicting Peri-operative complications in patients undergoing noncardiac surgery  
 Current Position: Assist. Prof. of Medicine, Tufts University Medical Center

Name: Larry Allen, M.D.  
 Training Period: 2004-2008  
 Research Project: Evaluation of outcomes in acute decompensated heart failure  
 Current Position: Associate Professor, University of Colorado

Name: Melvin Echols, M.D.  
 Training Period: 2008-2010  
 Research Project: Depression, race, and heart failure  
 Current Project: Assistant Professor, Morehouse

Name: Robb Kociol, M.D.  
 Training Period: 2008 – 2011  
 Research Project: Troponins in heart failure  
 Current Position: Assistant Professor of Medicine, Tufts Medical Center

Name: Mona Fiuzat, Pharm.D.  
 Training Period: 2008 – 2015  
 Research Project: Personalized medicine in heart failure  
 Current Position: Associate Professor of Medicine, Duke University

Name: Carlo Lombardi, M.D.  
 Training Period: 2009 – 2010  
 Research Project: Role of troponin in heart failure  
 Current Position: Cardiology Faculty, University of Brescia, Italy

Name: Valentina Lazzarini, M.D.  
 Training Period: November 2011- April 2012  
 Research Project: Antiplatelets in Acute Heart Failure  
 Current Position: Cardiology Faculty, University of Brescia, Italy

Name: Luca Bettari, M.D.  
 Training Period: 2010 – 2011  
 Research Project: Hyponatremia in heart failure  
 Current Position: Cardiology Faculty, Cremona, Italy

Name: Robert Mentz, M.D.  
 Training Period: 2010 – 2016  
 Research Project: Comorbidities in Heart Failure  
 Current Position: Associate Professor, Duke University Medical Center, Durham, NC

Name: Tariq Ahmad, M.D.  
 Training Period: 2010 – 2016  
 Research Project: Biomarkers, Metabolomics and Genomics in Heart Failure  
 Current Position: Associate Professor of Medicine, Yale University

Name: Kishan Parikh, M.D.  
 Training Period: 2014 – 2019  
 Research Project: Pharmacogenetics in Heart Failure  
 Current Position: Cardiology Fellow, Duke University Medical Center, Durham, NC

Name: Lauren Cooper, M.D.  
 Training Period: 2016 – 2019  
 Research Project: Drug Therapy Monitoring, Clinical Trials in Heart Failure  
 Current Position: Attending physician, HF & transplant, Northwell Health System

Name: Palak Shah, M.D.  
 Training Period: 2016 – Present  
 Research Project: Pharmacogenomics in Heart Failure  
 Current Position: Attending physician, HF & transplant, Inova Heart & Vascular Institute, VA  
 Assistant Professor of Medicine, George Washington University

Name: Mitchell Psotka, M.D.  
 Training Period: 2017 – Present  
 Research Project: HF Collaboratory, Clinical Trials in Heart Failure  
 Current Position: Attending physician, HF & transplant, Inova Heart & Vascular Institute, VA

Name: Emmanuel Ekanem, M.D.  
 Training Period: 2018-2021  
 Research Project: Health Outcomes, Cost, and Quality  
 Current Position: EP Fellow, Mt. Sinai Health System

Name: Mark Sullivan, M.D.  
 Training Period: 2018-2019  
 Research Project: End of Life Care  
 Current Position: Private Practice Physician, Alexandria, Virginia



Name: Federica Latta, M.D.  
 Training Period: 2018-2019  
 Research Project: Publication of Clinical Trials  
 Current Position: Cardiologist, Maria Cecilia Hospital, Cotignola, Italy

Name: Dario Cani, M.D.  
 Training Period: 2018-2019  
 Research Project: HFpEF and Clinical Trials Publication  
 Current Position: Cardiologist, University and Civili Hospitals, Brescia, Italy

Name: Marco Sbolli, M.D.  
 Training Period: 2019-2019  
 Research Project: Depression in HF, GDMT Optimization  
 Current Position: Private practice cardiologist, Brescia, Italy

Name: Annunziata Cotugno, M.D.  
 Training Period: 2019-2020  
 Research Project: Women and HFpEF  
 Current Position: Cardiologist, University of Brescia, Italy

Name: Carlotta Perego, M.D.  
 Training Period: 2019-2020  
 Research Project: RMST Statistical Analysis in HF Trials  
 Current Position: Cardiologist, University of Brescia, Italy

Name: Nasrien Ibrahim, M.D.  
 Training Period: 2019 - 2022  
 Research Project: Use of Natriuretic Peptides in Clinical Trials, Disparities in HF  
 Current Position: Attending physician, HF & transplant, Inova Heart & Vascular Institute

Name: Hooman Bakhshi, M.D.  
 Training Period: 2019-2022  
 Research Project: Association between proteomic biomarkers and myocardial fibrosis  
 Current Position: Interventional Fellow, John Hopkins, Baltimore, MD

Name: Leonard Genovese, M.D.  
 Training Period: 2019-2022  
 Research Project: Advanced HF and Cardiogenic Shock  
 Current Position: HF Fellow, Tufts Medical Center, Boston, MA

Name: Andrei Minciunescu, M.D.  
 Training Period: 2021- Present  
 Research Project: HF and Guideline Directed Medical Therapy  
 Current Position: Fellow, Inova Heart & Vascular Institute, VA

**Participation in Academic and Administrative Activities of the Medical Center & Insitute:**

Co-Chair, Inova Advanced Practice Providers Transformation Committee	2022-present
Member, Inova Research Advisory Committee	2022- present
Chair, IHVI Ambulatory Council	2022- present
Chair, IHVI Leadership Council	2021-present
Chair, IHVI Cabinet	2021- present
Member, Inova Clinical Research Steering Committee	2021- present
Member, Inova Executive Leadership Team (ELT)	2021- present
Member, IHVI Fellowship Council	2021-present

Member, IHVI Research Council	2021- present
Member, IFH Quality Committee	2020- present
Member, IHS Diversity, Equity, and Inclusion Council	2019-present
Member, Inova Health System CEO Search Committee	2019
Member, IHS Industry and Society Relationships Committee	2018-present
Member, IHVI Philanthropy Council President Search Committee	2018-present
Member, Inova Health Foundation Board	2018-present
Member, IHS Committee to Develop Outreach Strategy	2018-present
Member, Inova Health System Research and Education Council	2017-present
Member, Inova Center for Personalized Health Taskforce	2016-present
Chair, IHVI Executive Leadership Council	2015-present
Member, Inova Health System Executive Leadership Team	2015-present
Member, Inova Health System CEO Search Committee	2017-2018
Member, Department of Medicine Conflict of Interest Committee	2011-2015
Member, Cardiology Ambulatory Operations Committee	2010-2015
Member, Translational Research Steering Committee	2010-2014
Member, Pediatric Heart Executive Committee	2006-2014
Member, Heart Center Executive Leadership Committee	2006-2015
Director, Heart Center Operations Committee	2006-2014
Member, Medical Staff Executive Committee	2006-2015
Member, Cardiology Residency Selection Program	2006-2014
Member, Review of Fellowship Training Program Committee	2006-2014
Member, Duke University Cooperative Cardiovascular Studies Board of Directors	2006-2014
Member, Clinical Research Networks Subcommittee	2006-2015
Member, Clinical Affairs Steering Committee, Division of Cardiology	2006-2014
Member, Duke University Hospital / Duke University Health Systems Executive Committee	2006-2015
Member, Cardiology Fellowship Evaluation Committee	2006-2014
Member, IRB Divisional Research Checklist Committee	2006-2010
Member, Department of Medicine Operating Committee	2006-2010
Member, Conflict of Interest Committee	2003-2014
Member, Heart Failure Executive Committee	2003-2014
Member, Duke Cardiovascular Database Steering Committee	2003-2014
Member, Utilization Management Committee (Patient Flow)	2000-2006
Member, Heart Center Process Improvement Committee	2000-2006
Member, Cardiology Clinical Trials Steering Committee	2000-2005
Volunteer, Prima Health Peer Review and Credentialing Committee	2000
Member, Duke Databank for Cardiovascular Disease Organizational Structure Steering Committee	2000-2014
Member, DCRI Cardiovascular Faculty Advisory Board	2000-2007
Managing Partner, Duke Cardiology Associates	1996-2003
Director, Clinical Research Training Course of the Third Year Medical Students	1996-2000
Member, Student Research Scholarship Committee	1996-2000
Member, Managed Care Committee	1996
Chairman, Code 5 Committee	1994-2003
Managing Partners of Cardiology Associates	1993-2003
Member, Student Research Scholarship Committee	1992-2005
Member, Funding for DUCCS Trials Committee	1992-1996
Board of Directors, RB Chart	1992
Member, Medical Intern Selection & Steering Committee	1992
Member, Managed Care Committee	1992
Member, Review of Fellowship Training Program Committee	1992
Member, Clinical Affairs Steering Committee, Division of Cardiology	

Medical Director, 7300 Unit	1990-2000
Director, Duke University Cooperative Cardiovascular Studies Organization	1990-2000
Member, Funding for DUCCS Trials Committee	1990-2000
Medical Director, Save-A-Life Executive Committee	1990
Member, Board of Directors of the American Heart Association	1990